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Introduction and Overview of this Thesis 
Andreas Gruentzig initiated the era of interventional cardiology in 19n with the introduction of 
percutaneous transluminal coronary angioplasty (PTCA) (1). The acceptance of coronary angioplasty 
is obvious by the widespread use of the procedure (>300,000 cases in the United States in 1990), the 
growing list of patient indications and the existence of an extensive infrastructure to support the 
procedure Qncluding the expansion of catheterization laboratories, fellowship trainee programmes, and 
substantial involvement by industry that has dedicated itself to continued improvement in advanced x-ray 
imaging systems, and angiop!asty hardware equipment). Yet despite the growth and success of PTCA, 
the first human coronary stent implantations were performed in 1986 in Lausanne, Switzerland by Ulrich 
Sigwart and in Toulouse, France by Jacques Puel (2). In fact, in the past fwe years several other devices 
have been clinically tested as alternatives or adjuncts to PTCA including directional atherectomy, 
rotational abrasion, and different types of laser therapy. These devices have been introduced due to the 
limitations of balloon angioplasty, namely early occlusion and restenosis within the first 6 months 
following angioplasty, which have persisted despite extensive attempts to find pharmacological solutions 
to these problems (3-5). 
$tents are devices that are implanted intraluminally to provide mechanical support. A number of 
devices have been developed that differ in composition. design, and mechanical behavior. According 
to Dr. Philip Urban of Geneva, the initial attempts to implant tubes inside vessels, are described in an 
article published by Alexis Carrel from New York in September 1912 in the American monthly ~surgery, 
Gynaeco!ogy and Obstetrics· (6). In these early experiments. 7 dogs were implanted with short glass 
tubes into the thoracic aorta, 3 animals received aluminium tubes and in 1 animal a gold plated 
alluminium tube was inserted through a surgical incision inside the thoracic aorta. Thrombosis of the 
tube occurred in 5 cases between 5 and 97 days after the implantation. Two animals died from 
hemorrhage 8 and 11 days following the operation. 
In 1969, Charles Dotter revived the concept when he implanted impervious plastic tube grafts in the 
normal canine femoral and popliteal arteries (7). His initial attempts failed due to thrombosis within the 
first 24 hours but patency rates improved when he substituted stainless steel coils instead of tubes and 
included heparin infusions for 4 days after implantation {8). In 1991, a variety of endovascular stent 
designs are under cHnical and experimental evaluation. Changes in design, the use of metal alloys and 
miniaturization of the endoprostheses has resulted in the availability of several type of stents for 
experimental and clinical evaluation. 
The central topics of this thesis are the coronary stent and the response of the vessel wall after 
implantation. In chapter 2, as a prelude to the quantitative angiographic analyses of the coronary stent, 
the rationale for stenting an atherosclerotic stenosis as an adjunct to balloon angioplasty and the 
hyperplastic processes triggered in the vessel wall as a result of combined balloon dilatation and stent 
implantation are examined, based on our animal studies and human saphenous vein bypass grafts that 
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were surgically removed 3 days to 10 months after stenting. 
In chapters 3 and 4. some methodologic aspects of performing quantitative coronary angiographic 
(QCA) measurements in stented vessels are presented. The optimal method to analyse the immediate 
and late angiographic results after PTCA or stenting has not been determined. Although edge detection 
remains the main form of analysis, its use may be limited in eccentric lesions, particularly after 
dissections disrupt the anatomy of the vessel. Densitometry has been proposed as an alternative method 
because it theoretically is independent of the geometric shape. ln chapter 3, we performed an in~vitro 
study to assess the contribution of 3 currently investigated coronary stents to the densitometric 
measurement of a known stenosis contained within plexiglass phantoms. The results showed that 
stainless steel stents (the Wallstent and the Palmaz-Schatz stent) cause only minor increases (<8%) in 
the calculated minimal luminal cross~sectional area. However, tantalum~containing stents (eg. the Wiktor 
stent) may result in serious overestimation of lesion area by densitometry derived measurements. 
particularly if contrast is diluted or the vessel is not well filled. In chapter 4, we compared the results of 
minimal luminal cross~sectional area obtained by edge detection versus densitometry in 19 patients who 
under.Nent coronary stenting with the Wallstent. Although poor correlations between these two methods 
has been observed in previous studies after PTCA, we observed a much closer correlation after stenting, 
probably because of the smoothing of the vessel contours by the stent and remodeling of the stented 
segment into a more circular configuration. 
In chapters 5-8, the early and late follow~up results of the first clinically implanted coronary stent, the 
Wallstent, are reviewed. The six European centers involved with testing this device agreed to set up an 
angiographic core laboratory at the Thoraxcenter in Rotterdam for quantitative angiographic analysis to 
ensure objective assessment of the results. The Coronary Artery Analysis System (CAAS) which has 
been extensively validated, was used for all quantitative studies. In addition to the angiographic analysis, 
brief clinical histories were available. Clinical follow·up was obtained from patient charts and personal 
queries to the participating cardiologists. In chapter 5, the results of the initial 117 self~expanding stents 
implanted in 105 patients are presented. This study represents the first quantitative follow~up study of 
one of the new post angioplasty devices and is therefore of historical importance. The main feature of 
this report is the high occlusion rate (24% overall) which appeared to be due in part to patient selection. 
differing and changing anticoagulation regimens at the various centers and operator inexperience. 
Restenosis was also documented in 14% of the patent stents at follow~up, which in the absence of the 
occlusion problem, would compare favorably to historical PTCA studies. 
Chapters 6 and 7 include data collected on the 265 patients who had stent implantations performed 
in 308 lesions from March 1986-- March 1990. In chapter 6, we have identified the angiographic 
predictors of restenosis within the coronary Wallstent using a relative risk analysis. The use of multiple 
stentsjlesion, oversizing the stent (unconstrained stent diameter exceeding reference diameter > 0.7 
mm), bypass grafts and residual diameter stenosis significantly increased the risk of restenosis using 
either of two restenosis criteria. Since some of these factors can be avoided (excessive oversizing, use 
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of multiple stents, more optima! initial dilatation), recommendations to lessen the risk of restenosis in 
stented vessels are suggested. In chapter 7, an in-depth analysis of clinical results, occlusion rates and 
restenosis rates is presented for the entire study group and then according to date of implantation and 
vesset type. Since our experience with stenting was the first of its kind, the indications for and 
management of patients implanted with this particular prosthesis evolved with increased experience and 
knowledge. Coronary artery disease in the early patients (partly described in chapter 5) consisted 
predominantly of native vessels that had previously restenosed. The later patients mainly consisted of 
patients with bypass grafts who were stented for primary de-novo coronary lesions and native vessels 
stented as part of a bail-out strategy following complicated balloon angioplasty. Although not statitstically 
significant. there was a reduction in the in-hospital occlusion rate to 12% in the later group accompanied 
by an increase in the restenosis rate from 21% to 32%. The palliative role of stenting was also evident 
in the low actuarial event-free survival (freedom from death, myocardial infarction. bypass surgery or 
PTCA) for native vessels (46% at 40 months) and for bypass grafts (37% at 20 months). 
In chapter 8, the separate Thoraxcenter experience of stent implantations in diseased bypass grafts 
is presented in detail. Stenting is discussed as a treatment option in this growing group of patients that 
frequently do not respond well to reoperation or conventional balloon angioplasty. All of the patients 
stented at the Thoraxcenter had severe symptoms and the majority were considered high risk for surgery 
or PTCA. In hospital occlusion was noted in 10% of the patients and usually occurred in the setting of 
acute ischemic syndromes or anticoagulation interruption. Although stent related restenosis was high 
(47%) and patients frequently required reintervention, coronary stenting can be effective therapy in some 
medically refractory patients who are poor candidates for alternative procedures. 
In chapters 9-11, the results of examining coronary tissue removed by directional atherectomy from 
vessels including restenosis within coronary stents, by a number of histological, and molecular biology 
techniques are described. In chapter 9. the early and late results of directional atherectomy performed 
for restenosis within the coronary stent of 9 patients (1 o procedures) are examined. ln addition, the 
restenosls tissue was studied for eel! identification. proliferation rates and cell density using a 
combination of light and electron microscopy and immunohistochemistry techniques. The results were 
compared with a control (non-stented) group of patients who had restenosis tissue removed 14-597 days 
following an initial procedure (PTCA. atherectomy or laser). The angiographic results showed that 
directional atherectomy is an effective form of treatment of restenosis within the stent but is also limited 
by recurrences. The tissue studies indicated that smooth muscle cells are the main cell type found in 
restenosis lesions regardless of the initial type of procedure and that smooth muscle cen proliferation 
is an ear1y event and barely detectable 2 months after the procedure. In addition, the vast majority of 
smooth muscle cells modulate towards the contractile phenotype earty after the procedure and the 
lesion cellularity decreases as a function of time but with a large interindividual variability. 
In chapter 10, the origin of the smooth muscle cells found in coronary lesions was shown in a de 
novo human coronary artery stenosis after heart transplantation. A technique (DNA fingerprinting) was 
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used that is based on the differences in genetic content between donor and recipient at several highly 
polymorphic variable number of tandem repeat (VNTR) gene loci. These studies were performed on DNA 
that was isolated from the coronary atherectomy specimen along with samples from the donor 
myocardium and the recipient's blood, after amplification of the DNA by the polymerase chain reaction 
(PCR). The electrophoresis results confirmed that the vascular intima! lesions typically seen in 
atherosclerosis and restenosis consist primarily of smooth muscle cells that are derived from within the 
vessel wall and not the circulation. 
In chapter 11, the preliminary results of culturing smooth muscle cells from coronary atherectomy 
specimens (including restenotic lesions in stented areteries) are presented and compared with smooth 
muscle cells isolated from the media of umbilical arteries. The main findings of this study were that 
smooth muscle ce!ls can be serially passaged from a minority of lesions and that these cells show lower 
proliferation rates (SO%) but higher rates of synthesis of the extracellular matrix components, collagen 
(SO%) and sulfated glycosaminoglycans (>2x) than the umbilical smooth muscle cells. This cell culture 
system appears to be a useful model to study the processes of atherosclerosis and restenosis. 
The goals of this thesis are twofold. lnterventional cardiology has now entered the post balloon 
angiop!asty period and we are faced with challenges unforseen 15 years ago. We have witnessed an 
explosion of alternative devices to balloon angioplasty such as several types of stents, at least three 
different atherectomy devices and a comocupia of different laser catheters (energies, designs etc). 
Clinical acceptance of any of these new techniques must await rigorous scientific evaluation. At the 
present time, this can only be accomplished with the use of quantitative coronary arteriography. In this 
thesis, we have attempted to set a standard for objective angiographic analysis and reporting. Although 
other methods of evaluation may be implemented in the future (for example, intravascular ultrasound), 
interventional cardiologists must not restrict themselves to the technical aspects of some of these more 
demanding and complicated devices. but must be active in the acquisition of new knowledge that 
increases our understanding of the processes such as restenosis that hamper the late outcome. We 
must devote our efforts to combine research in the basic mechanisms of the biologic processes that we 
initiate with our interventions, with a rigourous scientific evaluation of our efforts in the catheterization 
laboratory. I hope that the studies described within this thesis will be considered with these goals in 
mind. 
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NEW TECHNOLOGY 
Stenting of Coronary Arteries: Has a Modern Pandora's Box 
Been Opened? 
PATRICK W. SERRUYS. MD. FACC. BRADLEY H. STRAUSS. MD. 
HELEEN M. VAN BEUSEKOM. MSc and WILLEM J. VAN DER GIESSEN. MD 
Rorrcrdam. The Netherlands 
Interventional cardiology has recently witnessed the ,::rowth of 
several alternatives to percutaneous translum.inal angioplasty. 
including coronary stenting. Although stenting appears to be 
useful in treating abrupt closure after coronary angioplasty. its 
ell'ectiwness in limiting tbe romplex processes responsible for late 
restenosis is much lcs..-. certain. Pathologic examination of ~'tented 
human saphenous bypass grafts shows extensive deposits of plate-
let.-., fibrin and leukocytes along the stent wires within the 1st week 
and fonnation of a neointima of variable thickness after 3 months 
without evidence of foreign body reaction. The long-term effects of 
The introduction of coronary balloon angiop!asty by An-
dreas Gruentzig (I) in 1977 provided the stimulus for rapid 
technologic growth in the field of intervcntional cardiology. 
This development has produced several new devices de-
signed to ablate coronary anery narrowlngs. recanalize 
occluded vessels and prevent rc~tcnosis. It is difficult to 
evaluate the relative merits of each intervention and to 
define their roles in clinical cardiology. In applying this new 
technology. cardiologists have limited their concern to the 
technical and procedural aspects, while sometimes over-
looking the complex biologic and physiologic mechanisms of 
atherosclerosis. and in particular of the rcstenosis process. 
In achieving the perceived benefit of therapeutic interven-
tion with these devices. the vessel wall is subjected to 
thermal and mechanical insults that may have hidden long-
term consequences. An example is the restenosis process, 
which has been iatrogenically induced in tens of thousands 
of patients. 
One of these newer developments has been the usc of 
cndoluminal vascular prostheses. although the original con-
cept of intravascular stcnting precedes the introduction of 
coronary artery interventional cardiology by. many years. 
Since the original description of Dotter"s tubular coil spring 
From the D.theterbation L.1.bomtory. Thor.t.\Center. Er."mu~ t;niver-
~itv. Rotterdum. The Netherland~. 
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Addrr" for rrnnnt-: Patrick W. Serruy~. MD. CJtheleri~ution Lubor..t-
tory, Thor.v;center. Emsmu~ Univel'>ity Rotterdam. P.O. Box 173$,3000 DR 
Rotterdam. The Netherland~. 
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continuous barotrauma induced by the expanded stent remain 
unknown. It is difficult to assess the relative merits of the new 
devices, but stenting has several theoretic advantages. It seems 
Jess disruptive to the underlying architecture of the vessel wall and 
enjoys favorable theoretic and effective expansion ratios. Wide-
spread clinical acceptance for ~"tenting will depend on demomtrat-
ing that its safety, efficacy and c~"t efficiency are superior to those 
of baUoon angioplasty. 
(JAm Coil Cardiol J991:17:143B--548) 
stent (2). many variants of the original concept have been 
introduced, including thermal shape memory alloy stents 
(3-6), steel spirals (7). stainless steel mesh stents (8-ll), 
slotted stainless steel tubes (12-15), zigzag stcnts (16-18). 
U-configuration bends {19). interdigitating coils {20-22). 
tantalum helical coil stents (23), knincd tantalum wire stems 
(24.25), removable. metallic mesh stents (26) and synthetic 
polymeric and biodegradable stcnts {27). These various 
devices differ greatly in their fundamental geometry (tube. 
mesh or single wire). composition (metal or plastic) and 
mechanical behavior (active or passive expansion). Funher-
morc. there are a variety of subtle differences that may be 
imponant in themselves. such as thickness of filaments. 
alloy composition. electrostatic behavior and biocompatible 
or therapeutic coatings. 
More than 7 years have passed since the first clinical 
report {8) of successful coronary stent implantations. Al-
though the current world experience haS now exceeded 
1.000 stent implantations. the clinical indications and appli-
cations of this prosthesis remain undetermined and even 
experienced investigators are uncertain on these issues. The 
current status of the coronary stent parallels that of other 
recently introduced technologic advances. including laser 
angioplasty and atherectomy (directional and nondircctional 
types). This raises a fundamental question: have we been 
unable to realize the full potential of these newer devices 
because of our limited understanding of the underlying 
biologic interactions. particularly those responsible for re-
stenosis? In this review. we address several relevant issues 
based on our experience in the evaluation of various coro-
nary stems. 
0735-1097/91/$3.50 
SERRUYS ET AL 
$TENTING OF CORONARY ARTERIES 
Rationale for Stenting an Atherosclerotic 
Stenosis During or Mter Balloon Dilation 
Short-term consideration: abrupt closure. Abrupt vessel 
closure after angioplasty occurs in 2% to II% of procedures 
(28-31). Intimal flaps induced by the arterial injury can 
disrupt flow by partially or completely occluding the lumen. 
Sluggish anterograde flow and the exposure of media to 
procoagulant blood-borne elements are potent thrombogenic 
stimuli that furtlier contribute to the process. The coronary 
stent. by acting as a splint. can physically contain the 
protruding obstructive flap and maintain flow as well as 
possibly prevent distal embolization of macroscopic debris 
originating from the plaque or flap (32). This scaffolding 
function appears to be a propeny common to both balloon 
and self-expanding stenting prostheses. Angiographic stud· 
ies (10) after stent implantation have shown that the self· 
expanding Wallstent has a smoothing effect that reduces 
calculated poiseuille and turbulent contributions to flow 
resistance. Several repons have documented successful 
deployment of the various types of stents in the "bail-out"' 
situation when the presence of intimal dissection has led to a 
poor and even critical hemodynamic result (33.34). 
Long-term considerations: restenosis. Rcstenosis remains 
lhe major limitation of coronary angioplasty. Despite a lack 
of uniformity of definition. several angiographic follow-up 
studies have documented a 20% to 40% incidence in the l st 
6 months after angioplasty (35-38). Restenosis has been 
defined angiographically as a significant deterioration in the 
luminal diameter of a lesion that had previously been suc-
cessfully dilated. and docs not necessarily indicate a cem· 
mon pathologic substrate. Diverse histologic processes may 
be responsible for restenosis depending on the time interval 
since angioplasty. 
Early restenosis. Restenosis has been documented in up 
to II% of lesions as early as I to 4 days after coronary 
angioplasty {38-40). It is believed that the early cases of 
angiographic worsening arc a result of several processes. 
including elastic recoil. vasospasm or platelet-fibrin thrombi. 
or combinations. This time interval is too brieffor significant 
fibrointimal hyperplasia to have occurred. for several rea-
sons. Pathologic studies (41-43) of vessels retrieved <10 
days after angiop!asty have not shown any significant intimal 
hyperplasia. Animal experiments (44.45) in carotid arteries 
of mts ha·1e demonstrated that smooth muscle cell migrat;on 
into the intima begins only at 4 days and maximal intimal 
smooth muscle cell proliferation is not noted before 7 days 
after balloon endothelial denudation. Furthermore. cell cui· 
tures of medial smooth muscle cells (46) have shown that the 
modulation of phenotype from the quiescent. contractile 
state (typical of normal medial smooth muscle cells) to a 
metabolically active. synthetic state occurs only after 6 to 7 
days. Smooth muscle cells obtained from intimal thickenings 
phenotypically resemble these synthetic-type smooth mus· 
cle cells observed in culture and share a common cytoskel-
18 
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eton protein profile that differs from typical medial smooth 
muscle cells {47.48). 
The stent and elastic recoil. The significance of elastic 
recoil has been demonstrated acutely during angioplasty. In 
a study of \51 dilated segments. the minimal luminal cross-
sectional area before angiop\asty was 1.1 ± 0.9 mm~ (49). 
Immediately after the procedure the cross-sectional area of 
the dilated vessel was 2.8 :': 1.4 mm~. Elastic recoil, defined 
as the difference between the balloon cross-sectional area 
(5.2 ::': 1.6 mm~) and the vessel area after angioplasty. was 
calculated to be 2.4 ::': 1.4 mm~. which is almost 50% of the 
cross-sectional area of the fully inflated balloon. In an 
ang:iographic study of the initial 117 stent implants. we 
demonstrated that the self-expanding Wallstent mitigates the 
effects of elastic recoil. Stenting immediately improved the 
minimal cross-sectional area from 3.0 :': 1.2 mm::. after 
angioplasty to 5.5 ::': 2.7 mm::.. In a subgroup of patients with 
angiography 24 hours later. the stent continued to expand 
and increased the cross-sectional area to 6.8 ± 4.4 mm::. 
(Sem1ys et al.. unpublished observations). 
Late restenosis. Two processes have been implicated in 
the development of late restenosis. In some cases it has been 
attributed to the organization and fibrous conversion of 
platelet-fibrin thrombi that form at the site of intimal dam-
age. However. a more imponant mechanism appears to be 
marked cellular proliferation within the vessel wall that is 
stimulated by complex interactions between platelets adher· 
ent to the damaged intima. macrophages. endothelial cells 
and medial smooth muscle cells. Pathologically. late rcsteno-
sis is char.J.cteriz:cd by an aggressive proliferation of smooth 
muscle cells that presumably have migrated from the media 
into the intima. resulting in a variable degree of luminal 
narrowing (43.50). lmmunoperoxidase staining of the cellu-
lar component of this fibrointimal tissue has identified the 
characteristic cytoskeleton proteins of medial smooth mus· 
cle cells-alpha actin. desmin and vimentin-confirming the 
origin of the cells responsible for this growth. 
What Causes Smooth Muscle Cell 
Proliferation? 
Abnormal smooth muscle cell proliferation is an intricate 
process that is only partially understood. Animal models 
have revealed that balloon denudation in arteries will stim-
ulate a sequence of events if either of two conditions is 
present: I) extensive endothelial denudation. or 2) significant 
medial smooth muscle cell injury. 
The pioneering work of Reidy et al. {44.45) showed that 
significant intimal hyperplasia occurred after balloon injury 
in rat carotid arteries that resulted in the loss of up to 25% of 
the vessel wall deoxyribonucleic acid (DNA). This loss 
reflects widespread medial smooth muscle cell injury. since 
endothelial cell loss alone could not account for such a major 
change in DNA content. Later. more sophisticated tech-
niques of vessel wall injury were used (5!), which localized 
JACC Vol. 17. No.6 
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damage to the endothelium, sparing the subcndothclium and 
medial layers. Subsequently, intimal thickenings developed 
only in regions of the vessels that were not re-covered with 
endothelium after 7 days. These studies ::;uggcsted that 
smooth muscle cell proliferation and migration arc sepa-
rately controlled processes. because some areas of rapid 
endothelial regrowth contained increased numbers of medial 
smooth muscle cells without a corresponding increase in 
intimal thickness. A separate series of autoradiographic 
experiments (52.53) showed that only 50% of intimal smooth 
muscle cells arc capable of proliferation, supporting this 
concept. 
Platelet-derived p-owth factor. Several mitogens have 
been implicated in the stimulation of smooth muscle cells. 
Platelet-derived growth factor. the most intensively studied 
factor, is a dimer compound composed of two homologous 
polypeptide chains (A and B) that are disulfide bonded (54). 
Although platelet-derived growth factor was. originally iso-
lated from platelets. further study has confirmed that it is 
released from several different cells. including vascular 
endothelium. macrophages and even activated smooth mus-
cle cells. perhaps explaining why smooth muscle cells con-
tinue to proliferate long after the initial platelet-vessel wall 
interaction (55-58). 
The binding of platelet-derived growth factor to its recep-
tor initiates a complex cascade of signal transduction within 
the cytoplasm and ultimately into the nuclcu::; of the smooth 
muscle cell, resulting in cell division and protein synthesis. 
Although these pathways have not been elucidated fully, 
important steps include the platelet-derived growth factor 
receptor-mediated phosphorylation of tyrosine kinase and 
activation of phospholipase C. which subsequently gener-
ates two important second messengers. diacylglycerol and 
inositol triphosphate (59.60). The platelet-derived growth 
factor receptor and both its chains have been sequenced and 
it is now possible to clone platelet-derived growth factor 
with recombinant technology. Monoclonal antibodies 
against both chains of platelet-derived growth factor and its 
receptor have also been produced. The gene that codes for 
the B chain mRNA of platelet-derived growth factor is c-sis. 
which is the cellular counterpart to the v-sis gene of the 
simian sarcoma virus. An intriguing connection between 
neoplasia and atherosclerotic lesions is the dcmonstmtion of 
an active human oncogene in atherosclerotic plaques (61). 
Cultured mouse fibroblast NIH 3T3 cells have been tmns-
formcd with transfccted DNA from these plaques (61). 
These transfomted cells have established slow·growing tu-
mors in "nude" mice. 
Other growth ractors. Other important growth factors 
that have been related to rcstenosis include interleukin·l 
(!L-1). fibroblast growth factor, colony stimulating factor. 
epidermal growth factor. insulin-like growth factor (so-
matomcdins), endothelin and serotonin. The relative influ-
ence of the individual factors and possible interactions arc 
largely unknown and indicate our limited understanding of 
the entire process. 
19 
$ERRUY$ ET AL. 
STENTING OF CORONARY ARTERIES 
FE::ure I. Scanning electron micrograph or a stcnted human saphe-
nous vein bypas~ graft removed 3 days after implantation. Extensive 
deposits of platelets. leukocytes and fibrin are evident on this detail 
of the stcnt filaments. 
Pathology of Restenosis: After Coronary 
Angioplasty and Coronary Stenting 
Although autopsy reports of late follow-up angioplasty 
cases (3 to 20 months) arc limited. the general consensus is 
that the characteristic features of restenosis are smooth 
muscle cell hyperplasia and a variable amount of extracellu· 
lar matrix and fibrosis depending on the timt: elapsed since 
angioplasty. In addition to data from chronic animal studies. 
stented venous bypass grafts have been retrieved from 
several patients for analysis. Although the extent of intimal 
hyperplasia is similar after stcnting to postangioplasty exam-
ination. several histologic features appeared to be unique to 
coronary stems. 
Patholo,;c :md histologic frotures. ln human saphenous 
vein bypass grafts and porcine coronary arteries retrieved 3 
to 7 days after stent implantation, extensive deposits of 
platelets. fibrin and leukocytes arc observed along the stent 
wires (Fig. !). In the pig. the stent wires become embedded 
in the vessel wall and are covered with a neointima within 7 
days. This ncointima consists of organizing thrombus di-
rectly adjacent to the wire and several layers of smooth 
muscle cells along the luminal surface (Fig. 2). Scanning 
electron microscopy has confirmed complete cndothclializa-
tion. 
At 4 weeks in porcine coronary arteries. few traces 
remain of the initial platelet-fibrin thrombus, which is repre-
sented by a few erythrocytes. leukocytes and lipid-laden 
foam cells that arc interspersed in a disorganized fibrocel-
lular layer (Fig. 3). At the luminal side two distinct layers of 
smooth muscle cells arc present, one in a circular orientation 
immediately below the endothelium and a deeper layer in a 
longitudinal orientation. 
After 3 months, a more extensive neointima forms in the 
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porcine coronary artery with only a small area adjacent to 
the stent wire containing leukocytes and cellular debris (the 
so-called ''Bermuda triangle") (Fig. 4). In human saphenous 
veln bypass grafts removed 3 to 10 months after the stenting 
procedure. the amount of neointima which develops is 
comparable with the amount of neointima in the porcine 
coronary artery. but the neointima in humans borders on the 
old atherosclerotic plaque (Fig. 5). At the junction between 
old plaque and recent neointima. abundant foam cells and 
extracellular lipid deposits arc found within the new neoint-
ima in addition to extensive extracellular matrix production 
(Fig. 6). 
Me<:hanisms. The causes and possible relations between 
these early and late histologic features are unknown. Two 
factors may be important. First. the regenerated endothe-
lium that covers the stented segment may be dysfunctional 
and thus permit abnormal and excessive lipid infiltration and 
macrophage penetration across the endothelial barrier. 
Scanning electron microscopy of the endothelial lining has 
indicated an irregular. raised endothelial surface in lieu of 
the normal smooth covering (Fig. 7) although no permeabil-
ity to Evan's blue dye was demonstrated in stentcd porcine 
arteries after 3 months (Van dcr Giessen ct al .. unpublished 
observations). Second. important chemotactic substances 
may be released by the cellular debris trapped in the tissue 
adjacent to the stent wires. This area appears to persist late 
after stenting for several reasons. including continued dam-
age from direct pressure necrosis and its deeper location in 
the vessel wall, which isolates it from laminar flow patterns 
predominating on the luminal aspect of the stent wires. 
Striking similarities exist between the biology of stentcd 
vessels at 3 months and chronic atherosclerotic lesions, 
namely. proliferation of smooth muscle cells. large amounts 
of connective tissue matrix including collagen. elastin and 
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FiJ!Ure 2. Light micrograph of a stented 
porcine femoral anery 7 day~ after implan-
tation. The voids (•) repre5ent the ~ites of 
the 70 J..l.m diameter stent wire~. which have 
been removed. There i~ a disorgunized layer 
of neointima IN) on the luminal aspect of the 
stent wire. containing smooth muscle cells. 
trapped red blood celb and fibrin. Above the 
disorganized layer is an organized neointima 
that contains smooth muscle cells covered 
ov endothelium. The internal elastic lamina 
i; interrupted at tht: left (arrow). A "' adven-
titia: M = media. 
proteoglycans. and lipid accumulation in the form of foam 
cells (smooth muscle cells and macrophages), and extracel-
lular deposits. The natural history of these post-stem lesions 
has not yet been determined. 
Fi:;:ure 3. Light micrograph of a porcine coronarv anery 4 weeks 
after implantation. showing the remnants of the ·initial thrombus. 
which now contain~ a few erythrocytes. leukocytes and lipid-laden 
foam cells that arc interspe!':ied in a disorgunizt:d fibrocellular laver. 
At the luminal side. two distinct lavel':i of ~mooth muscle cells. are 
present. one in a circular orientation tCJ immediatelY below the 
endothelium. and the other a deeper l:l.ver in a longitud.inal orienta-
tion (L). 1•1 =void representing the.site of a rtmoved 127 ,wn 
diameter stent wire. 
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Figure 4. Light micrograph of a stented porcine artery 3 months 
after implantation. A more extensive neointima has formed. with 
only two small areas adjacent to the stent -.vire cont.:lining leukocytes 
and cellul::tr debris (arrows). (*) = void representing the site of a 
removed 70 ,wn diameter stent wire. 
Stenting and Hyperplasia 
Role of stenting in hyperplasia. Several possible theories 
have been advanced to support the role of stenting in limiting 
intimal hyperplasia (32.63,64). However. there is minimal 
experimental evidence to justify this position. and available 
animal and clinical studies confirm that significant hyperpla· 
sia occurs within the stentcd segment. The extent and 
characteristics of this hyperplasia arc illustra1ed by the case 
of a 67 year old man who had recurrence of angina 3 months 
after stenting in a bypass graft. Angiography revealed a 
severe narrowing within the stcnt that was treated by com· 
bined balloon angioplasty and atherectomy (Fig. 8). The 
tissue specimen removed by the atherectomy device is 
shown in Figure 9. The microscopic evaluation shows abun· 
dant extracellular collagenous matrix and areas of marked 
cellularity that stain positively for two smooth muscle cell 
cytoskeleton proteins, alpha actin and vimentin (Fig. 10). 
Although hyperplasia is a consequence of stenting. the 
functional significance of this growth may be diminished. 
This is explained by the intrinsic dilating property of the 
self--expanding stent. which initially improves luminal area 
50% more than angioplasty by itself and in many patients 
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FigureS. Light micrograph of a human saphenous vein bypass graft 
removed 10 months after stent implantation. A prominent neointima 
(N) has formed and borders on the old atherosclerotic plaque (P). At 
the junction between the old plaque and the recent neointima. 
abundant foam cells are found in the new ncointima. (*) = void 
representing the site of a removed 70 .,.m diameter stent wire. 
more than compensates for the late proliferation. Unfortu-
nately, the ideal ratio of stent size to vessel size that will 
result in optimal dilation with minimal compensatory hyper-
plasia remains unknown. The importance of this relation ro 
the final outcome was illustrated recently by a Mayo Clinic 
study (65} in which a model for restenosis was developed by 
implanting stainless steel and tantalum coils with markedly 
oversized angioplasty balloons inflated to high pressures up 
to 14atm. 
Confounding Aspects of Stenting 
There are three additional aspects of stenting that further 
confound our understanding of the processes occurring in 
the vessel wall after injury. 
l. Foreign body interactions with the vessel wa1l. In con-
trast ro brief. transient balloon-induced injury. nonbiode-
gradab\e stents are permanent foreign bodies with poten· 
tially important interactions due to type of metal, 
electrostatic charges. and possible physical irritation from 
individual filaments. Whether the continued presence of a 
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Fi,are 6. A. Transmission electron micrograph of saphenous vein 
bypass graft 6 months after stcnt implantation. Extracellular lipid 
deposits and cholesterol clefts (arrow) are evident alongside the 
foam cel!s. B. Higher magnification of another part of the section in 
A. An abundant number of foam cells c.an be seen. The diagonal 
lines are artifacts produced by the ultramicrotome. (•) = void 
representing the site of .a removed 70 p;m diamettr stent wire. 
Abbreviations as in Figure 5. 
Figure 7. Scanning electron micrograph of the endothelial lining 
shows an irregular. raised endotheli.al surface. Two leukocytes are 
adherent to the endothelium (bar = 5 p;rnl. 
JACC Vol. 17. ~0- 6 
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foreign body in the vascular wall will continue to stimulate 
fibrointimal hyperplasia after the 6 months usually associ-
ated with balloon injury is also unknown. Concem has also 
been expressed as to whether the stem can trigger an allergic 
response. panicularly in individuals who are hypersensitive 
to the individual metals that make up the device. Although 
there have been reports of transient inflammatory infiltrates 
in the adventitia after stem implantation. it is reassuring that 
there have been no reports of foreign body cells in the 
immediate vicinity of the implanted device in the expcrimen-
22 
Figure 8. Coronary angiogram from a 67 year old patient who 
underwent stent implantation for a severe narrowing in the shaft of 
a 10 year old saphenous vein bypass graft. Three months later he 
was treated with ::tthercctomy for restenosis within the stent. 
JACC Vol. 17. No.6 
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Figure 9. Light micrograph of hyperplastic 
tissue removed by athercctomy from the 
narrowed stent in Fig. 8. The specimen con-
tains abundant smooth muscle cells and loose 
extracellular matrix. (Hematoxylin-eosin 
stain.) 
tal animal model (14.15). This has been confirmed in limited 
experience in retrieved human stented coronary bypass 
grafts. In vitro attempts (Vander Giessen et al.. unpublished 
observations) to identify endothelial membrane lipid perox-
idation by free radicals formed in the presence of metallic 
stent elements have been unsuccessful. although the theo-
retic possibility exists. 
2. Long~term effects of continuous bar-otrauma: role of 
exerted radial pressure. The chronic effects of continuous 
barotrauma induced by the expanded stent may have impor-
Figure 10. Smooth muscle cells are identified 
in the restenosis tissue obtained at atherec-
tomy by the dark brown staining. An anti· 
body specific for smooth muscle alpha actin 
has been coupled to a peroxidase reaction 
and is responsible for the dark color. 
23 
SERRUYS ET AL. 
STENT!NG OF CORONARY ARTERIES 
tam ramifications. Because the Wallstenfs properties are 
analogous to those of any spring. it tries to assume its 
equilibrium configuration. defined as the unconstrained di-
ameter where net radial force is zero. If it is stretched 
beyond or constricted below this equilibrium. it generates 
forces to return to this configuration. We have studied the in 
vitro force-length relationship of the Wallstent stcnt (Fig. 
II). These measurements have yielded calculations of the 
radial pressures exerted by this stent. both globally and 
locally at the site of the individual filaments if the stent is 
,-
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Figure ll. Radial pressures of the individual stent filament and the 
global pressure on the vessel wall of a self-expanding Wa.llstent 
(unconstrained diameter 6.25 mm} at varying degrees of expansion. 
maintained at a diameter less than that of the unconstrained 
diameter. Significant pressures are generated by the stent (as 
in any spring-loaded device) to return it to its unconstrained 
size. For example. an unconstrained 6.25 mm diameter stent 
generates a radial global pressure of 50 mm Hg and a radial 
local pressure of about 300 mm Hg at the stent filament if it 
is maintained at 5.5 mm. This increases to 90 mm globally 
and 500 mm locally at 4.5 mm diameter. These pressure 
calculations would be additive to the mean arterial pressure 
and could have an important impact in situations where 
oversized Wallstents are implanted. In fact. localized areas 
of necrosis adjacent to the stent wires have been seen. which 
are probably the result of a pressure phenomenon. 
3. Splinting the artery externally (casting) versus internaJiy 
(stenting): effect on wall stress. Parallels have been drawn 
between the effects of splinting the artery externally (cast-
ing) and internally (stenting). Thubikar et al. (66) showed 
that externally casting segments of rabbit aortas limits pul-
satile flow and atheroma development despite a high choles-
terol diet. On the basis of this observation. others (32) have 
speculated that nonflexing internal stents may also reduce 
wall stress and consequently diminish hyperplasia forma-
tion. However. this analogy is not impressive. Although 
some of the pulsatile stretch may be borne by the external 
cast or the internal stent. and thus favorably affect wall 
stress. this is achieved by separate means. In the casting 
model. there should be a reduction in intramural wall stress. 
since the vessel is casted at a radius smaller than the 
maximal systolic expansion. In contrast to casting. stenting 
results in dilation of the artery and an increase in wall stress. 
This important stimulus to intimal hyperplasia appears to 
overcome the inhibitory effects of reduction in phasic vessel 
wall expansion. Booth et al. (67) modified the external 
casting model with interesting results. By applying an exter-
JACC Vol. 17, No.6 
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nal nonoccluding_ Silastic collar on a rabbit carotid artery 
that did not affect end-systolic dimensions. they demon-
strated that focal hyperplastic lesions rapidly develop. This 
finding supports the concept that external casting must 
decrease the vessel radius in order to achieve inhibition of 
intimal hyperplasia. 
The State of Interventional Cardiology in 
1990: Debulking Versus Dilating 
lnterventional cardiology has moved in two directions: 
devices that primarily dilate coronary narrowings (balloon 
angiop!asty and $tenting) and devices that physically debulk 
coronary tissue by extraction. liquefaction or vaporization 
(laser. directional and rotational athcrectomy and spark 
erosion). At present. it is difficult to make comparisons 
among the various devices. However. there are several 
fundamental differences that may be important and merit 
further discussion. 
Comparison of the various techniques. The ideal coronary 
intervention should selectively reduce the effect of the 
atheromatous lesion with minimal alteration of the normal 
vessel wall components and architecture. None of the cur-
rently available techniques completely satisfy these require-
ments. Balloon angioplasty. atherectomy (rotational and 
directional) and laser devices all cause extensive traumatic 
changes within the plaque and usually major alterations to 
the vessel wall architecture as well. Balloon angioplasty. the 
earliest intervention. has been shown to create tears and 
dissections within and at the edges of atherosclerotic plaques 
and frequently disrupts the internal elastic membrane and 
medial layers (68-71). Theoretically. these disruptions may 
be advantageous since the liberation of lipid and debris from 
the atheromatous lesions. a sort of debridement. may favor-
ably affect the long-term biologic growth and behavior (if 
distal embolization of this material does not cause immediate 
clinical consequences) (72-74). 
However. mo-re important considerations may be the 
manner in which the healing process ensues in a damaged 
vessel with frayed. ragged membrane edges and separated 
muscular layers and the inherent problems of restoring the 
normal three-layered architecture of the arterial wall in an 
orderly fashion after such injury. Moreover. the extent of 
arterial disruption from angioplasty appears to be much less 
than in the actual removal of coronary tissue by dcbulking 
devices. Directional atherectomy in particular has been 
shown to be extremely effective in removing the atheroma 
but specimens include adventitia in up to 30% of cases (75). 
although there is no evidence to date that the rate of 
restcnosis is related to the depth of the vessel wall extracted. 
Alternatively. stenting seems to be the least disruptive to the 
underlying architecture. although the underlying atheroma-
tous lesion persists in the stcnted vessel with unknown 
future consequences. Stenting is able to "tack back" the 
cracks and tears induced by balloon angioplasty. which may 
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Figure 12. The natural progression of coronary artery disease as 
suggested by Glagov et ::t!. (76) is illustrated in the center row by the 
early compensatory enlargement and the late luminal narrowing of 
progressive atherosclerosis. The differential effects of stenting and 
atherectomy in restoring the vessel diameter are shown. Stenting 
(below) restores the eMiy compensatory enlargement in the vessel 
while it maint::tins the basic architecture of the vessel wall. By 
extracting vascular tissue. atherectomy (above) disrupts the under-
lying ~r':hitecture of the wall. Modified from Glagov Setal. (76) with 
permiSSIOn. 
diminish the stimulus for fibrosis in much the same way that 
a properly closed wound minimizes fibrotic scar in the 
healing phase. 
Table I. Expansion Ratios With the Coronary lnterventional Devices 
Device Ve~,e] Diameter 
Profile Prepr()(.:edure 
Jnlervention Procedures (mm) (mmJ 
Balloon angioplaqy .... , 0.7-1.3 1.1 :!: 0.3 
Stenting 
Self-expandable 357 1.6 1.3:!: 0.7 
Balloon-expandable 17 1.4-1.6 1.0:!: 0.3 
Atherectomy 
Directional 39 2.1-2.5 1.1 :!: 0.4 
Rotational 52 L>-2.0 0.9 ~ 03 
Excimer la-..er 55 1.4 0.5 :!: 0.4 
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Glagov revisited. Glagov et aL (76) observed that the 
diseased coronary artery is able to adapt to progressive 
plaque expansion by enlarging the size of the vesseL This 
compensatory mechanism maintains the luminal area until 
the plaque lesion occupies 40% of the area inside the internal 
elastic lamina. beyond which progressive luminal narrowing 
occurs. In other words. significant atherosclerosis can coex-
ist with nonnal or even enlarged luminal area until the limits 
of this adaptation are exceeded. 
Striking similarities exist between the chronic process of 
atherosclerosis and the situation in the stented vessel walL 
The stent is initially embedded in the intima. which results 
immediately in enlargement of the lumen and later in local-
ized medial thinning at the site of the stent wires. a com-
monly observed pathologic feature of atherosclerosis. Stent-
ing may be regarded as the invasive cardiologist's anempt to 
restore the aforementioned "Glagovian .. balance between 
plaque and luminal area. but in vessels that contain plaques 
>40% of the internal elastic lamina (Fig. 12). Stents effec-
tively alter the relation between plaque size and lumen area, 
res.ulting in a shift in the curve. Progressive vessel dilation 
by the stent can maintain adequate luminal area unless 
excessive fibrointimal hyperplasia upsets the new balance. 
Expansion ratio. Expansion ratio is an important concept 
that relates the final effect on the arterial diameter to the size 
of the catheter required to deliver this effect (32) (Table 1). A 
Maximal Achievnble Postprocedure Theoretic Effe~:tive 
Diameter/(Range) Diameter Expansion Expan~ion 
(mml (mm) RatiO Ratio 
~-9:!: 0.4 l.S:!: 0.4 2.2-4.1 1.4-~.6 
(2.0-3.5) 
4.0:!: 0.7 2.6 :!:M 2.5 1.6 
(2.5-6.01 (1.6--3.81 
3.3:!: 0.3 2.4:!: 0.3 2.1-~.4 1.5-1.7 
(3.0-4.0) 
3.3:!: 0.5· 2.5 :!: 0.6 1.3-1.6 1.0-1.2 
2.0 :!: 0.27 
1.9:!: 0.3 1.7 :!: 0.4 1.0 0.9-1.1 
n.S-2.01 
1.4 1.7 :!: O.S 1.0 1.2 
•With b'.dloon infiat~: t\With balloon deflated. Thi' table com pure~ the device profile and immediate angiop-:lphic re>ult' of ,ever.d inte!'>'entiom. The profile 
of the device i~ based on data on ~.0 to 3.5 mm diameter balloon catheter:. (771. the Wallstent (Medinvent) 'elf-expandable stent. Wiktor (Medtronic) 
balloon-expandable stent. Simpson Coronary Atherocath (DVI I directional atherectomy device. Rotablator (Heart T cchnologyJ rotational athcrectomy device and 
the model Max-10 excimer Ja,er (Te~:hnola,, Munich). The relation between the profile of the device and the maximal achievable diameter of the device i5 the 
theoretical expansion ratio. The maximal achievable dinmeter of the ve~~el i~ calculated according to the \ile of the device while it is operutional in the coronary 
vessel. In the ca.\C of balloon nn,:iopla.~ty, balloon-expandable stent and directional atherectomy. the maximal achievable diameter corresponds to the diameter 
of the device while the b'..tlloon is inflated and to the uncon~1rained diameter of the \elf-expandable ~tent. The rotational atherectomy device and the excimer laser 
do not alter their diameter during the procedure. The poo;tproc~ure diameter i5 meu~ured imm~iate1y after the procedure. The elfective expansion rnlio 
represents the ratio between the po>tprocedure result and the profile of the device and thus indicate~ not only the initial effect of the device but also the effect 
of ela.~tic recoil, which ;, primarily responsible for the deterioration in the diameter from the m:LXimal achievable diameter to the postprocedure diameter. The 
diameter values listed are the mean value :t SD of the different-~ized devices from each interventional studv: r..tnge~ are in parentheses. The preprocedure data. 
which may also affect the postproc~ure result. were ~imilar for all interventions (0.9 to 1.3 mm) except f~r the excimer la.ser, which may explain a somewhat 
lower postrecoil diameter and effective expansion Mio. The quantitative angiogrnphic data for all device~ except the rotational athere~:tomy device (Peterson K, 
unpublished observations) and the excimer la."'Cr (79), were colle~:ted at the Thoraxcenter. 
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favorable ratio is best exemplified by a small catheter 
delivery system that is able to pass severely narrowed 
segments and yet optimally dilate the stenosis. The maximal 
effect of the device may be partially lost because of the 
elastic recoil of the vessel. The current interventional de-
vices may have differential effects in these two areas: the 
immediate result when the device is initially used. and then 
the partial loss of the initial gain after the device has been 
removed. An attempt has been made to separate these two 
effects by subdividing the expansion ratio into the theoretical 
expansion ratio (a measure of the effect while the device is 
operational) and the functional expansion ratio (which takes 
into account the elastic recoil phenomenon). For example. a 
4 mm diameter balloon angioplasty catheter should achieve a 
vessel diameter of 4 mm at the time of balloon inflation but 
this is reduced immediately after deflation. primarily be-
cause of the elastic recoil of the vessel. Balloon angioplasty 
and stenting give extremely favorable theoretic and effective 
expansion ratios since they may be delivered on low profile 
catheters. The wide range for the theoretic and effective 
expansion ratios seen with balloon angioplasty is explained 
by the variation in the size of the balloons (2.0 to 3.5 mm) 
used in the study from which these data were obtained. The 
atherectomy devices are more limited by the profile of the 
device that is introduced into the coronary artery. The 
dimensions of the rotational atherectomy device and the 
excimer laser do not change while in operation and therefore 
both exhibit lower theoretic expansion ratios. However, by 
physically removing or vaporizing tissue. the potential elas-
tic recoil effect is diminished by atherectomy and excimer 
laser devices. 
Conclusion 
Once again the question is asked: Can the promises of the 
new technology. and in particular the coronary stent. ever be 
realized?. Stenting will only achieve clinical acceptance 
when the safety. efficacy and cost efficiency are superior to 
those of balloon angioplasty alone. Safety remains the major 
limitation of stenting. In the initial 105 patients with an 
implanted Wa!lstent. 20% had documented occlusion within 
the 1st 14 days. usually resulting in myocardial infarction 
and in some cases necessitating emergency bypass surgery. 
With further experience this was reduced to !3% in the next 
!00 patients. Schatz et al. (!5) recently reported a 3.6% 
subacute occlusion rate in contrast to a !6% rate in their 
early experience when warfarin treatment was omitted (78). 
However. the price of chronic anticoagulation therapy-
bleeding complications. prolonged hospitalization to initiate 
therapy and effects on the quality of life-must also be 
considered. With the increasing importance of third party 
payment. the cost differential among competing therapies 
will also dictate medical policies. Finally. these devices must 
show beneficial effect on late restenosis in order to gain 
clinical acceptance. The late follow-up results of quantitative 
coronary angiography for two of the stems will be published 
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in the next' several months and should provide more objec-
tive evidence with which to evaluate the future role of the 
stent. 
The early experience of modem interventional cardiology 
evokes lessons contained within Pandora's box. In this 
classic Greek myth. man. beguiled by the attraction of 
Pandora opened the box that exposed heretofore unknown 
perils and disease. while Hope (E!pis). the lone content of 
the box that could be controlled by man. remained hidden 
deep within the box. The allure of the newer techniques and 
devices in interventional cardiology. like Pandora herself. 
have brought us a new set of problems that we have been 
ineffectual in solving. However. Hope also exists within the 
modem Pandora's box and our capacity to realize hope will 
depend on a scientific approach to the problems of restcnosis 
and neointimal hyperplasia in a mutual effort (in concert with 
industry) of intervemional cardiologists. pathologists. mo-
lecular biologists. biochemists. pharmacologists and our 
patients. the general public. 
We thank Cornelius J. Slager for pres:.ure-length measurements on the 
~elf-expandable ~tenb. Helene vun Loon for hbtologic prepar-..1tions. Marie-
Angi:lc Morel and Eline Montuuban v;m Swijndregt for quantitative angio-
gr-..~phic analysi~ and Mrujo van Ee for preparation of the manuscript. 
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Do stents interfere with the densitometric assessment of a coronary lesion? An in-vitro study 
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Abstract 
This in-vitro study was designed to assess the contribution of 3 currently investigated coronary stents 
to the densitometric measurement of a known stenosis contained within two different sized plexiglass 
phantoms. These studies were periormed at two concentrations of the contrast agent iopamidol (50 and 
100%). The calculated minimal luminal cross-sectional area values in the control phantom ranged from 
0-18% higher than the theoretical values. Insertion of a stainless steel stent (Wallstenf or Palmaz-
SchatzTM) resulted in further minor increases (:s:8%) in the calculated minimal luminal cross-sectional 
area, except in the smaller phantom filled with 50% contrast medium. The WiktorTM (tantalum) stent had 
the largest impact of the three stents depending on the concentration of iopamidol (1 00% contrast 
medium: 9-13% values above control; and 50% contrast medium:, 23-56% higher). We conclude that 
although densitometry may overestimate the minima! luminal cross-sectional area in stented vessels, this 
effect is usually minor with stainless steel stents. However tantalum-containing stents may result in 
serious overestimation of lesion area. particularly if contrast is diluted or the vessel is not well filled. 
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INTRODUCTION 
Coronary stenting has been introduced as an adjunct or alternative to PTCA in obstructive coronary 
artery disease (1 ,2). A variety of devices have been developed which differ in their composition. design, 
radiopacity and mode of expansion. Although densitometry and contour detection appear to be 
comparable methods to assess the angiographic result after stenting with the Wallstent (3), the actual 
contribution of the individual types of stent to the densitometric value has not been systematically 
studied. The objective of this study was to assess whether the physical properties of three devices 
currently under investigation affect the dens'rtometric assessment of a fixed stenosis in a plexiglass 
phantom. 
MATERIALS AND METHODS 
Plexiglass Phantoms 
Plexiglass models were 6 em in length and circular in cross·section. The extremities of the phantoms 
had a fixed bore diameter of either 4 or 3 mm and abruptly tapered in the central part to a fixed 
concentric stenosis of 3 and 2 mm respectively. 
Stent Types 
The Wallstenf (Schneider. ZOrich) is a self·expandable stainless steel woven mesh prosthesis, 
constructed of 16 wire filaments, each 0.07 mm. wide. It is constrained in an elongated configuration on 
delivery catheter with the distal end covered by a removable plastic sleeve. The combined diameter of 
delivery catheter plus mounted stent measures 1.57 mm diameter. As the sleeve is withdrawn, the 
constrained device returns to its original unconstrained larger diameter and becomes anchored against 
the vessel wall (1 .2). Unconstrained stent diameter in this study was 2.5 mm in the 2 mm phantom and 
3.0 mm in the 3 mm phantom. 
The Palmaz-Schatz™ coronary stent (Johnson and Johnson, Warren. New Jersey} is a balloon 
expandable slotted stainless steel tubular stent composed of two 7 mm segments of slotted tubes that 
are connected by a 1 mm bridging strut (4). Each tube contains 12 rows of slots that are each 0.065 mm 
in diameter. The stent is mounted coaxially over commercially available balloon catheters. In this study 
the stent was cut at the bridging strut and only the tube was placed in the phantom. 
The Wiktor™ stent (Medtronic. Minneapolis) is a balloon expandable tantalum helical coil stent that 
is constructed of a single tantalum wire (0.127 mm in diameter) which is formed into a sinusoidal wave 
and wrapped into a helical coil structure. The prosthesis is crimped onto a deflated polyethylene 
angioplasty balloon and the maximal diameter of the balloon after inflation determines the ultimate size 
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of the prosthesis after implantation (5). 
Angiographic Protocol 
Angiograms were obtained with the use of a Siemens Blear X·ray system in the 5 inch cesium iodine 
image intensifier mode and a 0.8 mm focal spot of the X·ray tube. The focus to object distance was 90 
em and the object to image intensifier distance was 13 em. In each study, the stent was introduced into 
the plexiglass phantom and positioned across the narrowing at the center of the phantom. All three 
stents completely covered the central narrowing and extended on either side to the reference segment. 
The phantoms were then filled with contrast medium, lopamidoi..S?O, at a concentration of either 50% 
or 100%. 
Cinefilm was taken with an additional 17.5 em thickness of plexiglass blocks (12.5 em anterior and 
5 em posterior to the models). The addition of the plexiglass blocks resulted in a more appropriate kV 
level (82 kV) and in a scatter medium which more closely approximates the radiologic scatter in the 
human thorax during angiography. The studies were then repeated with the second concentration of the 
contrast reagent. The cinefilms were processed routinely and analyzed by the CAAS system. 
Angiographic Analysis 
All cineangiograms were analyzed using the computer assisted cardiovascular angiography analysis 
system (CAAS) which has previously been discussed in detail (6·9). The important steps will be briefly 
described. Any area of size of 6.9 X 6.9 mm in a selected cineframe (overall dimensions 18 X 24 mm) 
encompassing the phantom or the desired arterial segment can be digitized by a high resolution ceo-
camera with a resolution of 512 X 512 pixels and 8 bits of gray level. Contours of the "vessel~ segments 
were determined automatically based on the weighted sum of the first and second derivative functions 
applied to the digitized brightness information along scanlines perpendicular to the local centerline 
directions of the perspex modet. The centerline was manually defined by the user. A computer-derived 
estimation of the original dimension at the site of the narrowing is used to define the interpolated 
reference diameter. This technique is based on a computer-derived estimation of the original diameter 
values over the analysed region (assuming there was no narrowing present) according to the diameter 
function. Calibration of the diameter data is performed by applying the automated contour detection 
technique to the known outer diameter of the plexiglass model. 
The densitometric assessment, which relies on the relationship between pathlength of the X-rays 
through the segment and the resulting brightness values, requires a detailed analysis of the complete 
X-ray /cinejvideo chain, including the film development process. 
For the first part of the chain. from the X-ray source to the output of the image intensifier, we use 
Lambert Beer's law for the x-ray absorption and apply certain models for the x~ray source and the image 
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intensifier. From the output of the image intensifier up to the brightness values in the digital image, a 
simple linear transfer function was used. Details of this technique have been described elsewhere (6-8). 
The cross-sectional area of the perspex narrowing is then obtained as follows. Contours of the segment 
are detected by automated contour detection with the CAAS system as previously described. From the 
measured diameters along the analysed segment, the previously described diameter function is derived. 
On each scanline perpendicular to the local centerline direction of the vessel, a profile of brightness 
values is measured. This profile is transformed into an absorption profile by means of a simple 
logarithmic transfer function to correct for the Lambert-Beer Law. The background contribution is 
estimated by computing the linear regression line through the background points directly left and right 
of the detected contours. Subtraction of this background portion from the absorption profile within the 
perspex contours yields the net cross-sectional absorption profile. Integration of this function gives a 
measure for the cross-sectional area at the particular scanline. By repeating this procedure for all 
scanlines, the cross-sectional area function is obtained. An absolute reference densitometric area value 
can then be obtained by assuming a circular configuration in the reference segment and using the 
diameter measurements obtained from the diameter function. Figure 1 shows an example with the 
computed diameter function curve (upper curve) and area function curve (lower curve) displayed upon 
the video image. The minimal luminal cross-sectional area can then be calculated by the ratio of the 
absolute difference in brightness of the reference area and the narrowed segment, with the known cross-
sectional area of the reference segment. The complete procedure has been evaluated with the cinefilms 
of perspex models of coronary obstructions that did not contain stents. In this protocol, one frame from 
each study was analysed at least three times. 
RESULTS 
The densitometric assessment of the plexiglass models containing the stents is shown in Table 1. The 
theoretical minimal luminal cross-sectional areas of a 2 mm and 3 mm diameter phantom are 3.14 and 
7.06 mm2 , respectively. In the control phantom, the calculated minimal luminal cross-sectional area 
values ranged from 0-18% higher than the theoretical value in the 3x2 phantom, and was 8% higher in 
the 4x3 phantom (Figure 1a). Only minor increases in minimal luminal cross-sectional area (~8%) were 
noted in the phantoms that contained the Wallstent and Palmaz-Schatz stents compared with the control 
phantom except for the 3x2 phantom filled with 50% contrast medium (13 and 25% higher respectively). 
The minimal luminal cross-sectional area in the phantom containing the Wiktor stent was moderately 
higher (9-13%} than the control with 100% contrast medium. However, in the presence of 50% contrast 
medium, the Wiktor stent. had the most adverse effect (23-56% higher than control values) in the 
determination of the minimal luminal cross-sectional area. This effect was most pronounced in the 
smaller 3x2 phantom (Figure 1 b). 
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Figure 1. Control (A) and Wiktor-containing (B) plexiglass phantoms (3x2 mm) filled with 100% and 50% 
iopamidol contrast reagent respectively. Graphs show the diameter function (upper curve) and the 
densitometric area function (lower curve). Outside vertical fines on the graph and rightward two vertical 
lines on the phantom are lesion boundaries. The inner two vertical lines represent the minimal points 
on the diameter and densitometric graphs respectively. The multiple vertical lines in the left part of the 
graph and the leftward vertical line in the phantom represent the user defined reference segment. The 
numbers in the graph represent the maximum and minimum diameter. The boundaries of the Wiktor 
stem are visible in the phantom (arrowheads) and as a step-up in the densitometry graph (arrows). As 
a result of the Wiktor stent contribution to the densitometry values, the minimal cross-sectional area 
determination is overestimated compared with a control phantom. 
DISCUSSION 
This study illustrates two important points. First, in these particular models, densitometric 
determinations of minima! luminal cross-sectional area in control phantoms using the CAAS system are 
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overestimated. In most of the study conditions, this is a minor e-ffect except for the smaller diameter 
phantom at 100% concentration. This degree of error is in concordance with Whiting et al (10). 
Secondly, the addition of stents further contributes to an even spuriously higher measurement of the 
minimal luminal cross-sectional area, particularly with the Wiktor stent. 
The radiographic assessment of coronary stents includes several important features. During the 
procedure, the ability to visualize the stent is important for proper stent deployment to ensure adequate 
coverage of a lesion. The WiktorTM stent has a decisive advantage since tantalum is much more 
radiopaque than stainless steel, particularly at kv levels used in angiographic studies of the human 
thorax (Figure 2). Densitometry has a theoretical advantage over edge detection since it is a more direct 
measurement of stenosis cross·sectional area. This parameter appears to be more closely related than 
vessel diameter to coronary flow of hemodynamics (11). Thus densitometry may be an important method 
to evaluate the immediate angiographic result post stenting. and is particularly useful to analyse 
eccentric lesions since it is theoretically independent of the geometric shape. Although contour detection 
appears to be equally acceptable in Wallstent implanted lesions (3), it has been unreliable in some cases 
of Wiktor implantations due to detection of the radioopaque stent wires as the border instead of the 
narrowing within the stent (Figure 3). 
Figure 2. Radiopacity of three stems at two kilovoltage levels in plexiglass phantoms without contrast. 
(left) 50 kv, (right) 82 kv. J= Johnson and Johnson (Palmaz.Schatz™), W= Wallstenf, M= Medtronic 
(Wiktor™). The Palmaz·Schatz™ stem was not expanded in the phantom. 
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Figure 3. Edge detection and densitometric analysis of an obstruction within a Wiktor™ stent in the right 
coronary artery. The four vertical lines in the graph were explained in Figure 1. The boundaries of the 
stent are represented by the two horizontal lines in the angiographic image and the t\Vo outer vertical 
lines in the graph. A discrepancy between the t'No graphs is present and most severe at the vertical 
line which denotes the minimal densitometric value (arrowhead). The edge detection follows the outline 
of the stem and does not recognize the stenosis within the stem. 
This study suggests that densitometric assessment of Wiktor-containing lesions is also affected by the 
radiographic properties of this particular stent, especially in situations where the contrast medium is 
diluted or the vessel is not well filled. This effect consistently resulted in an overestimation of the minima! 
lumina! cross-sectional area by 9-56% from control values, depending upon the study conditions. 
Although the smallest differences between the Wiktor containing phantoms and control phantoms 
occurred with 100% contrast medium, these are also the conditions that resulted in the largest 
discrepancy between the control phantoms and the true values. Thus, the overall error in Wiktor 
containing phantoms with 100% contrast medium compared with the true value was in the range of 18-
33%. At a lower contrast reagent concentration. the overestimation of minimat luminal cross-sectional 
area in the Wiktor stent was more pronounced compared with the control phantom. especially in the 2 
mm phantom narrowing since there is relatively less contrast (and thus less iodine) present in the smaller 
phantom in comparison to the amount of tantalum contained in the stent wires. Therefore, the 
contribution of the stent wires to the overall densitometric value is more significant and results in the 
higher calculated values of the minimal luminal cross-sectional area. This may have important 
consequences in follow-up cases of restenosis where the vessel lumen may be critically reduced in 
calibre. 
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The radiopacity of a stent is affected by several variables including the composition of the material 
(and its atomic number). the total suriace area of the wires in the stent and the cross sectional area of 
the stent wires encountered by the X-ray beam in any particular projection. The Wiktor stent is made of 
radiopaque tantalum which, due to its higher atomic number than stainless steel has a higher attenuation 
constant and thus increased radiopacity than the two stainless steel containing stents. X-ray energy 
dispersion spectrometry studies were done in all 3 stents to determine if other metals were present that 
could alter the attenuation coefficient (Figure 4). The Wiktor™ stent contained only tantalum. The 
composition of the Wallstent and the Palmaz-Schatz stent were very similar except for the presence of 
cobalt in the WailstentR. However, this would only minimally affect the attenuation constant. 
Fe 
Ta 
Mo U~l 
=====-
Wallstent (Medlnvent) Wiktor stent (Medtronic) Palmaz-Schatz stent {J & J) 
Figure 4. X-ray energy dispersion spectometry identifies the composition of the metals used in each 
of the three stents. Mo~Molybdenum, Cr=Cromium, Co=Cobalt. Fe=lron, Ni=Nickel, Ta~Tantalum 
The cross sectional wire area of the stent is dependent on the number and thickness of the wire(s) 
at any particular point along the stent. This is more difficult to estimate in the Wiktor™ stent due to the 
asymmetric and helical design of the stent and the orientation of the wire loops. Consequently, the 
cross-sectional area of the stent is not uniform at each segment over the length of the stent. lt is 
estimated that at any one segment, a cross-section could contain from 4 to 8 cut wires w·1th a probable 
average of 6 wires. This corresponds to a cross-sectional area of the stent ranging form .0005 cm2 to 
.001 cm2 , and an average value of .00075 cm2. The total wire cross-sectional area of the Wailstent and 
Palmaz-Schatz stent, which are easier to calculate due to the more uniform design of each stent, are 
0.00062 cm2 and 0.00039 cm2 respectively. 
Since the composition and total wire cross-sectional area of the two stainless steel stents are nearty 
identical, It is not surprising that these two stents had a similar effect. This effect in general was quite 
consistent and minimaL Although the largest discrepancy between stainless steel stented and control 
phantoms occurred in the smaller phantom at 50% contrast concentration, these were the exact 
conditions that no overestimation of minimal luminal cross-sectional area occurred in the control 
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phantoms compared with the true value. 
In conclusion, densitometry may overestimate the minimal luminal cross~sectionar area in stented 
vessels. Relatively minor and probably clinically insignificant changes occur in the Palmaz-Schatz stent 
and the Wallstent. However densitometric analysis of lesions containing the Wiktor stent, particularly if 
the vessel is not well opacified, will result in serious overestimations of the minimal luminal cross~ 
sectional area. Clinical trials that compare various stents or stenting to PTCA using densitometry should 
consider this effect in tantalum containing stents. 
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Table 1. Videodensitometric determlnallon of minimal luminal cross-sectional area In plex!glass phantoms containing no (control) or 3 different metallic stents. 
(%) = % difference bet:ween the stented and control phantoms. 
lopam!dol Reference Stenosis Minimal Luminal Cross-Sectional Area (mm2) 
Concentration Diameter Diameter 
(mm) (mm) True Control Palmaz~Schatz Wallstent Wlktor 
100% 3 2 3.14 3.70±.10 3.55±.10 (-4%) 3.93±.11 (+6%) 4.17±.23 (+13%) 
4 3 7.06 7.61 ±.30 8.19±.25 (+8%) 7.78±.50 (+2%) 8.33±.21 (+9%) 
50% 3 2 3.14 3.14±.13 3.91 ±.31 (+25%) 3.54±.07 (+13%) 4.89±.08 (+56%) 
4 3 7.06 7.65±.21 7.92±.07 (+4%) 7.81 ±.50 ( +2%) 9.40±.38 (+23%) 
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Edge Detection Versus Densitometry for 
Assessing Coronary Stenting Quantitatively 
Bradley H. Strauss, MD, Yves Juilliere, MD, Benno J. Rensing, MD, 
Johan H. C. Reiber, PhD, and Patrick W. Serruys. MD, PhD 
The optimal method used to analyze quantitatively 
the immediate angiographic results of coronary 
stenting in the coronary arteries has not been stud-
ied. Accordingly, miniimalluminal cross-sectional 
area was determined by 2 methods, edge detection 
and densitometry, in :1.9 patients who underwent 
percutaneous transiuminal coronary angioplasty 
(PTCA) and then coronary stent implantation for 
symptomatic coronary stenoses. The correlation 
coefficient, 0.73 before angioplasty, decreased to 
0.59 after coronary angioplasty and then im:reased 
to 0.83 after stent implantation. The mean differ· 
enws between edge detection and densitometric 
determinations of minimal luminal cross-sectional 
area were 0.31 ± 0.51 mm2 before PTCA, -6.38 
± 1.22 mm2 after angioplasty and 0.35 ± 0.79 
mm2 after coronary stenting. It is concluded that, 
although the correlation and variability in the mea-
surement of minimal luminal cross--sectional area 
between edge detedion and densitometry deterio-
rate after PTCA, they are improved after stenting, 
probably because of smoothing of the vessel con-
tours by the stent and remodeling of the stentec!l 
segment into a more circular configuration. There-
fore, in the stented coronary artery, edge detection 
and densitometry are equa(Jy acceptable methods 
of analysis. 
(Am J Cardio! 1991:67:484-490) 
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S tenting of the coronary arteries is currently being investigated as an adjunct to percutaneous trans-luminal coronary angioplasty (PTCA). 1 The opti-
mal method used to analyze the immediate angiograph-
ic results of stenting in the coronary arteries has not yet 
been determined and is part of a general and unsettled 
controversy in the immediate assessment of PTCA. 
Computer-based automatic edge detection angiographic 
analysis systems have reduced the variability resulting 
from visual and caliper-determined contour detection.2·4 
but their use may be limited in eccentric lesions. partic-
ularly after angioplasty. when acute tears and dissec-
tions additionally distort the anatomy. Densitometry 
has been proposed as an alternative method of angie-
graphic assessment of the severity of coronary obstruc-
tions because it is independent of the geometric shape.s.o 
The hemodynamic significance of a lesion has previ-
ously been shown to be most closely correlated with the 
minimal cross-sectional area.7-~ The determination of 
this parameter from edge detection programs from a 
single projection requires an assumption. often incor-
rect. that the vessel cross section is circular.9.JO Our 
group has previously shown that discrepancies exist in 
the postangioplasty analysis between edge detection and 
videodensitometric methods. although conflicting data 
have also been published.5 • 11 • 1 ~ However. the situation 
after stenting of the coronary arteries may be altered. 
because the arterial wall typically assumes a smoother, 
more circular appearance. We therefore undertook this 
study to determine if stenting of coronary arteries after 
PTCA improves the correlation and agreement between 
videodensitometry and edge detection methods. 
METHODS 
Study patients: Nineteen patients. 13 men and 6 
women. ranging in age from 41 to 70 years (mean 56). 
were enrolled after giving informed consent for stent 
implantation. The dilated and stented coronary artery 
was the left anterior descending coronary artery in 12 
patients, the circumflex coronary artery in 2. the right 
coronary artery in 3 and a coronary artery bypass vein 
graft in 2. This series consisted of the first 19 patients in 
whom edge detection and videodensitometry were used 
to evaluate the immediate results of the procedure. In 
each patient. the coronary artery stenosis was dilated 
first. After successful angioplasty. the balloon catheter 
was exchanged for tl1e stent delivery system over a 
0.014-inch exchange guidewire. Unconstrained stents of 
15 or 20 mm in length. depending on the lesion. were 
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TABLE I Quantitative Angiographic Data 
Mln1m~llum1nJI Cross-Sect1onJI Arco 
Otx.truct1on Diameter 
Age(yr) PTCA Dlometer Stenosis Edge Detection Densitometry 
Pt. No &Se> Vessel (mm) (%) (mm2] (mm~ 
I PreP 70M Conduit 0.9 67 07 0.4 
PostP 2.2 24 3.8 4.7 
PostS 3.0 8 7.1 7.1 
2 PreP 70M Conduot 1.2 
" 
1.2 0.4 
PostP 1.6 22 2.1 2.3 
Po,; 2.3 10 4.1 2.3 
3 PreP 52M Roght 1.8 50 2.6 2.5 
PostP 2.1 46 3.5 5.3 
Po,; 2.8 23 61 57 
4 PreP 42M LAD 1.0 54 0.9 0.2 
PostP 1.6 31 2.1 19 
p- 1.8 23 2.5 27 
5 PreP 52M LAD 1.3 47 L3 0.9 
PostP 
- - - -
PO>tS 1.7 26 2.3 Ll 
6 PreP 46M Right 1.0 67 07 0.3 
PostP 1.8 46 2.5 4.8 
P~<S 2.5 2S 4.9 57 
7 PreP 69M LAD Ll 62 0.9 1.0 
PO>tP 1.6 40 20 21 
PO>tS 2.1 2S 3.5 3.0 
8 PreP 64F LAD 1.5 
"" 
1.8 2.0 
PMtP 2.0 26 3.3 30 
PO>t$ 22 21 3.8 3.6 
9 PreP 62F LAD 07 73 0.4 0.4 
PostP - - - -
p- 2.2 16 3.8 4.0 
10 PreP SIM LAO 1.7 27 2.2 1.4 
PostP 2.0 21 3.1 2.4 
PO>tS 2.3 IS 4.1 3.6 
11 PreP 41M LAO 06 81 03 0.3 
PO>tP 1.6 51 2.0 2.6 
PO>tS 2.5 30 4.9 3.8 
12 PreP SIF LAD 09 61 06 1.3 
PO>tP 2.1 25 3.5 4.3 
p- 2.0 26 31 2.9 
13 PreP 69M LAD 1.3 59 1.3 1.2 
PostP 2.1 30 3.5 3.5 
P~<S 2.4 20 4.5 4.5 
14 PreP SIF Right LO 60 0.8 0.3 
PostP 2.3 22 41 3.4 
PostS 2.4 21 4.5 5.0 
15 PreP 54M LC 1.2 52 Ll Ll 
PostP 1.6 39 2.0 2.6 
p,,; 23 26 4.1 4.1 
16 PreP SSF LC 0.8 61 0.5 0.2 
PostP 1.6 37 2.0 3.1 
Po,; 1.9 2S 2.8 2.6 
17 PreP 54F LAO 1.2 61 Ll 1.2 
PostP 1.7 35 2.3 4.5 
PostS 21 20 35 3.9 
18 PreP 52M LAO 1.9 52 2.8 1.2 
PostP 27 39 5.7 7.1 
PostS 1.9 36 2.8 2.5 
19 PreP 65M LAD II 63 D.9 0.0 
PostP 2.3 17 4.1 1.6 
Po,; 2.6 13 5.3 2.9 
MeJn±SD 
PreP { 1.2±0.4 
·{58± 11 1.2±0.7 0.9±0.7 
PostP 1.9±0.3 32±10 3.0±1.0 3.5± LS 
Po,; T { 2.3±0.3 ·{22±7 4.1 ± 1.2 3.9±1.4 
• p 8 0.0000;1 p-0.0002. 
t.AD • !eft ~ntcrlor d<:">Ccndmg 3rtery: LC- lett orcumflex ~rtery: PreP~ before IX'fCLit~""""' twn'l~m•n.:>l coroM<y ~nl)<lpbsty; P~tP- ~ncr IX'fCut~neo-us tr~n,<um•""-'' 
<;QTOrt.><y 3ng!O~<t>ly; PCI$tS n ~Iter st<'!1tlng; Right- right coronory Jrtery; SO ~ st.:.nd~rd d<""~IIOn. 
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placed to cover the entire dilated arterial segment. Med-
ications at the time of the initial angiogram were intra-
venous heparin. acetylsalicylic acid. dipyridamole, ni-
trates and calcium antagonists. Coronary angiograms 
were performed before and after angioplasty. and after 
stent implantation. 
Description of the stent: In this trial, the endovascu-
lar prosthesis, Wallstent®. was provided by Medinvent 
SA. Lausanne. The method of implantation and de-
scription of this stent have been reported previously. 13·14 
Pre PTCA 
MLCA BY EDGE DETECTION (MM~) 8r 
r- 0.73 / 
A 
B 
6 
/" 
.;"' 
/." 
~0 /·"". 
0 2 ' 6 
MLCA BY VIOEOOENSITOMETRY (MM1 
Post.PTCA 
8 Mr LCA BY EDGE OETECT>ON (MM ~ 
r- 0.59 
6 
0 2 4 6 
MLCA BY VIOEODENSITOMETRY (M~) 
8 
8 
This stent is a self-expandable. stainless steel-woven 
mesh prosthesis that can be positioned in the coro-
nary artery with the standard over-the-wire technique 
through an 8Fr or 9Fr guiding catheter. The device is 
constructed of sixteen 0.08-nun-wide wire tllaments. It 
is constrained in an elongated configuration on a 1.57-
nun-diameter delivery catheter, with the distal end cov-
ered by a removable plastic sleeve. As the sleeve is 
withdrawn. the constrained device returns to its original 
unconstrained larger diameter and becomes anchored 
against the vessel wall. Unconstrained stent diameter 
was selected to be 0.50 nun larger than the reference 
diameter of the stented vessel. 
Quantitative coronary angiography: All cineangio-
grams were analyzed with the computer-assisted cardio-
vascular angiography analysis system. which has been 
discussed in detail previously. 1 S- 1 ~ The important steps 
will be briefly described. Any area sized 6.9 X 6.9 nun 
in a selected cineframe (overall dimensions 18 X 24 
mm) encompasing the desired arterial segment can be 
digitized by a high-resolution CCD-camera with a reso-
lution of 512 X 512 pixels and 8 bits of gray level. Ves-
sel contours are determined automatically based on the 
weighted sum of the first and second derivative func-
tions applied to the digitized brightness information 
along scanlines perpendicular to the local centerline di-
rections of an arterial segment. A computer-derived es-
timation of the original arterial dimension at the site of 
the obstruction is used to defme the interpolated refer-
ence diameter. This technique is based on a computer-
derived estimation of the original diameter values over 
the analyzed region (assuming there was no disease 
Post Stent 
MLCA BY EDGE DETECTION (MM"J 
·r 
r- 0.83 
6· 
,. 
2 
oL·/--------~----~--~ 
0 2 
' 
6 8 
c MLCA BY VIOEODENSlTOMETRY (MM"J 
FIGURE 1. Individual data for minimal luminal a-ou-sectional area (MLCA) determined by edge detection and videodensito-
metry (A) before and (B) after pei'CUtaneou$ transluminal coronary angioplasty (PTCA) and (C) after stenting. Diagonal/inc, 
equal meU~~nments by the 2 methods. Values above line were higher by edge detection and below line higher by densitometry. 
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present) according to the diameter function. The abso-
lute diameter of the stenosis as well as the reference 
diameter are measured by the computer, which uses the 
known guiding catheter diameter as a calibration factor. 
All contour positions of the catheter and arterial seg-
ments are corrected for pincushion distortion. The mini-
mal cross-sectional area of the narrowed segment and 
the interpolated percent area stenosiS arc then derived 
by assuming a circular model and comparing the ob-
served stenosis dimensions to the reference values. The 
angiograpbic analysis was done using the view in which 
the arterial narrowing appeared the most severe and all 
interventions were performed. 
Densitometric .analysis: Densitometry is based on 
the approximate linear relation that exists between the 
optical density of a contrast~enhanced lumen and the 
absolute dimensions of the arterial segment. Constitu-
tion of the relation between the path length of the x-
rays through the artery and the brightness values re-
quires a detailed analysis of the complete x-ray /cine/ 
video chain, including the film development process. 
For the f:trst part of the chain, from the x-ray tube to 
the output of the image intensifier, we use Lambert 
Beer's law for the x-ray absorption and apply certain 
models for the x-ray source and the image intensifier. 
From the output of the image intensifier up to the 
brightness values in the digital image. we use a simple 
linear transfer function. Details of this technique have 
been described elsewhere.S·I5-IS 
The cross-sectional area of a vessel is then obtained 
as follo~s: When selecting a Cmeframe for the densito-
metric analysis. we ensure that the main axis of the seg-
ment is reasonably perpendicular to the incoming x-rays 
(i.e .• a nonforeshortening view is chosen). Contours of 
the artery are detected by automated contour detection 
as previously described. From the measured diameters 
along the analyzed segment, the diameter data de-
scribed above are derived. On each scanline perpendicu-
lar to the local centerline direction of the vessel. a pro-
flle of brightness values is measured. This proflle is 
transformed into an absorption proflle by means of a 
simple logarithmic transfer function. The background 
contribution is estimated by computing the linear re-
gression line through the background points directly left 
and right of the detected contours. Subtraction of this 
background portion from the absorption proflle within 
the arterial contours yields the net cross-sectional ab-
sorption profile. Integration of this function gives a 
measure for the cross-sectional area at the particular 
scanline. By repeating this procedure for all scanlines. 
the cross-sectional area function is obtained. A refer-
ence densitometric area is obtained following the same 
principles as previously described for the diameter mea-
surements. It is clear that homogeneous mixing of the 
contrast agent and the blood must be assumed for the 
measurement to be correct. The complete procedure has 
been evaluated with the cinefllms of Plexiglas® models 
of coronary obstructions. It> 
To determine whether the physical properties of the 
stent itself interfere with the densitometric assessment. 
Wallstents® were placed inside known stenoses within 
perspex models and the minimal luminal cross-sectional 
area was calculated by densitometry. These cylindrical 
models. 5 mm in diameter at the ends and tapering to 
either 2 or 3 mm in the center. were filled with iopami-
dol (50 or 100% concentration) and angiographic stud-
ies were done at 75 kV to approximate the clinical set-
ting. The calculated values for minimal luminal cross-
sectional area were 0 to 12% higher in the stented 
models. compared with identical phantoms that did not 
contain stents. 
Statistical .analysis: The individual data for minimal 
luminal diameter and minimal luminal cross-sectional 
area by edge detection and densitometry. respectively. 
were used to Calculate the mean value ±standard devi-
ation (Table I). Analysis of variance was performed to 
compare the mean minimal luminal diameter before 
and after PTCA and after stenting and. if significant 
differences were found, 2-tailed t tests were applied. A 
value <0.05 was considered statistically significant. 
To measure the strength of the relation between the 
2 methods of analysis-edge detection and densitome-
try-in determining minimal luminal cross-sectional 
area. the product-moment correlation coefficient (r) 
and its 95% confidence intervals were calculated at the 
3 distinct times of study. The agreement between the 2 
measures was assessed by determining the mean and the 
standard deviation of the between-method difference. as 
MEAN DIFFERENCE {mm~ 
3 
2 1 
' T 
' 
-
0 
-
-1 i-
' 
-2 '-
_,L ! 
PRE-PTCA POST-PTCA POST-STENT 
FiGURE Z- Mean difference between edge detedion and den~ 
sitometry and SS% eonfidenee intervals before and after per-
cutaneous transluminal coronary angioplasty (PTCA) and af-
ter stenting. Mean d"rfferences were slightly positive (O.:u. 
0.35 mm2) before PTCA and after stenting. respectively. and 
slightly negative {-G.38 rrzmZ) after PTCA. The widest 95% 
confidenee interwal WOI$ in the analysis after PTCA,. indicating 
the poorest association between the 2 methods, compared 
with the analysis. before PTCA and after stenting. 
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suggested by Bland and Altman. 1 Q At each interval this 
was done by computing the sum of the individual differ-
ences between the 2 methods to determine the mean 
difference and the standard deviation. 
RESULTS 
The individual data obtained by contour detection 
and videodensitometric analysis arc listed in Table I. 
There was an overall significant increase in the minimal 
luminal diameter and a decrease in percent diameter 
stenosis after angioplasty (1.2 ± 0.3 to 1.9 ± 0.3 nun 
and 58± 11 to 32 ± 10%. respectively) and after stent-
ing (2.3 ± 0.3 mm. 22 ± 7%). 
The correlation between edge detection and densi-
tometry in the assessment of minimal luminal cross-sec-
tional area before and after PTCA. and after stenting is 
shown in Figures IA. IB and lC. respectively. Before 
angioplasty. correlation coefficient was 0.73 (95% cop.fi-
dence interval. 0.41 to 0.89), indicating a reasonably 
linear relation. However. this deteriorated after PTCA. 
resulting in a correlation coefficient of 0.59 (95% confi-
dence interval. 0.15 to 0.83). However, linearity was 
significantly improved with the implantation of a coro-
nary stent (correlation coefficient. 0.83:95% confidence 
interval, 0.61 to 0.93). 
The agreement between the 2 measures is illustrated 
in Figure 2. The determination of minimal lumi.Tlal 
cross-sectional area was slightly higher by edge detec-
tion than by videodensitometry in the before PTCA and 
after stenting analyses (mean differences.. 0.31 and 0.35 
nun~. respectively) and slightly lower after PTCA 
(mean difference, -0.38 nun::). The variability as deter-
F1GUR:E 3. Edge contour and deftsitometrie analysis of an obstruction in the left anterior deseending (LAD) artery before perc;u-
taneous transluminail coronary angioplasty [PTCA] (A), during balloon inflation (B). ~ PTCA (C) and after stenting (D). 
Graplm show the diagnostic cfoameter function (upper eurre) and the densib>metric area function (lower curve). Lower hori:zo& 
tal line (0.81 mm in frame. A) is the minimal luminal d~meter. Outside verticalli'ncs on the graph and the 2 vertical/inc$ on the 
angiogram an: le$ion boundaries. Inner vertical lines on graph an: the site in the lesion of minimal lumina! diameter. In the an-
giogram before PTCA {A). eontour and densitometry curves Me paraDe!. There was a marked improvement in the minimal lumi-
na! diametC'J" of the lesion during baBoon inflation {B). After PTCA (C), contour and densitometry curves diverge {arrow) at the 
site of an inb-aluminal haziness (arrowhead). In the diameter 1unetion, there is a dcseencfmg limb of the curve that reaehes ana-
dir and immediately ls fo!Sowed by an ascending limb. However, the demftomctry curve shows a deseending ramb followed by a 
ptate.au. Aftet" stenting (D), the relation between the 2 curves is restored. 
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mined by the standard deviation of the differences be-
tween the 2 measurements was highest in the analysis 
after PTCA (1.22 mm~). compared to before PTCA 
and after stenting (0.51 and 0.79 mm~. respectively). 
A.."J. individual example is shown in Figure 3. 
DISCUSSION 
The ideal method by which to perform angiographic 
analysis after coronary interventions, including balloon 
angioplasty and stenting. remains debatable. Although 
densitometry is independent of geometric shape. its ap-
plication is limited in the presence of branch vessels that 
may cause errors in the background correction tech-
nique and in situations where the x-ray beam is not per-
pendicular to the long axis of the vessel. Additional clin-
ical factors that contribute to the inaccuracy of densi-
tometry include x-ray scatter. light scatter within the 
image intensifier (veiling glare) and beam hardening of 
the polychromatic x-ray flu.x because of iodine and tis-
sue thickness. Discrepancies between edge detection and 
densitometry are most likely to occur when the shape of 
the vessel wall at the level of the lesion deviates furthest 
from a circular configuration, because this is a basic 
assumption in the calculation of minimal luminal cross-
sectional area by edge detection. 
This study illustrates several important points. First. 
we have shown that a relation exists between the 2 
measurements at all stages of the procedure. but the 
A 
8 
strength of this relation. based on the magnitude of the 
correlation coefficient. deteriorates after PTCA and 
then improves after stenting. Furthermore. although 
mean differences between the 2 methods were small in 
all analyses. the greatest variability and thus the poorest 
agreement occurred in the analysis after PTCA. The 
before and after PTCA results are in accordance with 
earlier observations by our group.5 At that time we sug-
gested that measurement of cross-sectional area from a 
single view is inaccurate. Subsequent studies by Tobis et 
all 1 comparing edge detection in 2 orthogonal views and 
by Lesperance et al 1 ~ comparing single versus the mean 
of multiple views have shown similar and high correla-
tions both before and after PTCA. However. use of the 
correlation coefficient alone is not an adequate measure 
of agreement between 2 measurement techniques for 
several statistical reasons. 19·~o Determination of the 
mean and standard deviation of the between-method 
differenCes should be included in the analysis. 
Two factors probably contributed to the improved 
agreement after stem implantation. V esse! contours ap-
peared more regular and smooth and in some cases inti-
mal flaps appeared to be tacked back by the scaffolding 
property of this stent. However. even more important. 
the self-expanding property of this stem not only addi-
tionally dilated the vessel. but also probably remodeled 
the stented segment into a more circular geometry. This 
has previously been shown in vivo after the implantation 
of coronary stents in animals and in some human coro-
nary vessels (Figure 4. A. B and C). 
A potential limitation of densitometry in the analysis 
after stenting may be a spuriously high determination of 
minimal luminal cross~sectional area (up to 12% in the 
F1GURE 4. A, angiogram of left .anterior des.cending artery 
stenosis after dissection (arrow) during pcrart.aneous translu-
minal coronary angioplasty. B. angiographie appearance of 
krit .anteriw deseending artery lesion after stenting: sholring 
smooth a>ntour. C, in vitro intravascular ultrasound examina-
tion of this vessel 24 hours after stenting (patient d""l(!(l from 
intracerebl al hemorri'aage 12 hours after stenting:). The inner 
drde is: due to intravascu~r probe. The outer echodense pat~ 
tern is due to stem wires (large arrow). The lumen (small 
open arrow) is the echo-free space inside the stent. The stent 
effuetivefy tacked back the diuec:tion and restored the circ:u~ 
Jar configuration of the vessel (courtesy of 0,.. Bernardino 
Tuc:iiJo). 
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phantom studies) because of interference from the stent 
itself. This is probably related to the composition of the 
stent. surface area or additional factors. sur.h as in-
creased scatter in the stenotic section because of the 
stent. Although the mean differences in minimal lumi-
nal cross-sectional area between the edge detection and 
densitometry were small. the negative mean diff'!rence 
in the analysis after stenting (i.e .• larger values by densi-
tometry) in contrast to the positive mean difference af-
ter PTCA can be partly explained by this contributio:t 
of the stent to the densitometrically determined values. 
The effect of other currently available stents should 
be separately assessed and considered in angiographic 
analyses using densitometry. 
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ANGIOGRAPHIC FOLLOW-UP AFTER PLACEMENT OF A SELF-EXPANDING CORONARY-
ARTERY STENT 
PATRICK w. SERRUYS. M.D., BRADLEY H. STRAUSS, .M.D .• KEVI"' J. BEATT, ~LB., B.S .. 
MICHEL E. BERTRA~D, M.D._jACQt:"ES PUEL, M.D., ANTHOXY F. RICKARDS, M.B .• B.S., 
BERNHARD MEIER. :M.D.,jEAN·jACQUES Gov. M.D., PrERRE VocT, M.D., LuKAS K-\PPENBERGER, M.D., 
AXD lJLRICH SIGWART, M.D. 
Abstract Background. The placement of stents in cor· 
a nary arteries after coronary angioplasty has been investi-
gated as a way of treating abrupt coronary-artery occlu-
sion related to the angioplasty and of reducing the late 
intimal hyperplasia responsible for gradual restenosis of 
the dilated lesion. 
Methods. From March 1986 to January 1988, we im-
planted 117 self-expanding. stainless-steel endovascular 
stents (Wallstent) in the native coronary arteries (94 
stents} or saphenous-vein bypass grafts (23 stents} of 
105 patients. Angiograms were obtained immediately be-
fore and after placement of the stent and at follow-up 
at least one month later (unless symptoms required angi-
ography sooner}. The mortality after one year was 
7.6 percent (8 patients}. Follow-up angiograms {after a 
mean [±SDJ of 5.7=4.4 months) were obtained in 95 pa-
tients with 1 OS stents and were analyzed quantitatively 
by a computer-assisted system of cardiovascular angie-
graphic analysis. The 10 patients without follow-up angie-
grams included 4 who died. 
Results. Complete occlusion occurred in 27 stents in 
TWO major limitations of coronary angioplasty are acute occlusion and late restenosis. The con-
cept of implanting an endoluminal stent in the coro-
narv-arteries after balloon dilation to circumvent these 
problems was first suggested in 1964. 1 This procedure 
was successfully performed in patients in 1986.~ In 
May 1988, the five European centers testing this de-
vice agreed to set up a core laboratory for quantita-
tive angiographic analysis to assess the results ob-
jectively. The early follow-up results reported by 
the core laboratorv showed that immediatelv after 
stent implantation, .there was an additional inc;ease in 
the minimal luminal diameter of the vessel and a de-
crease in the percentage of stenosis of the diameter.> 
However, after three months slight but diffuse narrow-
ing was observed in the artery containing the stent:1 
In the present study, we have focused on the results 
From dx Cathe!enw.tion Labor-~tory. Ern,mu' Uoiv-er-.•ty. Roncrd.llm. the 
Nelhcrl~od' (P.W.S .. B.H.S .. K.J.B.); th~ Otvl>~on of Curdiolof:y. Departrru:nt 
of McdiCI!l<:. Centre Ho,pitalier Univc,.,otairc Vuudo"· Lau."'-"'ne. Swiu:c-rland 
(J.-J.G .. P.V .. L.K.): the Department of Oinocal and Spcnment.~l Curdiolor:y. 
Centr<: Ho,pita.licr Regional Un•v=•ta•re. RMf:UCJI. Toulou»e, Fruncc ().?.); th~ 
Dcparli!lalt of Clinical Mea.wrement, National Hcmln"itute. London (A.F.R .. 
U.S.); the Cardiology Center. Unive,.,ity Ho,pltal. Geneva (B.M.); and the De-
pattme-ntofCu-diolO):Y. Hiipita.l Cardiotog1que, L•lle. Fr-...ncc (M.E.B.). Addrc-.' 
reprint reque:;(l; to Dr. S<:my' at the Cat.hcteri7.:t!ion Laboratory. £ra_,mu' Uo•· 
vers~ty. P.O. Box 1738. 3000 DR Rotterdam. the Nethe-rland ... 
Supponcd in pan by ;-:r-..mt' from the Dutch Mini'tty of S<:Jcnce and Education. 
The Hague (87159). and from the Sw"' Natoonul Fund (3.<:35.083). Dr. Str-~u" 
;, lite rceipicm of o Re:-.eo.rch Fellow•Jup from lite Canadian Hem Foundation. 
Dr. Bean is the reciptcnt of a Rc,earch Fctlo.....,htp from the Bnti'h and l'cthcr-
lands Heart Foundation. 
25 patients (24 percent}; 21 occlusions were documented 
within the first 14 days after implantation. Overall, immedi-
ately after placement of the stent there was a significant 
increase in the minimal luminal diameter and a significant 
decrease in the percentage of the diameter with stenosis 
(changing from a mean [:tSD] of 1.88±0.43 to 2.48±0.51 
mm and from 37=12 to 21 =10 percent, respectively; 
P<0.0001}. Later, however, there was a significant de-
crease in the minimal luminal diameter and a significant 
increase in the stenosis of the segment with the stent 
(1.68=1.78 mm and 48±34 percent at follow-up}. Signifi-
cant restenosis, as indicated by a reduction of 0.72 mm in 
the minimal luminal diameter or by an increase in the per-
centage of stenosis to o::SO percent, occurred .in 32 per-
cent and 14 percent of patent stents. respectively. 
Conclusions. Early occlusion remains an important 
limitation of this coronary-artery stent. Even when the 
early effects are beneficial, there are frequently late 
occlusions or restenosis. The place of this form of treat-
ment for coronary artery disease remains to be deter-
mined. (N Eng! J Med 1991: 324:13-7.) 
of long-term angiographic follow-up of the initial 
117 stent implantations. 
METHODS 
Study Patients 
One hundred five P"-ticnb g;J.ve informed con~ent and were· en-
rolled at particip"-ting 'tudy center> between March 1986 and Janu-
ary 1988. The ~tudy protocol wa~ approved by tht" ethic~ commit· 
tee:- of the individu"-.1 ho~pitab. The clinical characteristic:>- of the 
P"-tienb are ~hown in Table l. 1\inety-five p.~ticnt' received one 
"cnt, and 10 received more th"-n one (T:oble 1). Seven of the 10 
putient~ who received multipk 'tenb rt-quired two overbpping 
(""tele:-coping'") 'tent' to cover long Je,ion' adequately, and the oth-
er 3 required ,tents in multiple vc"eb or in di!Ter-ent locution~ in the 
'ame ves.,eJ. The site' of 'tent placement are shown in T"-blc l. 
Seventy-<Jne ~tent.~ were implanted after rcdilation of a re:;teno,is. 
1+ were placed as "-n cmcrf!:ency procedure durins: an angioplasty 
complicated by .~cute occlu,ion, 5 were placed after angioplasty for 
chronic occlusion. and 27 were placed as an adjunct procedure to 
primary percutuncou' transluminul coronary angiopl"--'lY (PTCA). 
Some of the patienb who received stent.~ for bypa.% graftin~; or 
"-brupt clm.ure have been included in previou' reports.''·'• 
In thi' trial. the endovuscular prosthe:;i, \\'allstcnt (Medinvent, 
LaUS"-nnc, Switzerland) w.:.s used. The method of imp !an tation and 
a description of thi' ~tent have been prcviO"--'ly reported.' Thi' stent 
i, a self-exp"-ndinf', stainle,_,·,teel, woven-me:;h pro,the,is that can 
be positioned in the coronary arte!)· with an 8-French or 9-French 
,;:uidin,; catheter, according to the 'tundard over-the-wire tech-
nique. The device i' comtructed of 16 wire filament.,, each 0.08 mm 
wide. It is constr;J.ined in an elong<Hcd confit:;uration on a deliver.· 
cathet~r 1.57 mm in diameter; the di,tal end of the prosthesi., ~' 
covered by a removable pb.,tic 'lccvt". A' the :Jeeve i._.; withdrawn, 
the constrained device return' to it' ori~inal. lary;:er diameter and 
becomes unchored again't the ve,._,e] wall. The di"-meter of the 
pro,thesix range:; from 2.5 tO 6 mm when the stent is uncon~traincd. 
Reprinted from the New England Journal of Medicine 
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Table 1. Clinical Characteristics of the Study 
Patients. 
No. of patient< 
Age (yr)" 
Sex {M/F) 
No. ofstenlS 
Site of >-~<:m impl:.nwtion (no. of stent') 
Ldt :.ntenor decending artery 
Circumflex artery 
Right wronnry :mery 
Bypa:.s gmft 
lndJCation for impl:mtlltion (no. of stent<) 
Resteno,;,. 
PTCA with aeute occlw.ion 
PTCA as adjunct procedure 
Chronic ocdusion 
Tm1e to angiographic follow-up {mo)• 
All patients 
Patients with patent <tents 
No. of stent:. per patient (no. of patients) 
""' T~
Th= 
·~"""'"so. 
'" 57:!:9 
9II14 
"' 
" 6 
" 
" 
" 
" 
" 5 
S.7:!:4A 
7.1:!:3.6 
95 
8 
We selected a diameter 0.50 mm larger than the reference diameter 
of the stenosed vessel. 
Anticoagulation regimens evolved throughout the study p<:riod, 
and different protocols were used at the various centers. In the fir:;t 
23 of the 32 patients treated in Toulouse, heparin was administered 
subcutaneously three times a day to ma.inuin the activated cepha-
lin-kaolin time (an index of coagulation status) at twice the control 
value, starting three to five days before the procedure and continu-
ing for six weeks afterward. During the procedure, the 7th through 
the 32nd .patients received an additional 10,000 units of heparin 
intr..venously and 20,000 to 50,000 units of streptokinase by intr..-
coronary infusion. Aspirin (100 mg) and dipyridamole (300 mg) 
were given daily by mouth, starting 24 hours before the procedure. 
The 24th through the 32nd patient.~ treated in Toulouse re<:cived a 
vitamin K antagonist (warhrin or acenocoumarol) by mouth, start-
ed on the day of the procedure and continued for three to six 
months. The subcutaneous heparin inje<:tions were stopped after a 
therap<:utic level of or..! anticoagulant was reached (International 
Normalized Ratio, ;;,:2.3). In the other c~ntcrs, aspirin (1 g or..lly) 
was started one day before the procedure. Heparin (10,000 to 15,000 
units) and urokinase (100,000 units by inrracoronary infusion) were 
administered during the procedure. Heparin was given intravenous-
ly, and then the vitamin K antagonist by mouth for three to six 
months as described above. Aspirin (initially 1 g daily and later 100 
mgdaily). dipyridamole (300 to 450 mg daily), and in some patient> 
sulfinpyra.zone (400 mg daily) were also administered. The first four 
patients treated in Rotterdam did not receive aspirin. 
Quantitative Coronary Arteriography 
All cineangiograms were analy..:ed at the core labor..tory in Rot-
terdam by means of a computer·a.~sisted cardiovascular-angiogr..-
phy analysis system. discu>J.SCd in detail elsewhere. 7·" The imporr:mt 
steps will be briefly described. Selected areas of the cine frame 
encompassing the desired arterial segment were optically magni-
fied, displayed in a video format. and then digitally converted. Ves-
sel cont~ur was determined automatically on the b...,is of the 
weighted sum of the first and second derivative functions applied to 
the digiti..:ed information on brightness. A computer-derived esti-
mation of the origlnal dimensions of the artery at the site of the 
obstruction was used to determine interpolated reference values for 
arterial diameter and area. The absolute diameter of the segment 
with stenosis as well as the reference diameter was measured bv the 
computer. which used the diameter of the guiding catheter -as a 
calibration Gctor. after correcting for pincushion distortion. The 
interpolated percentage of stenosis of the narrowed segment was 
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then derived by assuming a circular model and comparing the ob-
served value for stcnosi~ with the reference value. The minim;,.] 
luminal diameter of each segment immediately proximal and distal 
tO the stent was also measured. The angiographic analysis was per-
formed b.-fore and after angioplasty. immediatdv after stt'nt im-
plantation. and at lon!<·term follow-up <.'valuation in all patients, 
with the use of the average of multiple match~d view~ with orthog-
onal projections whenever po~~ible. 
Restenosis 
Two different sets of criteria were applied to determine the r..te of 
restenosis. We have found a reduction of 0.72 mm or more in the 
minimal luminal di.amctt'r to be a reliable indicator of angiographic 
progression of vessel narrowing. 7·" This value takes into account the 
Jimiutions of coronary angiographic me...,urt'ment>. and represents 
twice the long-term variability of repeat mca:;urements of a coro-
nary-artery obstru<:tion with the cardiovascular-angiography analy-
sis svstem. The other criterion for restenosis w;u; an increa.~e in the 
p<:rc~ntage of stenosis from 1~ than 50 p<:rcent after stent implan-
ution to 50 p<:rcent or more at follow-up evaluation. Thi~ criterion 
was selected since common clinical pr..ctice has continued to ex-
press lesion severity as a percentage of stenosis. 
Statistical Analysis 
Values obtained by quantitative angiogr..phic analysis arc ex-
pressed a:; mean..~ ~SD. The mean:; for each angiographic variable 
before PTCA, after PTCA, immediately after placement of the 
Stent, and at follow-up were compared by analysis of variance. If 
~ignificant difference:~ were found, two-tailed !-tests were applied to 
paired data. A sutistical probability of les.s than 0.05 was consid-
ered to indicate significance. 
The results of angiographic and clinical follow-up were expressed 
in a life-table format according tO the Kaplan-Meier method. 10 
Stent occlusions. cardiac deaths (which were a.~sumed to be due to 
occlusion, for sutistica! purposes). and r~stenosis as defined by the 
two criteria were considered angiographic end point.~. The following 
event.~ were considered clinical end points: death. myocardial in-
farction, bypa:;s sur,-:ery, and nonsurgical rcvuscularization (PTCA 
or athcrectOmy). The life rabk wa.~ constructed according to the 
initial clinical event. 
REsuLTS 
The overall mortality after one year was 7.6 percent 
(eight deaths) (Table 2). The mean (±SD) period of 
angiographie follow-up was 5.7::!:::4.4 months in all pa-
tients and 7.2±3.6 months in patients whose stents 
were patent at follow-up. Angiographic follow-up 
(Fig. 1) was performed in 95 patients (90 percent) 
with 105 stents (90 percent); 78 stents were patent, 
and 27 were occluded (Table 3). Angiographic follow-
up could not be obtained in 10 patients for the follow-
ing reasons: 4 patients died, 4 refused follow-up angi-
ography, and 2 had follow-up angiograms that were 
technically inadequate for analysis (but did not show 
total occlusion). Twenty angiograms were obtained 
during the first month after stent implantation; all 
were obtained because clinical symptoms had oc-
curred, and all showed occlusions. Angiograms ob-
tained after the first month were part of the routine 
follow-up evaluation; all showed patent stents except 
in five patients with stent occlusions. Overall, the 
minimal luminal diameter increased from 1.21::!:::0.56 
mm to 1.88::!:::0.43 mm after PTCAand then further, to 
2.48::!:::0.51 mm, immediately after stent implantation 
(P<O.OOO 1) because of the intrinsic dilator function of 
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the device (Table 4). At follow~up the diameter was 
found to have decreased to 1.68± 1.20 mm. The per* 
centage of stenosis changed similarly, with an initial 
decrease from 61±14 to 37±12 percent after angio~ 
plasty and an additional decrease to 21±10 percent 
immediately after stent placement (P<O.OOOl). How~ 
ever, at follow~up the percentage of stenosis had in· 
creased to 48:!::34 (P<O.OOOl). When only patent 
stents were included in the analysis of late follow-up, 
the minimal luminal diameter and the percentage of 
stenosis were 2.26±0. 78 mm and 30::<.: 17 percent. re-
spectively. A small, nonsignificant increase occurred 
in the reference diameter after stent placement (from 
3.15±0.54 to 3.22±0.79 mm). During the study, no 
significant change was seen in the minimal luminal 
diameter of the proximal or distal segments adjacent 
to the stent. 
The incidence of restenosis (Fig. 2) depended on the 
definition of stenosis (Fig. 3). When a change of 
~0. 72 mm in minimal luminal diameter was used as a 
criterion, restenosis was observed within the patent 
stent in 17 patients (19 stents), in the proximal seg~ 
ment adjacent to the stent in 3 patients, in the segment 
immediately distal to the stent in 2 patients, and in 
both proximal and distal regions in I patient. There~ 
fore, the total rate of restenosis was 32 percent among 
stents and 33 percent among patients. At follow·up the 
percentage of stenosis had increased to ~50 percent 
within 10 stems (13 percent) in 9 patients (13 percent) 
and in the segment proximal to the stent in 1 stent in 
I patient, for a total rate of 14 percent. After one year 
of clinical follow~up, two of the patients with resteno~ 
Table 2. Deaths after Stent Implantation. 
PAnr.NT T! .. L MT!Oil 
NO l"P1.ANTATION CAC'"· or DLATH 
<14 hr Stenl ocdu:<.oon :U"!er vc...'-C! cl<>"U"' 
during PTCA 
4.$ hr Sudden dca!h 
2 day' Stcm ocdu,ion af!er 2-t hr. followed by 
erne~ bypa." proccdu~ 
8 day' Stcnl ocdu,.ion durint implanumon. 
myocardial inf:u-ction. ~hock 
II day' Sudden dca!h 
I Y.- mo Sudden dcalh 
2Y.- mo Surgery for new lc;ion of lef! mrun ar-
tery. after bypa." procedure 
6 mo Chronic conge,live heart faiiLl"' 
sis underwent repeat balloon angioplasty, one patient 
(two stems) underwent atherectomy, performed with· 
in the narrowed stent, and six patients underwent cor~ 
onary bypass surgery. Death or myocardial infarction 
did not occur in any of these nine patients. 
DISCUSSION 
The data from the six European centers at which 
the coronary~artery stent described abJve was used 
show a stent~ocdusion rate of 24 percent. The antico~ 
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Figure 1 Anglographic and Clinical Follow-up In 95 Patients Who 
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Received 1 OS Stents. 
Occlusion of the stent, cardiac death, and restenosis as deter-
mined by either or both of the criteria used {~50 percent stenosis 
of the vessel and a change of ~72 mm in the minimal luminal 
diameter) were considered angiographic end points (Panel A). 
Death, myocardial infarction, bypass surgery. and PTCA or ather-
ectomy were considered clinical end points (Panel B). 
agubtion regimens and methods for selecting patients 
differed among the centers, which may explain some 
of the variability in the occlusion rates between 
centers. The highest occlusion rate (39 percent) was 
observed at the Toulouse center, where the initial 
patients were treated with long~term subcutaneous 
heparin after placement of the stent, instead of a vita~ 
min K antagonist. The clinical factors that contribut~ 
ed to the occlusions could be identified in II patients 
- i.e., disorders of the coronary artery that arc asso~ 
ciated with thrombosis (unstable angina, recent myo~ 
cardia! infarction, and chronic occlusion) in 5 pa-
tients, technical problems in stent placement in 
3 patients, interruption of anticoagulation because of 
Table 3. Findings at Angiographic Follow-up. 
No_ 0> $~LN"J'; NO- O• hTIC-Nn 
1:-1 ~ !171 (N- IOSl 
Pment _,ten! 78167) 70 (67) 
O:cluded ~len! 27 (23) 25 (14) 
No follow-up angiography 
""""' 
6 (5) 4 (4) 
Refuo.al 4 (3) 4 (4) 
Iruodequate >ludy 2 (2) 2 (2) 
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Table 4. Findings at Quantitative Angiography.* 
A11"ut $TLNT 
IMI"lANTAT!O' AT Fo!.LOW·U~ 
Minim.al 1urmnal diameter (mm} 
S~nO>t~ (%} 
1.21:!:0.56 L\0l::0.43 Z.48:o:0.51 
Zl:':IO 
Z.Z6:o:0.73 
30:!:17 
1.6&:!:1.20 
4&:34 61:!:14 37~.1~ 
P<0.0001 P<O.OOOI P<O.OOOl 
P<O.OOZ 
·vo~~><> (mcJlll> :::SD) w<= cornpar«l by anaiY"""f >ananc<. lf ''~nH1CMt dJffeo:oc.-.. w.:rc foond. """"'"-lied t·tN> w= appll<d '" pon-.. of <i<ua. A probobthty oro OS """-' 
conotdered 10 tnd!cmte ola!l>tlcal olgnificane<. 
A 
B 
Figure 2. Restenosis Six Months after Implantation of a Stent in a 
Bypass Graft. 
In the follow-up angiogram (Panel A), the outline of the stent 
appears slighly radiopaque and hyperplasia has resulted in a 
complex narrowing within the vessel segment containing 
the stent. 
In the gross specimen (Panel B) of the surgically retrieved bypass 
graft containing the segment shown in Panel A, the longitudinal 
cross section of the vessel shows the stent filaments (arrow) pro-
truding from the wall. The striking similarity between the angie-
graphic contours of the vessel and its actual appearance 
is evident. 
bleeding problems in 2 patients, and hemodynamic 
compromise before placement of the stent in 1 patient 
with cardiogenic shock. In view of the early expe-
rience with stent occlusion, the investigatOrs agreed 
to avoid placing stents in patients with acute coro-
nary artery disorders and chronic occlusions or in pa-
tients with poor distal runoff (vessels with collat-
eral flow, small vessels less than 3 mm in diameter, 
or vessels supplying akinetic or severely hypokinetic 
myocardium). In addition, four patients with six 
stents died before undergoing angiographic follow-
up. Some of these deaths were sudden, suggesting 
possible stent occlusion. It was difficult to determine 
whether late occlusion (after 14 days) was super-
imposed on marked restenosis. Therefore, the rates 
of occlusion and restenosis may have been underesti-
mated. 
The patients in this study underwent two serial 
interventions, balloon dilation and then stent implan-
t:nion. Quantitative coronary angiography showed 
that the initial etfect of angioplasty in t_hese patients 
was similar to that observed in previou$ angiograph-
ic studies.ij- 1 ~ and moreover, the result immediately 
after placement of the stent was markedly improved. 
However. the minimal luminal diameter in the entire 
study group at follow-up (including patients known 
to have occlusions) was 1.68 mm, which is compa-
rable but not superior to values previously document-
ed in late follow-up studies of coronary balloon 
angioplasty (1.69 to 1.82 mm)_R.II The rate of re-
stenosis in patent stents, when based on a change 
of ~0. 72 mm in the minimal luminal diameter, was 
23 percent among segments within the stent and 
8 percent among segments adjacent to the stent, for a 
total rate of 31 percent. When the alternative crite-
rion, ~50 percent stenosis of the luminal diameter. 
was used, the rate of restenosis was 13 percent 
among seg-ments within the stent and l percent among 
segments adjacent to the stent. Two previous stud-
ies that used similar quantitative methods for late 
follow-up evaluation after coronary balloon angio-
plasty have been published. In one study,8 the reste-
nosis rate for angiograms obtained at four months 
was 25.5 perccnt when the criterion of a change of 
0.72 mm was used, and 13.2 percent when the crite-
rion of 50 percent stenosis was used. In the other 
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Figure 3. Change in the Minimal Luminal Diameter of 78 Patent 
Stents between Stent Implantation and Anglographic Follow-up. 
The diameter of each segment immediately after implantation Is 
plotted against the diameter at follow-up. The lines on each side 
of the identity line (diagonal) represent the limits of long-term 
variabillty of repeat measurements (a change of :;,Q.72 mm 
[arrows]). The symbols below the right-hand line represent 
stents with involvement by severe hyperplasia. 
study, 12 when the criterion of 50 percent stenosis was 
used, the restenosis rate was 37 percent for angie-
grams obtained four to seven months. after angio-
plasty. 
Studies in animals have confirmed that fibrointimal 
hyperplasia may develop in arterial segments contain-
ing stems. Within one week after stents (Wallstent) 
were implanted in normal porcine arteries, the pros-
theses became completely covered by endothelium 
and the vessel lumen had diffuse narrowing, varying 
in thickness from 60 to 125 J.Lm. 13•14 By si." months. 
the thickness of the ncointima increased from SO 
to 400 ,u.m, 15 corresponding to a decrease of 0.1 to 
0.8 mm in the vessel diameter. 
Early thrombotic occlusion remains a serious clini-
cal problem with this prosthesis despite anticoagula-
tion. It remains to be detennined whether increased 
experience of operators. changes in the anticoagula-
tion regimen, or selection of patients will circumvent 
this limitation. New biologic coatings that may make 
the stent less thrombogenic are currently under inves-
tigation. Angiographically detectable narrowing, 
probably due to fibrointimal hyperplasia, occurs to a 
marked degree in patients whose stents are patent at 
late follow-up. Although si."' months is assumed to be 
the time frame for the development of restenosis after 
angioplasty, this may not be true of stent implanta-
tion. The clinical indications for the use of an endo-
,;ascular prosthesis remain unclear. Controlled clini-
cal trials are imper:J.tive tO determine whether such 
devices can decrease the rate of resrenosis among pa-
tients who have undergone PTCA and whether they 
can be of any benefit in particular clinical situations or 
subgroups of patients. 
\\-'o: arc indebted to Dr. jan Ty~sen. Dr. Ro~er Thalmann. :Marie-
Ango!le MoreL and Eline :Mont:wb . .m van Swijndregt for a~'istance. 
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Abstract 
Background: Late angiographic narrowing has been observed following coronary implantation of the 
WallstentR_ To identify the angiographic variables that predict restenosis within the stented segment, a 
retrospective study of data from the European Wal!stent core laboratory was performed. 
Methods and Results: Fol!ow-up angiograms (excluding patients wtth in hospital occlusions) were 
analyzed for 214 lesions in 176 patients (78% restudy rate). The incidence of restenosis within the 
stented segment was 35% by lesion and 35% by patient for Criterion 1 (~0.72 mm loss in minimal 
luminal diameter) and 24% by lesion and 24% by patient for Criterion 2 (diameter stenosis ~50% at 
follow-up). The association between 16 variables and restenosis was determined by a relative risk ratio 
assessment Variables with significant risk ratios for restenosis with Criterion 1 were use of multiple 
stentsjlesion (relative risk 1.56, 95% confidence interval (C!) 1.08-2.25) and oversized (unconstrained 
stent diameter exceeding reference diameter >0.7 mm) stents (relative risk 1.64, 95% Cl 1.10-2.45); and 
for Criterion 2, oversizing by >0.70 mm (RR 1.93, 95% Cl1.13-3.31), bypass grafts (relative risk 1.62, 
95% C! 0.98-2.66), use of multiple stentsjlesion (relative risk 1.61, 95% C! 0.97-2.67) and residual 
diameter stenosis > 20% post stenting (relative risk 1.51, 95% Cl 0.91-2.50). 
Conclusions:lt is concluded that several angiographic variables are significantly associated with late 
angiographic narrowing after stenting in the coronary arteries. We suggest that stent operators avoid 
excessive oversizing in the selection of stent diameter and the use of multiple stents per lesion to lessen 
the risk of late restenosis. 
Key Words: Stents, Coronary Angioplasty, Restenosis, Coronary Artery Disease 
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INTRODUCTION 
The implantation of stents in coronary arteries or saphenous vein bypass grafts as an adjunct or 
alternative to percutaneous translumina! coronary angioplasty (PTCA) was initially proposed to prevent 
late restenosis (1). Since March 1986. the coronary WallstentR has been the most intensively studied 
endovascu!ar prosthesis in Europe. As a result of cooperation among the six participating European 
centers, a central core laboratory was set up in Rotterdam to objectively assess the follow up of stents 
with quantitative coronary angiography. In our previous report on the initial117 stents implanted in 1 OS 
patients, we observed that late angiographic narrowing occurs in a signfficant number of patients (2). 
To further characterize the factors associated with angiographic restenosis within the stented segment, 
we retrospectively studied the predictive ability of several angiographic variables, based on our 
experience of 214 separate lesions implanted with the coronary Wallstent in 176 patients. Since the core 
laboratory was set up only as an angiographic data bank, detailed clinical data was not available for this 
analysis. 
METHODS 
Study Patients 
Two hundred and sixty-five patients were enrolled after obtaining informed consent between March 
1986 and March 1990 at the six participating centers. The study group consisted of 222 men and 43 
women with a mean age of 58 ± 1 1 years. Sixty-two percent of the stents were implanted in native 
vessels and 38% were placed in bypass grafts. In the overall group, angiographicfollow up was obtained 
in 218 patients (82%). However in-hospital occlusions (40 patients, 41 lesions) were excluded from this 
study since these were definite thrombotic events and the objective of this study was !ate angiographic 
narrowing. Follow-up angiograms were quantitatively analyzed in 176 patients (78%) of the 225 patients 
who were discharged from hospital without known occlusion (Figure 1 and 2). Patients could not be 
restudied for the following reasons: death (n = 10), early bypass surgery as per protocol for the MbaH-outM 
indication at one institution or due to contraindication to anticoagulation (n= 11), anglograms that were 
technically inadequate for quantitative analysis (n=3) or refusal for restudy (n=25). The study group 
consisted of 176 patients who had a total of 259 stents implanted in 214 lesions. The mean length of 
angiographic follow-up in the study group was 6.6 ± 4.8 months. 
In this trial. the endovascular prosthesis, WallstentR, was provided by Medinvent SA, Lausanne. The 
method of implantation and description of this stent has previously been reported (1 ,2). This stent is a 
self-expandable stainless steel woven mesh prosthesis that can be positioned in the coronary artery 
using standard over-the-wire technique through a SF or 9F guiding catheter. The device is constructed 
of 16 wire filaments, each 0.08 mm wide. 
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Hospital discharge 
No occlusion 
Patients 225 
Lesions 267 
Patients 265 
Lesions 308 
In hosp.ltal (Early) 
Occlusions 
Patients 40 ( 1 5%) 
lesions 4 1 ( 13%) 
Late Angiographic Follow up 
Yes (78%) 
Patients 176 
Lesions 214 I 
No (22%) 
Patients 49 
Lesions 53 
Figure 1. Flow diagram showing the angiographic follow-up in 265 stented lesions. In hospital (early) 
occlusions occurred in 40 patients (15%). In the remaining 225 patients that were discharged from 
hospital without known stent occlusion, 176 patients (78%} with 214 stented lesions had quantitative 
angiographic follow-up. 
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Figure 2. Timing of late angiographic follow-up after stent implantation. In this cumulative cuNe, the 
inteNal (in months} between date of implantation and final angiographic follow-up is shown for the study 
group. 
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It is constrained in an elongated configuration on a 1.57 mm diameter delivery catheter with the distal 
end covered by a removable plastic sleeve. As the sleeve is withdrawn, the constrained device returns 
to its original unconstrained larger diameter and becomes anchored against the vessel wall. 
Unconstrained stent diameter ranged from 2.5-6 mm and was selected to be 0.50 mm larger than the 
stented vessel based on a visual estimate of the pre stent angiogram by the investigator. In an effort to 
alleviate the problem of acute thrombosis, the stent design was changed in April 1989 with the 
introduction of a polymer coated stent (Biogold~ for certain stent sizes. By August 1989, all 
manufactured stents contained this particular polymer coating. 
Quantitative Coronary Arteriography 
All cineangiograms were analyzed at the core laboratory in Rotterdam using the computer assisted 
cardiovascular angiography analysis system (CAAS) which has previously been discussed in detail (3,4). 
The important steps will be briefly described. Selected areas of the cineframe encompassing the desired 
arterial segment (from side branch to side branch) are optically magnified. displayed in a video format 
and then digitally converted. Vessel contour is determined automatically based on the weighted sum of 
the first and second derivative functions applied to the digitized brightness information. A computer· 
derived estimation of the original arterial dimension at the site of the obstruction is used to define 
interpolated reference diameter and area. The absolute diameter of the stenosis as well as the reference 
diameter are measured by the computer which uses the known guiding catheter diameter as a 
calibration factor, after correction for pincushion distortion. The percentage diameter of the narrowed 
segment is derived by comparing the observed stenosis dimensions to the reference values. The length 
of the lesion (mm) is determined from the diameter function on the basis of a curvature analysis. Using 
the reconstructed borders of the vessel, the computer can calculate a symmetry coefficient for the 
stenosis. Differences in distance between the actual and reconstructed vessel contours on both sides 
of the lesion are measured. Symmetry is determined by the ratio of these two differences with the largest 
distance between actual and reconstructed contours becoming the denominator. Values for symmetry 
range from 0 for extreme eccentricity to 1 for maximal symmetry {that is, equal distance on both sides 
between reconstructed and actual contours). The angiographic analysis was done pre and post 
angioplasty, immediately post stent implantation and at long term fo!low·up in all patients using the 
average of multiple matched views with orthogonal projections wherever possible. 
Restenosis 
The restenosis rate was determined according to two criteria. We have found a loss in minimal luminal 
diameter (MLD) of 0.72 mm or more to be a reliable indicator of angiographic progression of vessel 
narrowing (3,4). This value takes into account the limitations of coronary angiographic measurements 
and represents twice the long term variability (ie.the 95% confidence interval) for repeat measurements 
of a coronary obstruction using CAAS. The second criterion for restenosis was an increase in diameter 
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stenosis (OS) from less than 50% after stent implantation to greater than 50% at follow-up. This criterion 
was selected since common clinical practice continues to assess lesion severity by a percentage 
stenosis. 
Angiographic Variables 
Based on the quantitative angiographic data. multiple variables were identified and recorded for each 
lesion. These variables. either discrete (two or three distinct responses) or continuous (a range of 
responses), were grouped according to lesion, stentor procedural factors (Tables 1.2). These particular 
variables were of a priori clinical interest on the basis of previously published PTCA and stent reports 
(5-11 ). 
Statistical Methods 
A relative risk analysis was performed for the aforementioned discrete and continuous variables {12). 
The continuous variables were dichotomized for the risk ratio analysis. To avoid arbitrary subdivision of 
data in continuous variables, cutpoints were derived by dividing the data into two groups, each 
containing roughly 50% of the total population. This method of subdivision has the advantage of being 
consistent for all variables and thus avoids any bias in selection of subgroups which might be 
undertaken to emphasize a particular point. The incidence of restenosis in the two groups was compared 
using a relative risk analysis. A relative risk of 1 for a particular variable implies that the presence of that 
variable poses no additional risk for restenosis; relative risks greater than 1 or less than 1 imply 
additional or a reduction in risk. respectively. For example a relative risk of 2 for a particular parameter 
implies that the presence of that factor increases the likelihood of restenosis by a factor of two. The 95% 
confidence intervals were calculated to describe the statistical certainty. Statistical significance was 
defined as p < 0.05. and was determined using the Pearson Chisquare (BMDP statistical software, 
University of California, Berkeley, California, 1990). 
RESULTS 
The incidence of Krestenosis" depended upon the definition. Using a criterion of a change in minimal 
luminal diameter of ~ 0.72 mm, restenosis occurred within the stented segment in 35% of lesions and 
35% of patients. An increase in percent diameter stenosis to ~ 50% at follow-up was seen in 24% of 
lesions and 24% of patients. 
The relative risk and 95% confidence intervals for each variable using either of the two criterion for 
restenosis are shown in Figure 3. The variables with statistically significant associations with restenosis 
using the 0.72 mm criterion were multiple stents and oversizing the stent (unconstrained diameter) with 
respect to the reference diameter by more than 0.70 mm which had relative risk ratios (RR) (and 95% 
confidence intervals (CI)) of 1.56 (1.08-2.25) and 1.64 (1.1 0-2.45) respectively. The second criterion, 
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:;.;SO% diameter stenosis at follow up, was associated with oversizing by >0.70 mm (RR 1.93, 95% Cl 
1.13-3.31), bypass grafts (RR 1.62. 95% Cl 0.98-2.56). multiple stents(lesion (RR 1.61. 95% Cl 0.97-2.67) 
and residual diameter stenosis > 20% post stenting (RR 1.51, 95% Cl 0.91-2.50). The actual restenosis 
rates for these variables are included in Tables 3 and 4. 
N fo.5;1.Sf2.S~ 0 0.5 1 1.:5 2 2.:5 3 
VESSEL BRANCH-LAD 571111 
-
STENT TYPE-NORMAL 160/214 
REFERENCE DIAM. (> 3.25) 89/199 
INTRASTENT DILATATION 74/200 
INDICATION PRIM. PTCA 90/214 
-STENT LENGTH (>20mm) 102/214 
-MLD-PRE < 1.12 mm 101/206 
t.. POST STENT {>1.3mm) 107/206 
OS-PRE > 60'Y. 1051206 
SYMMETRY (< O.S8) ss11ea 
-
STENT DIAM (~ 3.Smm) 104/198 
LESION LENGTH (> Smm) 102/197 
OS-POST (> 20'Y.) 107/209 
STE_NT NUMBER-MULT. 45/214 
VESSEL TYPE-BYPASS 103/214 
OVERSIZE(> 0.7mm) 901186 
-
____ ..,, 
Figure 3. Relative risk ratios (with 95% confidence intervals} tor the angiographic variables using the 
two restenosis criteria ( :<!0.72 mm loss in minimal luminal diameter from immediately post stenting to 
follow-up and diameter stenosis :<!50% at follow-up). The relative rlsk is indicated by the thick vertical 
line in the center and the outside vertical line represent the 95% confidence limits. The hatched vertical 
line signifies a relative risk of 1 (no additional risk for restenosis). Variables with values greater than or 
less than 1 imply additional or a reduction in risk respectively (see text for details). The variables are 
listed in the left hand column. N represents the number of lesions analyzed for each particular variable. 
Although 214/esions were analyzed in total, some lesions could not be analyzed for certain variables. 
The denominator for vessel branch (111} represents the total number of lesions that were stented in 
native vessels. (CI, confidence interval; OS, diameter stenosis,· LAD, left anterior descending artery; 
DIAM., diameter; PRIM., primary; PTCA, percutaneous transluminaJ coronary angioplasty; MLD, minimal 
luminal diameter; j, absolute change; MULT., multiple) 
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DISCUSSION 
Despite progress in techniques and equipment, the rate of late angiographic narrowing following 
PTCA, a process popularly termed "restenosis", has not been altered since its clinical introduction 13 
years ago. This failure has provided the impetus for the development of newer alternative forms of 
coronary revascularization such as stenting, atherectomy and laser. However the effectiveness of all 
forms of nonoperative coronary interventions remains limited by the restenosis process(es). 
Restenosis is a complex process that is only partially understood. Pathological studies of patients who 
have died more than 1 month following angioplasty have demonstrated the presence of intimal 
hyperplasia, presumably due to proliferation and migration of medial smooth muscle cells into the intima, 
and associated production of extracellular matrix collagen and proteoaminoglycans (13,14). It has been 
suggested by Uu et al that the two major factors that determine the absolute amount of intimal 
hyperplasia are (1) the depth of injury and (2) the regional flow characteristics (which are determined 
by the geometry of the dilated lumen of the lesion and blood flow velocity patterns across that lumen) 
(15). Two separate PTCA follow-up reports support the concept that the greater the diameter change 
post PTCA Qmplying a greater degree of disruption to the vessel wall), the more extensive is the absolute 
amount of reactive hyperplasia (16,17). On the basis of several angiographic studies from the 
Thoraxcenter, immediate results following stent implantation are superior to angioplasty alone (mean 
minimal luminal diameter of 2.5 mm versus 2.0-2.1 mm) and thus favor a more aggressive proliferative 
response post procedure (2.4,18). The second factor is illustrated by the inverse relationship between 
the level of wall shear stress and subsequent intimal thickening. In the presence of a significant residual 
stenosis, the post stenotic region is a site of flow separation and row wall shear stress. This may retard 
endothelial recovery and prolong the period of smooth muscle cell proliferation which is partially 
dependent on restoration of regenerated endothelial barrier (19). Stenting appears to diminish the effect 
of post stenotic wall shear stress by significantly improving the hemodynamic effects of the stenosis 
(based on the calculated reductions in Poisseuille and turbulent contributions to flow resistance) (20). 
It is extremely difficult if not impossible to predict restenosis in the individual patient following PTCA 
(21). This problem can be partially understood when one considers that the two factors (ie. depth of 
injury and regional flow characterist-ICS) affecting the extent of intimal proliferation act ·In opposition to 
the other and thus make it hazardous to predict outcome of this interaction in a particular patient. In 
large population of patients, relative risk analyses following PTCA have identified several patient, lesion, 
and procedural variables that predict late restenosis. However the situation following stenting may be 
different where the mean loss of minimal luminal diameter at !ate follow-up is twice that of PTCA alone 
(0.62 mm versus 0.31 mm) (2, 18). Therefore, this study was designed to identify factors that were 
associated with an increased risk of restenosis following stenting. 
Lesion Factors 
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Stented bypass grafts had a greater risk of restenosis than native vessels (30% versus 19%) but this 
finding was restricted to the DS criterion. The increased susceptibility of bypass grafts to the restenosis 
process has previously been documented following PTCA (9.22~26). Although left anterior descending 
(LAD) lesions have been shown to be a risk factor in several PTCA studies (5,15,16), this was not evident 
in our study. The reference diameter of the vessel also had no relationship to restenosis. Forty-three 
percent of the vessels had reference diameter between 3-4 mm and 43% were 3 mm or less. lesion 
length and the severity of the lesion, in absolute minimal luminal diameter or diameter stenosis, prior to 
the procedure have been cited by several authors as important risk factors for restenosis following 
angioplasty although our data did not show this association (6-9). Lesion length is probably not an 
important factor for restenosis if lesions can be covered by a single stent (see below). We believe that 
this is due to a more uniform and optimal dilatation with stenting. long lesions treated with angioplasty 
are frequently less successfully dilated along the entire length of the lesion and the ragged irregular 
surface of the vessel may predispose to rheological factors critically involved in restenosis. Total 
occlusions have been reported as an important predictor of restenosis in angioplasty studies. However, 
this accounted for only 4.5% of the lesions in our study which was too few for this analysis. Although 
there was a trend for higher restenosis in more eccentric lesions, this was not statistically significant. 
Stent Factors 
Multiple stents (RR: MLD 1.56 (1.08-2.25); DS 1.61 (0.97-2.67)) and unconstrained stent diameter 
exceeding reference diameter by > 0.7 mm (RR: MLD 1.64 (1.1 0-2.45); DS 1.93 {1.13-.3.31)) significantly 
predicted restenosis with both criteria. Preliminary reports from four separate groups working with the 
Palmaz-Schatz stent have shown a similar relationship between multiple stentsjlesion and restenosis (27-
30). In our study, multiple stents placed in tandem were overlapped at the extremities (so called 
"telescoping") which may be the reason for the observed increase in restenosis rates. The segment of 
the vessel that was covered by the overlapping stents was subjected to the dilating force of two separate 
stents as well as an increased density of metal. We have observed that restenosis commonly occurred 
at these sites of overlapping between extremities of stents. Since the length of the lesion and the 
absolute length of the stent required to cover a lesion were not significant predictors. it seems prudent 
to implant longer stents rather than two or more shorter stents in tandem. 
Selecting an oversized stent (unconstrained diameter > 0.7 mm larger than the reference diameter) 
was a particularly important stimulus for hyperplasia with the self-expanding Wallstent. Schwartz et al 
have described an aggressive proliferative response in a porcine model as a result of severe stent 
oversizing (0.5 to 1.5 mm) (31). This effect, which they attributed to penetration of the internal elastic 
lamina by the stent wires and subsequent deep medial injury. was much less pronounced when the stent 
diameter was matched more closely to the vessel diameter. Furthermore, due to its self expanding 
property, the Wallstent (and particularly when it is oversized) continues to expand the vessel wall for at 
least 24 hours post implantation (32). The vessel is subjected to increasingly higher wall stress than after 
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implantation of a balloon expandable stent (which is maximally expanded at the time of implantation), 
a factor which may adversely stimulate the proliferative process. It may seem paradoxical that oversizing 
the stent by >0.7 mm would result in a higher restenosis rate with the 50% DS criterion. However, the 
diameter stenosis post stent was not different in the two groups despite the oversizing. The main effect 
of oversizing then was not particularly a superior immediate result but rather a more aggressive 
"hyperplastic'' reaction and a smaller MLD at follow-up than if less oversized stents were implanted. The 
absolute value of the unconstrained stent diameter and the addition of the polymer coating (Biogold~ 
had no significant relationship to late restenosis. 
Procedural Factors 
No significant relative risk coutd be attributed to a particular indication for the procedure. Restenosis 
rates for primary cases were not significantly different than for bail-out or restenosis cases (MLO 
Criterion:37%,42%,33%; DS Criterion: 24%.27%.24%) although an increased rate of restenosis has been 
described with the Palmaz-Schatz stent in patients with previous restenosis (30). The absolute change 
in diameter from the pre to the post stent result and dilatation within the stent after implantation (the so-
called "Swiss Kiss") did not appear to affect the late restenosis. This post stent dilatation was performed 
to dissipate clot within the stent and to accelerate early expansion of the stent. A post stent diameter 
stenosis > 20% tended to be predictive of a follow-up diameter stenosis > 50% (RR 1.51, 95% Ct 0.91-
2.50) although not for the MLD criteria. The larger the residual stenosis following stenting (ie. less optimal 
result), the less hyperplasia is required to reach a reach a particular diameter stenosis at follow-up such 
as the 50% diameter stenosis criterion. 
Limitations of Study 
Severa! important limitations of this study must be mentioned. Although this study suggest several 
factors that may be predictive of restenosis following stenting, it does not address the actual 
mechanisms of restenosis in the stented vessel. By comparing the predictors of restenosis following 
stenting to angioplasty. we have assumed that the underlying mechanism(s) responsible for late 
angiographic narrowing are similar (i.e. primarily intimal hyperplasia). Although almost every stenting 
procedure was accompanied by balloon dilatation at some particular time during the procedure, several 
other mechanisms may be important. Elastic recoil. which in the first few days following the procedure 
may be a significant factor in causing renarrowing, may be less important in stented vessels than 
angioplasty alone due to the scaffolding function of the stent. Although organization of thrombus at the 
site of intimal damage following PTCA has been recognized as a cause for !ate restenosis, it has not 
been particularly regarded as an important factor based on late pathological studies following PTCA. 
However this may be an extremely important cause of late restenosis after stenting. Although h: is difficult 
to histological!y discriminate thrombus organization from intimal hyperplasia, we have observed a 
disorganized layer of intimal thickening directly above the stent wire associated with remnants of 
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thrombus in segments of several bypass grafts that have been surgically retrieved up to 10 months 
following stent implantation (33,34) (Figure 4). Therefore we consider organization of residual thrombus 
to be a potentially important cause of late anglographic narrowing in addition to the major occlusion 
problems early after stenting. This may partially explain why commonly regarded determinants of 
restenosis following PTCA (eg. lesion length, left Anterior Descending Artery) do not appear to be 
significant in this analysis since a different pathological processes may predominate. This also has 
important clinical implications since therapy to limit smooth muscle proliferation may be quite different 
than therapy to minimize thrombus formation. 
There are two statistical limitations to this study. Due to the relatively small sample size, we can not rule 
out a signiflcant beta error. Secondly, in performing multiple statistical comparisons. there is a risk that 
some of them may be significant by chance alone. Therefore. this data requires confirmation by other 
studies. 
In conclusion, the European coronaryWallstent experience has demonstrated that restenosis following 
stenting is increased in bypass grafts and in the presence of multiple stents and excessive oversizing 
of the stent (>0.7 mm) and less optimal results immediately post stenting (>20% diameter stenosis). 
Since some of these factors can be modified, we recommend against the use of multiple stents and 
excessive oversizing to reduce the probability of late restenosis. 
Figure 4. Light micrograph of stented bypass graft removed 10 months after stent implantation. The 
void (*) represents a 70 micron diameter stent wire. Immediately adjacent to the stent wire are cellular 
debris and foam cells (arrowhead). Directly above the stent wire is a layer of disorganized fibrointimal 
hyperplasia. (counesy of HMM van Beusekom) 
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Table 1. Discrete parameters 
lesion related 
Stent related 
Procedural related 
Vessel Type (Native I Bypass) 
Vessel Branch (LAD I non LAD) 
Stent Type (Polymer Coated I Noncoated) 
Stent Number (Single I Multiple) 
Indication (Primary 1 Restenosis 1 Bailout) 
lntrastent Dilatation ("Swiss KlssH 1 No SK) 
lAO = left anterior descending coronary artery 
Table 2. Continuous parameters 
lesion related 
Stent related 
Procedure related 
Obstruction diameter (mm) ·Pre 
Diameter stenosis (%) .Pre 
lesion length (mm) 
Reference diameter (mm) 
Symmetry 
Unconstrained stent diameter (mm) 
Unconstra·1ned stent length (mm) 
Oversize (mm) 
Change in obstruction diameter (mm) 
Diameter stenosis {%) .Post Stent 
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Median 
1.20 
60 
8.0 
3.25 
0.85 
4.0 
20.0 
0.7 
1.3 
20 
Table 3. Restenosis rates according to Criterion 1. (~ 0.72 mm Loss in Minimal Lumen Diameter) 
Parameter n Restenosis Rate 
Stent Number Multiple 22/44 50% 
Single 53/165 32% 
Stent Oversize > 0.7 40/90 44% 
~ 0.7 26/96 27% 
Table 4. Restenosis Rates according to Criterion 2. (> 50% Diameter Stenosis at Follow Up) 
Parameter n Restenosis Rate 
Vessel Type Bypass 30/103 30% 
Native 20/111 19% 
Stent Oversize > 0.7 29/90 32% 
s: 0.7 16/96 17% 
Diameter stenosis- Post Stent > 20% 30/107 28% 
~ 20% 19/102 19% 
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Abstract 
Coronary stenting has been investigated as an adjunct to percutaneous transluminal coronary 
angioplasty (PTCA) to obviate the problems of early occlusion and late restenosis. From March 1986-
March 1990. 265 patients (308 lesions) were implanted with the coronary Wallsten'f in six European 
centers. For this study, the patients were analyzed according to date of implantation (Group 1 :March 
1986..January 1988; Group 2: February 1988~March 1990) and vessel type (native arteries versus bypass 
grafts). Quantitative angiographic follow-up was performed in 82% of the study patients. 
The early in-hospital occlusion rate in the overall group was 15%. Group 1 patients had a 20% rate 
in contrast to 12% rate in Group 2 (p = NS). The early occlusion rate in native vessels and bypass grafts 
was 19% and 8% respectively (p=0.019). Restenosis was determined by two criteria (Criterion 1: ::!:0.72 
mm loss in minimal luminal diameter (MlD) from post stent to follow-up; Criterion 2: 2:SO% diameter 
stenosis at follow-up) within the stent and in the segments immediately proximal and distal to the stent. 
The restenosis rate with Criterion 1 was 43% in the overall group of patients; 35% in Group 1 versus 49% 
in Group 2 (p=NS); 34% in native vessels versus 54% in bypass grafts {p=0.016). The second criterion 
was met by 27% of patients in the avera!! group; 21% in Group 1 versus 32% in Group 2 (p=NS); 18% 
in native vessel patients versus 39% in bypass grafts (p=O.OOS). 
The overall mortality during the study period was 6.6% in native vessel patients and 8.9% in patients 
with bypass grafts (6% and 7.9% at 1 year respectively). The actuarial event-free survival (freedom from 
death, myocardial infarction. bypass surgery or PTCA) for native artery patients was 46% at 40 months 
and for bypass graft patients was 37% at 20 months. 
It is concluded that early in-hospital occlusions remain a major problem with this device despite 
improvement in the later experience. Although bypass grafts had a significantly lower early occlusion 
rate than native vessels. a significantly higher rate of late restenosis limited the early benefits of stenting. 
Restenosis occurs in a significant number of patients, particularly in bypass grafts. The indications for 
stenting remain unknown and require results of randomized clinicat studies. 
Key Words:stents, restenosis, coronary artery disease 
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INTRODUCTION 
In 1986, the first coronary Wallstent implantation ushered in a new era in interventionai cardiology with 
the purpose of circumventing the two major limitations of coronary angioplasty, early acute occlusion 
and late restenosis {1). As with all new procedures, operators ofthe device had to struggle with their 
own learning curves at the same time that anticoagulation regimens and clinical indications and 
contraindications evolved from their clinical experience. In May 1988, the fiVe European centers testing 
this device agreed to set up a core laboratory for quantitative angiographic analysis in Rotterdam to 
objectively assess the results. In a previous publication from our group. the late angiographic and clinical 
follow-up of the inltal 105 patients (2). These stent implantations were predominantly performed in native 
coronaryvessels.ln the period from February 1988 until March 1990, a further 160 patients under.vent 
stent implantation in the coronary circulation. This second group was characterized by a predominance 
of byPass vessels and a different set of indications. In this report, we compare the late quantitative 
angiographic and clinical follow-up of this second group of patients with the initial group, and for bypass 
grafts versus native vessels. In particular, we were interested to determine whether the changing patterns 
of patient selection and management based on the initial experience, resulted in improved rates of early 
occlusion and late restenosis and whether the results of stents implanted in bypass grafts differed from 
native vessels. 
METHODS 
Study Patients 
Two hundred and sixty-five patients (308 lesions) were enrolled after obtaining informed consent 
between March 1986 and March 1990 at the participating centers. The study protocol was approved by 
the individual hospital ethics committees. The mean age of the population was 58 ::<:: 11 years and 84% 
were male. The study patients were grouped according to the date of implantation (March 1986-January 
1 988, February 1988-March 1990 Groups 1 and 2 respectively) and the vessel type stented (native vessel 
versus bypass graft) (Tables 1.2). The first period of stent implantations. until January 1988, has 
previously been reported (2). Almost 90% of the first group were implanted at either Lausanne (n=56) 
or Toulouse (n=32). However. in the second period, about SO% of the patients were implanted in 
Rotterdam (n=80) and in Lausanne (n=43). In Group 1, 117 stents were implanted in 1141esions, of 
which 82"/o were in native vessels (and in particular the !eft anterior descending artery). In group 2. 266 
stents were implanted in 194 lesions, predominantly in bypass grafts (60% of cases).ln this group, the 
right coronary artery was the most common vessel stented in the native circulation. Two patients had 
stents placed in both a bypass graft and a native vessel. The indications for stenting also differed 
between the two vessel types (Figure 1). 
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REST EN 
NATIVE BYPASS 
Figure 1. The indications for stenting in native arteries and bypass grafts. (Primary 
atherosclerotic lesion that has not been previously treated by PTCA or stenring-) 
Primary 
Native vessels were primarily stented to prevent a second restenosis or as a baH·out procedure for 
angioplasties complicated by abrupt closure or large dissections that interrupted anterograde flow and 
were associated with clinical and electrocardiographic signs of ischemia However in bypass grafts, the 
principle indication was for primary lesions in bypass grafts that had not been previously treated with 
angiop!asty. 
In this trial, the endovascular prosthesis, WaUstentR, was provided by Schneider Europe. Zurich. The 
method of implantation and description of this stent has previously been reported (1,2,5-7). 
Unconstrained stent diameter ranged from 2.5-6 mm and was selected to be 0.50 mm. larger than the 
stented vessel. !nan effort to alleviate the problem of acute thrombosis, the stent design was changed 
in April1989 with the introduction of a polymer coated stent (BiogoldR) for some stent sizes. By August 
1989, all manufactured stents contained this particular polymer coating. 
The anticoagulation for the first period of implantation has previously been described (2). Based on 
this initial clinical experience, a uniform anticoagulation schedule was followed at the centers. 
Acetylsalicylic acid 1 gram orally was started 1 day before the procedure. At the beginning of the 
procedure. patients recieved heparin 10.000 international units intravenously and in some cases, dextran 
infusions (500 mgj 4 hours) were also given. Additional heparin (10,000 international units) and 
urokinase 100,000 units intracoronarywere administered during the procedure. Following the procedure, 
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the heparin infusion was adjusted according tho the activated partial thromboplastin time (APTT 80-120 
seconds) in addition to initiating oral Vitamin K antagonist therapy. Heparin was discontinued after the 
therapeutic oral anticoagulation level was stabilized (International Normalized Ratio of 2.3 or more). 
Acetylsalicylic acid 100 mg daily, dipyridamole (300 to 450 mgjday) and in some patients sulfinpyrazone 
400 mg daily were also administered. 
Quantitative Coronary Arteriography and Restenosis Criteria 
All cineangiograms were analyzed at the core laboratory in Rotterdam using the computer assisted 
cardiovascular angiography analysis system (CAAS) which has previously been discussed in detail (3,4). 
The minimal luminal diameter and % diameter stenosis were determined pre and post angioplasty, 
immediately post stent implantation and at long term follow-up in all patients using the average of 
multiple matched views with orthogonal projections wherever possible. The minimal luminal diameter 
(and the diameter stenosis using the reference diameter of the segment) of each segment immediately 
proximal and distal to the stent was also measured. 
Two different set of criteria were applied to determine the restenosis rate. We have found a change 
in minimal luminal diameter (MLD) of 0.72 mm or more to be a reliable indicator of angiographic 
progression of vessel narrowing and by no means implies functional or clinical significance(3,4,8). This 
value takes into account the limitations of coronary angiographic measurements and represents two 
tlmes the long term variability ( ie. the 95% confidence intervals) for repeat measurements of a coronary 
obstruction using CAAS. The other criterion for restenosis chosen was an increase of the diameter 
stenosis from less than 50% after stent implantation to greater than or equal to 50% at follow-up. This 
criterion was selected since common clinical practice continues to assess lesion severity by a 
percentage stenosis. The two criteria were assessed within the stent and in the segment immediately 
adjacent (proximal and distal) to the stent 
In this study, late (ie. documented after the initial discharge from hospital) occlusion (n = 10 patients, 
16 lesions) were regarded as restenoses. This contrasts with our earlier report in which we calculated 
a total occlusion rate which was then separated into early (in hospital) and late occlusions (2). In this 
earlier report. the early and late occlusions were analyzed separately from the restenotic lesions. The 
current change was initiated to be consistent with our reports of late follow-up of PTCA (4,9). 
Statistical Methods 
The data obtained by quantitative angiographic analysis are given as mean ::o: standard error of the 
mean. The means for each angiographic variable pre PTCA, post stent and at follow-up were compared 
by analysis of variance. if significance differences were found, two tailed T-tests were applied to pairs 
of data. The occlusion and restenosis rates were compared using a chi square test. A statistical 
probability of less than 0.05 was considered significant. 
The late clinical follow-up was determined according to a life table format using the Kaplan-Meier 
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method (10). The following events were considered clinical endpoints: death, myocardial infarction, 
bypass surgery or nonsurgical revascularization (PTCA or atherectomy). The life table was constructed 
according to the initial clinical event. 
RESULTS 
The angiographic follow-up for the entire study population was 82% (Table 3). This includes patients 
with documented early occlusions during hospital admission (n =40) in addition to patients who had rate 
(after the initial hospital discharge) angiographic controls. The reasons why follow-up angiography could 
not be performed are listed in Table 3. The time to angiographic follow-up was 6.6 ± 4.8 months it early 
occlusions are excluded and 5.7 = 5.0 months with the early occlusions. 
The angiographic data for individual lesions in bypass grafts and native vessels is presented in Figures 
2 and 3. In native vessels, there was a mean increase in minima! luminal diameter from 1.17 ::!: .04 mm 
to 2.53 ::!: .04 mm immediately post stenting (p<0.0001) but a late deterioration to 1.99 ::!: .07 mm 
(p<0.0001 versus the post stent result) if early occlusions are excluded and 1.59 ± .09 mm with the 
inclusion of the early occlusions (p<0.0001} (Figure 2a). Similarly, the minimal luminal diameter 
increased significantly in bypass lesions from 1.39 ± .06 mm to 2.81 ::!: .06 mm post stenting with a late 
reduction to 2.21 ± .11 mm and 2.03 ± .12 mm with the exclusion and inclusion of early occlusions, 
respectively (p<0.0001). Diameter stenosis was significantly reduced from immediately post stenting in 
bypass grafts from 60 ± 1% to 23 ± 1% but increased at late follow-up to 43 ± 3% and to 38 ± 3% with 
and without the early occlusions respectively (p<O.OOOi versus the post stent result). Similar changes 
were observed in native vessels (Figure 2b). 
!n the overall group, the incidence of early in-hospital occlusion was 15% by patient and 13% by 
lesion (Table 4). In bypass grafts, early occlusions were documented in 7% of lesions (8% of patients) 
versus 18% of lesions (19% of patients) in native vessels (by lesion p=O.OOS;by patient p=0.016). Three 
of these native vessel occlusions occurred during the procedure and could not be recanalized. The 
remaining occlusions presented clinically as acute ischemic syndromes following a successful stenting 
procedure. Early occlusions were less frequent in Group 2 patients (12%) than in Group 1 (20%) but not 
statistical!y significant. Detectable angiographic narrowing (0.72 mm loss in MLD) in the overall group 
was 42% by lesion and 43% by patient (fable 5). Using the 50% diameter stenosis criterion, restenosis 
occurred in 27% of lesions (27% of patients). Restenosis according to either definition was significantly 
higher in bypass grafts (MLD criterion:54% by patient; DS criterion:39% by patient) than in native vessels 
(34% and 18% respectively) (MLD: p=0.016; OS: p=0.001). Group 2 patients (MLO criterion:49% by 
patient; OS criterion: 32% by patient) did not have significantly greater restenosis than Group 1 patients 
(MLO criterion:35%; OS criterion:21 %). 
87 
MLD (mm) 3 r 2.81 
2.5 
2 
1.5 
1 
0.5 
1.391-" 
1.17 
J. 
2.53 
2.21 
.. · .... .T 
..... -...... .T 2.03 
1.99 
BYPASSES 
NATIVES 
1.59 
QL---r-------+-------+-------,_ __ _ 
PRE POST FU FU 
(-EARLY OCCL) (+EARlY OCCl.) 
Figure 2a. Minima/luminal diameter (MLD) of native vessels and bypass grafts pre procedure, post 
stenting, and at follow-up. The mean values at follow-up have been calculated with and without the 
inclusion of the early in-hospital occlusions. 
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Figure 2b. The % Diameter stenosis (OS) of native vessels and bypass grafts pre procedure, post 
stenting, and at follow-up. The mean values at follow-up have been calculated with and without the 
inclusion of the early in-hospital occlusions. 
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Figure 3. Change in the minima/luminal diameter (MLD) for individual lesions in native vessels (Figure 
3A) and in bypass grafts (Figure 38) between stent implantation and angiographic follow-up (FjU). The 
diameter of each segment immediately after implantation is plotted against the diameter at follow-up. 
The lines on each side of the identity line (diagonal) represent the limits of long-term variability of 
repeat measurements (a change of ;£J.72 mm [arrow]). All symbols below the right-hand line represent 
stents with involvement of angiographic detectable hyperplasia. The filled squares represents lesions 
with follow-up diameter stenosis ~ 50%. Occlusions are located along the x axis and those lesions that 
occurred within the first two weeks are marked by an asterisk. 
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The overall mortality during the study period was 8.9% (n=9) for bypass grafts and 6.6% (n=11) for 
native vessels (7.9% and 6% at 1 year respectively). ln the bypass group, four of the nine deaths 
occurred during the initial hospitalization. Two of these deaths resulted from intracerebral hematomas 
related to the anticoagulation and two were from myocardial infarctions due to stent occlusion. Two of 
the 5 late deaths were sudden (at 2 and 18 months). two were clearly unrelated to the stent (chronic 
congestive heart failure, chronic renal failure) and the other death occurred after bypass surgery. ln the 
group with native vessels, 7 of the 11 deaths were in-hospitaL These were all due to myocardial 
infarctions resulting from stent occlusion with the exception of one intracerebral bleed and one patient 
who was stented 24 hours after an extensive myocardial infarction with cardiogenic shock. Two of the 
four late deaths were sudden (at 1.5 and 19 months). one was noncardiac (pneumonia) and the other 
resulted from complications post bypass surgery. The actuarial event-free survival (freedom from death, 
myocardial infarction, bypass surgery or PTCA) for native artery patients was 4&k at 40 months and for 
bypass graft patients was 37% at 20 months (Figure 4). 
DISCUSSION 
The coronary Wallstent was initially introduced as an endovascular device to prevent the !ate 
restenosis process that limits percutaneous transluminal coronary angioplasty. The indications for and 
management of patients implanted with this particular prosthesis have evolved as experience and 
knowledge have increased. In this study, an attempt has been made to separate two important factors 
in the late outcome of patients with stent implantations. The first division, according to date of 
implantation, provides the clearest picture of the changes in stent applications based on the early 
experience. Investigators originally believed that the stent could be safely implanted in native vessels and 
that the benefit of stents would be most apparent in lesions that had already restenosed on at least one 
occasion. However, a high in-hospital occlusion rate was noted, particularly in patients with unstable 
syndromes, evolving myocardial infarction or angiographic evidence of thrombus. These occlusions, 
often with disastrous clinical sequelae, convinced most of the investigators that native vessels in general 
and particularly in the left anterior descending artery (due to the large territory at risk), should only be 
stented in bail-out situations. Group 2 mainly consisted of patients with bypass grafts who were stented 
for primary lesions and native vessels who were stented as part of a bail-out strategy following 
complicated balloon angioplasty. Bypass grafts in particular were selected for stent implantations due 
to an extremely high rate of restenosis after PTCA alone and the larger diameter of these grafts seemed 
less likely to thrombose than smaller calibre native arterial vessels (11-14). Bypass lesions, which were 
the majority of lesions stented in Group 2, were more complex in general than Group 1 lesions due to 
the advanced age and diffuse nature of the disease in the bypass grafts. As a result, more stents per 
lesion (1.4 versus 1.1 in native vessels) were required to cover these lesions. 
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Figure 4. Clinical follow-up in native vessels up to 40 months (Figure 4A) and bypass grafts up to 20 
months (Figure 48). Death, myocardial infarction, bypass surgery, and PTCA or atherectomy were 
considered clinical end points. 
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Therefore, the significantly lower rate of in-hospital occlusion in bypass graft patients versus patients with 
native vessels (8% versus 19%) and trend in Group 2 versus Group 1 (12% versus 20%) is indicative of 
several possible factors including improvements in anticoagulation regimens, operator experience andjor 
larger calibre vessels despite more complex case selection. 
Recently, the initial clinical experience with the Palmaz-Schatz stent has been reported (15). Using a 
similar anticoagulation schedule in 174 patients, a o.SO.k in hospital occlusion rate was demonstrated. 
The discrepancy between a substantially higher occlusion rate in our series with the Wallstent and the 
Schatz study can not be entirely explained. The stent itself does not appear to be more thrombogenic. 
ln a model of stents placed inside a polytetrafluoethylene graft in exteriorized arteriovenous shunts in 
baboons. no difference in acute platelet deposition and thrombus formation was noted between the two 
types of stents (16). Differences in study design such as patient selection (collateralized vessels, 
predominantly right coronary arteries and exclusion of patients with recent myocardial infarction and 
abrupt closure following PTCA in the Schatz study) may account for some of the differences. 
Higher restenosis rates by both criteria were demonstrated in bypass grafts compared with native 
vessels and in Group 2 than in Group 1. There are two possible explanations for this increase. First, 
bypass grafts, which are overrepresented in Group 2, are known to have higher restenosis rates than 
native vessels (11, 12,13). Secondly, higher restenosis rates may be the "priceH for lower occlusion rates. 
Organization of thrombus at the site of intimal damage may be an important cause of late restenosis 
after stenting. Although it is often difficult to histologically differentiate thrombus organization from intimal 
hyperplasia, we have observed an extremely disorganized pattern of intimal thickening in the stented 
segments of several bypass grafts that have been surgically retrieved or obtained by atherectomy 1-5 
months following stent implantation (17). By diminishing the formation of early occlusive thrombus with 
more effective anticoagulation, the residual non occluding thrombus could form the substrate for late 
restenosls. Although the second group had a higher proportion of bail-out cases, a previous study from 
our group did not identify increased relative risk for restenosis from bail-out cases in comparison to stent 
implantations performed in primary or restenosed lesions (18). 
The problems of prolonged anticoagulation are an additional consideration. Increased morbidity 
(increased femoral hematomas, gastrointestinal and genito-urinary tract bleeding) and mortality (3 
patients died from intracerebral hemorrhage) are directly attributable to the intensive anticoagulation 
regimen. The duration of hospitalization is also lengthened to ensure therapeutic levels of 
anticoagulation. 
The high incidence of late adverse clinical events in stented patients is a cause for concern. A 
mortality rate of 8.9% in bypass grafts and 6.6% in native vessels is higher than in reported PTCA studies 
(19,20,21 ). However, it must be stressed that a large number of stents in native vessels were implanted 
for abrupt closure following PTCA which dramatically increases the risk of the procedure (21). Actuarial 
event free survival (freedom from death, myocardial infarction, bypass surgery or repeat PTCA or 
atherectomy) was 37% at 20 months in bypass patients and 46% at 40 months in native vessels. In the 
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bypass group, about 30% of the adverse events were unrelated to the stented lesion and were due to 
worsening of a different lesion or to development of new lesions. In the native vessel group, 12% of the 
adverse events were unrelated to the stented lesion. Jn addition, 9 of the 30 bypass operations in stented 
native vessel patients were performed as part of a protocol for patients stented for the baH-out indication 
(22). Although there are no comparable series of native vessel patients in the literature because of the 
unique set of indications in our study, three recent reports have been published of late clinical follow-up 
(Kaplan-Meier analysis) after PTCA in bypass grafts. The Thoraxcenter reported that only 4 ~% of patients 
were alive and event-free (myocardial infarction, repeat CABG, repeat PTCA) at a median follow-up of 
2.1 years (23). A review of the overall Dutch experience also showed limited late beneficial results with 
a two year and fNe year event free survival of 52% and 26% respectively in 454 bypass patients (24). 
Webb et al have described a 71% freedom from death, infarction and surgery at 5 years in bypass 
patients who underwent PTCA at their institution but did not include the 27% incidence of second 
angioplasty procedures also required in their patient group (11). However it must be stressed that our 
study was not a randomiZed tria[ designed to compare stenting with PTCA but rather an observational 
study with a first generation coronary stent. Nevertheless, all of these late follow-up studies of 
nonoperative coronary revascularization clearly show that these are palliative procedures and not long-
term solutions to the underlying problems of progression of underlying coronary disease and 
iatrogenicaHy induced restenosis. 
Several important points emerge from this study. First, although in hospital occlusion rates improved 
in the later experience, WatlstentR coronary thrombosis continues to limit its use. Restenosis rates with 
the 50% OS criterion do not seem to be significantly improved when compared with historical post 
angiop!asty results, although definitive statements must await randomized trials. Bypass grafts in 
particular have a high incidence of late restenosis rate although early occlusion occurred less 
significantly than in patients with native vessels. Based on our experience. there is insufficient evidence 
at this time to suggest implantation of this particular stent outside of a randomized trial with the following 
exceptions: (1) ball-out for abrupt occlusion. (2) suboptimal (inadequate dilatatation) results following 
PTCA, and (3) bypass grafts at high risk for distal embolization with PTCA (friable lesions that may 
benefit from the scaffolding property of the Wal!sten-f). If the low occlusion rate with the Palmaz-Schatz 
stent is confirmed in other studies, that particular stent would appear to be a more suitable candidate 
for randomized trials of presently available stents. 
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Table 1: Stent implantations according to date of implantation. 
Group 1 
(March 1986-Dec 1988) 
Vessels 107 
Bypass 18% 
Native 82% 
lAD 54% 
ex 7% 
RCA 21% 
Stent(lesions 117/114 
Table 2: Stent implantations according to vessel type. 
Natives 
Patients 166 
Vessels 171 
Stent/Lesion 193/173 
lAD 55% 
ex 10% 
RCA 35% 
94 
Group 2 
(Jan 1989-March 1990) 
175 
60% 
4()% 
15% 
5% 
20% 
266/194 
Bypass Grafts 
101 
110 
192/135 
Table 3: Angiographic Follow-up 
Implantations (LesionsiPts) 3081265 
Early Occlusions 41 140 
Late Follow Up 2141176 
Total 2551216 (82%) 
No Angiographlc Follow-up 53149 (18%) 
Death 10 (4%) 
Early CABG 11 (4%) 
Refusal 25 ( 9%) 
Technical 3 ( 1%) 
Time to Angiographic Follow Up 
Excluding Early Occlusions 6.6 = 4.8 
Including Early Occlusions 5.7 ± 5.0 
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Table 4: Angiographlc Results: Earty Occlusions 
Total 
Lesions 3081265 
Early Occlusions 40 (13%) 1 39 (15%) 
Group 1 Group 2 Native Vessels Bypass Grafts 
1141105 1941160 1731166 1351101 
21 (18%) 121 (20%) 20 (tO%) 1 t9 (12%) 32 (18%) 132 (19%) 9 (7%) I 8 (8%) 
Table 5: Late Anglographlc Follow Up: Restenosls w~hln and lmmedlally adjacent to the Stent. 
Total Group 1 Group 2 Native Vessels Bypass Grafts 
Lesions/Patients 214 1 176 85 1 75 129 1 tot 111 1104 103 I 74 
0.72mm Criterion 
Within Stent 75 I 61 25 1 21 5o I 40 34 1 30 40 I 3t 
Adjacent to Stent 14 I t4 5 I 5 9 I 9 5 I 5 91 9 
Total 89 I 75 30 126 59 I 49 40 1 35 49 1 40 
(42% I 43%) (37% I 35%) (46% I 49%) (36% 1 34%) (48% I 54%) 
50% DS Criterion 
Within Stent 51 1 42 t7 I t5 34 I 21 2t 1 t8 30 1 24 
Adjacent to Stent 6 I 6 1 I t 5 I s 1 I t 5 I s 
Total 57 1 48 18 I t6 39 I 32 22 I t9 35 I 29 
(27% 1 27%) (22% I 2t%) (30% I 32%) (20% 1 ta%) (34% I 39%) 
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Stenting of venous bypass grafts: A new treatment modality 
for patients who are poor candidates for reintervention 
IK de Scheerder, BH Strauss, PJ de Feyter, KJ Beatt, LHB Baur, W Wijns, 
GR Heyndrix, H Suryapranata, M van den Brand, B Buis, PW Serruys 
(submitted) 
101 

Abstract 
During a two year period, 136 self-expanding Wallstents (Medinvent, Lausanne) were implanted in 
saphenous vein bypass grafts in 69 patients with end stage coronary artery disease. All patients had 
severe symptoms and the majority were poor candidates either for repeat surgery or conventional 
bypass coronary angioplasty due to unfavorable native anatomy, impaired left ventricular function or a 
high risk bypass lesion anatomy for coronary angioplasty. 
All procedures were technically successful without major complications and need for emergency 
bypass surgery. However, during hospital stay, acute thrombotic complications occurred in 7 patients 
(1 0%) resulting in one death and acute myocardial infarction in 5 patients and necessitating emergency 
rePTCA in 2 patients and reCABG in 4 patients. Twenty three patients had serious hemorrhagic 
complications directly related to the rigorous anticoagulation schedule. Two patients died due to fatal 
cerebral bleeding. 
During follow-up. another five patients died accounting for a total mortality rate of 12%. At late 
angiographic follow-up (4.9 = 3.4 months, n = 53), 25 patients {47%) developed a restenosis (.::: 50% 
DS) within or immediately adjacent to the stent, necessitating reintervention in 19 patients (PTCA: n = 
12; reCABG: n = 7). In the patient group without stent related restenosis (n = 28), 15 patients developed 
progression of disease in either the native or bypass vessels leading to recurrence of major anginal 
symptoms, within 1 to 24 months. Ten of these patients required further intervention (Stent: n = 6; 
PTCA: n = 3; reCABG: n = 1). 
$tenting in saphenous coronary bypass grafts can be performed safely with excellent immediate 
angiographic and clinical results. Early occlusion, late restenosis and bleeding complications associated 
with the aggressive anticoagulant treatment remain significant limitations. Reintervention due to 
restenosis or progression of disease in other lesions is common. $tenting of diseased bypass grafts in 
symptomatic patients with end stage coronary artery disease (who are at high risk for conventional 
angioplasty or surgical reintervention) may be useful as palliative therapy. 
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INTRODUCTION 
Patients presenting with medically refractory anginal symptoms following saphenous vein bypass surgery 
pose a difficult problem for cardiologists and cardiovascular surgeons. These patients are generally 
older, with more extensive, diffuse disease involving the native coronary arteries and venous bypass 
grafts. Repeat coronary bypass surgery for recurrent ischaemia is technically more difficult, is associated 
with a higher mortality and morbidity, and has inferior long-term clinical results when compared to a first 
bypass operation (1-3). Conventional balloon angioplasty offers an alternative mode of revascularization 
in selected patients. The immediate results of this procedure have been shown to be favourable in 
patients with discrete lesions in venous bypass grafts, but considerably Jess satisfactory in diffusely 
diseased, ulcerated, or thrombosed venous grafts (4..£). Furthermore, it appears that the restenosis rate 
is high, varying from 40-70% depending on the site of the lesions in the graft and the overall extent of 
disease in the conduit (7-13). 
Stent implantation has been proposed as an alternative or adjunct to PTCA for diseased venous 
bypass grafts. Early studies wtth small numbers of patients have shown that stents can be placed safely 
and successfully in bypass grafts with an encouraging low rate of restenosis {14-21). Therefore, we 
initiated this observational study to assess the acute and late results of stent implantation in stenosed 
coronary artery bypass grafts in symptomatic patients with diffuse extensive native coronary artery and 
bypass graft disease who represent poor candidates for conventional balloon angioplasty or 
re-operation. 
METHODS 
Study population (Tables I and II) 
Between January 1988 and March 1990, 136 stents were implanted in 69 (12 female, 57 male) 
patients in the four participating hospitals in the Netherlands and Belgium. The study protocol was 
approved by the individual hospital ethics committees and informed patient consent was obtained. A 
senior investigator (PWS) was present for all stent implantations. 
The decision to implant a stent was reached after combined discussion between cardiologists and 
surgeons (Table Ill). Forty-two patients were considered inoperable, either due to high riskjbeneftt ratio 
related to repeat surgery (n ""28), unfavourable coronary vessel anatomy such as diffusely diseased distal 
vessels (n,4), poor left ventricular function (ejection fraction < 35%) (n=6). or concurrent noncardiac 
risk factors (n=4). Conventional coronary angioplasty was considered high risk in 39 patients due to the 
age of the grafts, the length of stenosis andjor unfavorable angiographic features (tandem lesions, 
eccentric lesions, lesions containing ulcers, aneurysm, calcifications or dissections) (Rgures 1-4). 
The mean patient age was 63 years (range 44-78). and the age of the implanted bypass graft was 
83 months (range: 1 - 166). Forty-eight patients had at least one previous myocardial infarction, and 8 
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had undergone more than one previous bypass procedure. Single vessel. double vessel and triple vessel 
disease were present in 3, 23 and 74% of the patients respectively. Eleven patients were in NYHA class 
11,27 in NYHA class Ill, 29 in NYHA class IV and in 2 patients the stents were implanted during evolving 
myocardial infarction. AU patients had documented electrocardiographic evidence of ischemia. The 
stent implantation data is presented in Table IV. A single stent was implanted in 30 patients, 2 stents in 
24 patients, 3 stents in 7 patients, 4 stents in 5 patients, 1 patient received 5 stents and finally 2 patients 
had 6 stents implanted. The stent was placed in single grafts in 25 cases and in sequential grafts in 44 
cases. In 5 patients, the stent was implanted into totally occluded vessels (during an evolving myocardial 
infarction (n=2) and in three chronic occlusions). 
Implanted device 
In the first 26 patients we used the Medinvent WallstentR (Medinvent, Lausanne, Switzerland), later 
we used the polymer coated Medinvent Biogo!dR stent. The stent consists of a stainless steel a!loy with 
a self-expanding mesh design (15). The unconstrained length varied between 15 and 27 mm and its 
diameter in fully expanded state was between 3.5 and 6.0 mm and was selected to be 0.50 mm larger 
than the reference diameter of the vessel. 
After stent implantation. the patients were monitored in the coronary care unit The rigorous 
anticoagulation regimen has previously been described (22). All patients received aspirin the day before 
the procedure and intravenous heparin (1 0.000 I.U) at the beginning of the procedure. Prior to stent 
implantation 10.000 LU. heparin and dextran 500 mg/4 hrs, were given intravenously. Immediately after 
stent implantation, 100,000- 250,000 I.U. urokinase was infused into the coronary bypass graft via the 
guiding catheter. Intravenous heparin administration was continued at a minimum dosage of 24,000 I.U./ 
24 hrs; the dosage was adjusted according to the activated partial thromboplastin time (APTT: 80-120 
sec). Oral acenocoumarol was started the day of implantation. The heparin infusion was continued until 
the prothrombin time measured by ThrombotestR (Nycomed, Oslo, Norway) (TT) was lowered to 5- 1 0% 
for 2 subsequent days, and discontinued slowly thereafter. Following stent implantation, the patients 
were also given aspirin (300 mgjday), dipyridamole (300 ~ 450 mgjday}, and nifedipine (30 ~ 60 mgjday) 
which in addition to the oral anticoagulant were maintained for 3 ~ 6 months after the procedure. The 
patients were followed at our out patient dinic at one and three months and underwent a repeat 
coronary angiogram 6 months after the initial procedure. or earlier if symptoms recurred. 
Quantitative coronary angiography 
The quantitative analysis of the stenotic coronary segments was carried out with the computer 
assisted Cardiovascular Angiography Analysis System (CAAS), which has been described in detail (23-
28). The angiographic analysis was done pre- and postangiop!asty, immediately post stent implantation 
and at follow~up in all patients using the average of multiple matched views with orthogonal projections 
wherever possible. 
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Figure 1. Jump graft to the left anterior descending artery (arrow), then to the first diagonal branch and 
then to a marginal branch. A. Two lesions in the jump graft between the diagonal and marginal 
branches (arrowheads). B. Immediate result post stenting. The distal end of the stent may have 
extended into the native coronary artery. 
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Figure 2. Top Panel. Two tandem lesions with an aneurysm of the bypass graft located proximal to the 
first lesion. 
Second Panel. Balloon angioplasty catheter in position across the lesion. Balfoon dilatation resulted 
in a dissection. 
Third Panel. After implantation of distal stent, intraluminal flap (arrow) is still evident in proxima/lesion. 
Lower Panel. After implantation of the second stent in the proxima/lesion. 
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Figure 3A. Bypass graft to the right coronary artery (7 inch image intensifier). A long segment of the 
bypass vessel is severely diseased with involvement of the ostium and several complex features 
including ulceration in the proximal aspect of the graft (arrow) and intraluminal defect in the mid graft 
(arrowhead). 
Figure 38. After placement of 3 stents (5 inch image intensifier). 
Figure 3C. Six month angiographic follow-up showing a late excellent result. 
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Figure 4A. Complex lesion with ulceration (arrow) in jump bypass graft prior to stenting. 
Figure 48. Immediate result post stenring. 
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Figure 4C. Six month angiographic follow-up showing restenosis within the stent. The outline of the 
stent is faintly visible. 
Restenosis 
Two different sets of criteria were applied to determine the restenosis rate. We have found a change 
in minimal lumen diameter of 0.72 mm or more to be a reliable indicator of angiographic progression 
of vessel narrowing (23-25). This value takes into account the limitations of coronary angiographic 
measurements and represents two times the long-term variability for repeat measurements of a coronary 
obstruction using CAAS. The other criterion for restenosis was an increase of the diameter stenosis from 
less than 50% after stent implantation to greater than or equal to 50% at follow-up. This criterion was 
selected according to common clinical practice (29). 
RESULTS (Table IV) 
Stent implantation procedure 
All patients underwent successful stent implantations (D$<50% immediately following placement of 
the stent). In 2 cases, the initial stent was not optimally positioned and did not cover the entire lesion 
so that an additional procedure was required to implant another stent to achieve an optimal result 
Although no immediate major complications occurred during the procedure. two patients required 
intracoronary thrombolytics due to distal embolization without subsequent CK elevation. Three other 
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patients developed minor CK rises ( <200 IU). 
In hospital complications (Table V) 
Acute thrombotic events in the stent occurred in 7 patients (1 0%). One of these occlusions was 
related to cessation of anticoagulation treatment. This patient (considered inoperable) developed a 
severe retroperitoneal haematoma 7 days after implantation of the stent, which necessitated 
discontinuation of the anticoagulation therapy. Thirty days after implantation, the patient developed an 
acute myocardial infarction, leading to cardiogenic shock and death. One patient who had the stent 
implanted during an evolving myocardial infarction, developed an acute thrombotic closure of the 
stented vessel one day after stent implantation. The resulting myocardial infarction was treated 
conservatively. 
Two other patients. who had unstable angina pectoris and angiographic defects consistent with 
thrombi, developed acute thrombotic occlusions and myocardia! infarctions 7 and 12 days after stent 
implantation respectively. One of these patients, who was treated conservatively, died suddenly 6 months 
following implantation. having remained stable with mild angina pectoris. The other patient underwent 
coronary bypass surgery after emergent reopening of the vessel during rePTCA. The last thrombotic 
occlusion occurred one day after implantation in one of the patients with stent implantation after 
recanalization of a chronically occluded graft:. This patient was referred for reCABG. 
Two patients developed unstable angina pectoris 3 and 10 days after stent implantation. related to 
an angiographically visible but non-occlusive thrombus. In one patient. this thrombus was related to 
cessation of anticoagulation 6 days after the procedure due to a Maflory~Weiss syndrome with persistent 
gastro-intestinal bleeding (30). Due to symptomatic recurrent ischemia, the patient was sent for surgery. 
The second patient, who had been treated for unstable angina pectoris developed rest angina pectoris 
one day after implantation of two stents. Angiography revealed a partially occlusive thrombus between 
the two stents and another stent was placed between the two previous stents. The following day. rest 
angina pectoris recurred and the patients was treated surgically. 
Bleeding complications occurred in 23 patients (33%). Two patients suffered fatal intracranial bleeds, 
one patient had a retroperitoneal haematoma and two patients developed gastric bleeding. An additional 
18 patients had hematomas at puncture sites requiring blood transfusions and 7 of these patients 
required surgicat repair of a false aneurysm. Bleeding complications were associated with a considerably 
longer hospital stay: 18 days in comparison to 7 days when the postimplantation course was uneventful. 
Discharge status 
Stent implantation resulted in complete relief of angina pectoris (NYHA 1) in 45 patients (64%). Ten 
patients (14%) still had mild symptoms (NYHA !I) after stent implantation, and 5 patients (7%) remained 
in NYHA class Ill. Four of these patients were considered inoperable and the fifth was referred for 
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reoperation. 
Long-term follow-up 
(i) Angiographic (Table 5) 
Jn fifty-three (90%) of the 59 patients with successful stenting and no major in-hospital complications, 
follow-up angiography was performed at 4.9 ± 3.4 months. Of the remaining 6 patients without 
angiographic follow-up, 5 refused a control angiogram, and in another patient the implantation film was 
technically inadequate for analysis although no significant restenosis was seen at follow-up. 
In the overall group the mean minimal luminal diameter increased significantly from 1.4 ± 0.82 to 2.7 
± 0.7 mm (p<0.001) and the diameter stenosis decreased significantly from 58± 15% to 24 ± 9%. 
However at late fo!low-up Qncluding occlusions) there was a significant reduction in mean minimal 
luminal diameter to 1.9 ± 1.1 mm (p<0.001} and a signfficant increase in diameter stenosis to 43 ± 30 
% (p<0.001). 
The incidence of restenosis depended on the definition. Using a criteria of a change in minimal 
luminal diameter of 0.72 mm, detectable angiographic narrowing occurred within the stent in 25 patients 
(47%). An increase in diameter stenosis to 50% at follow-up was seen in 21 patients (40%) and 
immediately adjacent to the stent in 4 patients (7%). Stent occlusion was found in 3 of these patients. 
(ii) Clinical 
In the group of patients with angiographic restenosis (DS>SO% criterion) (n""25), 19 patients 
experienced recurrence of angina pectoris, necessitating reintervention (rePTCA: n""10, atherectomy: 
n""2, reCABG: n = 7). Three of the patients who underwent surgery died during the postoperative period. 
In the group without restenosis (n = 28), 15 patients had recurrence of significant angina pectoris 
within 1 to 24 months foltowing stent implantation. Ten patients underwent further intervention. In 6 
patients a second stent was implanted in either the same or another bypass graft. Three patients 
underwent PTCA of one or more native vessels and one patient had repeat bypass surgery. The fiVe 
remaining patients were treated medically. One patient. without significant restenosis at 6 month 
angiography, died suddenly 500 days after stent implantation. 
DISCUSSION 
The management of recurrent ischaemia in patients who have had previous bypass surgery presents 
a serious and growing problem. Symptoms of myocardial ischemia recur or progress in about 5% of 
patients per year {3,26,27) and after 5 years, up to 25% of vein grafts are occluded and .25% may show 
stenoses greater than 70% (28). Reoperation is technlcaily more complicated to perform and is generally 
associated with a higher mortality and morbidity than a primary operation, and achieves symptomatic 
relief in only 60% to 70% of patients. as compared to the 80% to 90% success after primary operations. 
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The peri-operative myocardial infarction rate varies among surgical groups between 2.0% and 11.5%. 
The mortality rate following repeat bypass surgery ranges from 1.2 to 12.5% (1--3). Conventional balloon 
angioplasty has reported angiographic success rates of 75-100% for bypass grafts (7-13), w·rth 
complications rates similar to angioplasty in native vessels. However, restenosis appears to occur more 
frequently with rates as high as 46% reported for proximal sites (24,27). 
The majority of our patients were considered high risk for surgery or repeat PTCA. Since all of these 
patients had severe symptoms in spite of maximal medical therapy, it was decided to try to attempt 
stenting of the angina-related bypass graft although in some cases it was clear that full relief could not 
be expected due to diffuse native vessel disease that prohibited additional intervention. Most of the 
procedures were done without surgical stand·by. Since the introduction of stenting of stenosed 
saphenous bypass grafts in our institution in 1988, 69 patients were (succesfully) treated by this new 
intervention compared with only 84- patients who undetwent conventional angioplasty for stenosed 
saphenous bypass grafts during the period 1980·1988. This new treatment modality has significantly 
expanded our therapeutic options in this particular patient group. 
Our results show that stenting bypass grafts is technically feasible with excellent immediate results. 
Two advantages of the WaUstenf for use in bypass grafts are: (1} the length ofthe stent can be selected 
up to 25 mm for long lesions, and (2) the self·expanding property appears to be an effective splint to 
tack back friable, protuberant atheromatous material and minimize embolization into the native coronary 
circulation. In 30 patients. the stent was implanted directly without prior balloon dilatation for lesions that 
looked high risk for embolization. No CK rise was documented in this group of procedures. 
Several important lessons emerge from this study. First, the majority of stent occlusions occurred in 
patients with acute ischemic syndromes (myocardial infarction or unstable angina pectoris with 
angiographic evidence of thrombi). The combination of thrombi during evolving myocardial infarction 
and unstable angina and the implantation of intracoronary stents seems to be highly thrombogenic 
leading to further thrombus formation and acute occlusion of the stent Therefore, we now carefully 
select our patients and when the diagnostic angiogram is suggestive for intravascular clots, the patients 
are treated with intravenous heparin (25000 IV /24 hr) for one week before stent imptantation. Although 
improved patient selection should decrease the occurrence of acute stent closure, it will remain an 
unpredictable event as evidenced by stent occlusion in 1 patient who was optimally anticoagulated and 
without the previously described risk factors. Furthermore, the timing of stent occlusion was also 
unpredictable (between 2 and 12 days) which complicates discharge planning decisions. Second. a 
meticulous anticoagulation schedule must be followed with frequent monitoring to minimize bleeding 
complications. As our experience evolved, bleeding and occlusion problems were encountered much 
less frequently and as a result, sulphinpyrazone was withdrawn due to lack of evidence for its efficacy 
in the prevention of acute closure. Special care must also be given to femoral arteria! sheath insertion 
and removal since this accounted for the majority of bleeding complications. !n particular, removing the 
sheath >12 hours post implantation was associated with increased vascular comp!ications. During the 
113 
last 15 stent implantation procedures, no thrombolytics were administered leading to a considerable 
decrease in groin bleeding problems. Furthermore, oral coumadins were started the day before stent 
implantation leading to a quicker optimalization of the oral anticoagulation therapy which made a shorter 
hospital stay possible. 
Stent related restenosis (47%) seems to be comparable to historical studies of conventional 
angioplasty in venous coronary bypass grafts (4,5,30). However, these comparisons may not be valid 
since our population consisted of patients who were less than suitable candidates for conventional 
angioplasty. Earlier reports from Lausanne suggested much lower restenosis rates (9%) in lesions 
implanted with the Medinvent stent in bypass grafts (17,32). However, these differences may be due to 
either differences in selection criteria andjor methods of angiographic assessment (quantitative versus 
visual estimation). 
Frequent reintervention in our study group was required due to restenosis or progression of disease 
in other lesions, a problem similar to conventional angioplasty in bypass grafts. Three recent reports 
have been published on the late clinical follow-up of patients with conventional angioplasty in bypass 
grafts. The Thoraxcenter reported that only 41% of patients were alive and event-free (myocardial 
infarction, repeat CABG. repeat PTCA) at a median follow-up of 2.1 years (4). A review of the overall 
Dutch experience also showed limited late beneficial results with a two year and five year event free 
survival of 52% and 26% respectively in 454 bypass patients (5). Webb et al have described a 71% 
freedom from death, infarction and surgery at 5 years in bypass patients who underwent PTCA at their 
institution but did not include the 27% incidence of second angioplasty procedures also required in their 
patient group (31). It is clear that stenting and angioplasty are only short-term solutions and do not affect 
the underlying problems of progressive graft atherosclerosis and iatrogenically induced restenosis 
Conclusion 
Patients with severe coronary artery disease and previous bypass surgery who have refractory 
symptoms due to progression of disease in the bypass graft comprise a difficult challenge to the 
physician. In patients who are poor surgical risks and unsuitable candidates for balloon angioplasty due 
to unfavorable anatomy, coronary stenting with the WallstentR can be pertormed successfully and offers 
an alternative therapy. However, stent implantation remains complicated by acute thrombotic occlusion 
and bleeding complications associated with the intense anticoagulation. The early benefits of stenting 
may be mitigated by the progression of disease in bypass grafts and iatrogenic induced restenosis. 
Stenting should be considered a palliative procedure in medically refractory patients with coronary 
bypass graft disease. 
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Table I. Study population 
Number of patients 
Number of bypasses 
Number of lesions 
Number of stents 
Ejection fraction (%) 
Risk factors : 
Hypercholesterolemia > 7 mmol/1 
Hypertension 
Smokers 
Diabetes mellitus 
Table II. Specific Lesion Characteristics 
Number of bypasses 
Age of the bypass graft (mths) 
Mean diameter of the graft (mm) 
Mean minimal lumen diameter (mm) 
Length of the stenosis (mm) 
115 
69 
74 
95 
136 
53.9 (26-71) 
26 
15 
46 
14 
74 
83 (1 - 166) 
3.3 (1.6 - 7.0) 
1.4 (0- 2.9) 
16.5 (2- 50) 
Table Ill: Reasons for preferring stent implantation (categories are not mutually exclusive) 
-Patients not suitable or high risk for re-CABG 
Reasons: - high riskjbenefrt profile 
- unfavourable coronary vessel anatomy 
- poor left ventricular function (EF <35%) 
- concurrent noncardiac risk factors 
- Patients considered high risk for conventional PTCA 
Reasons: -long lesions (>15 mm) 
-tandem lesions 
- lesions containing: 
ulcers 
dissections 
clot 
-diffusely diseased bypass graft 
- eccentric lesins 
Table IV. Stent implantation data 
Number of stents 
Mean diameter of stent (mm) 
Position 
ostial 
shaft 
distal anastomosis 
Procedure Type 
Single $tent-Single Lesion 
Multiple Stent-Single Lesion 
Multiple Stent-Multiple Lesion 
116 
42 
28 
4 
6 
4 
39 
32 
23 
25 
17 
18 
34 
53 
136 
4.3 (3.5 - 6.0) 
7 
127 
4 
30 
90 
16 
Table V. Clinical follow-up 
IN HOSPITAL COMPUCATIONS 
- Acute thrombotic complications 
-Death 
- Ml 
- Acute surgery 
- Bleeding problems 
-Death 
- Recurrence AP 
- re-CABG 
PATIENTS WITH ANGIOGRAPHIC FOLLOW UP 
- Angiographic Restenosis (OS > 50%) 
- re-PTCA 
- Atherectomy 
- re-CABG 
-AMI 
-Death 
-Patients without angiographic restenosis 
15 progression of disease at another site 
-Native 
-Bypass 
- re-stent 
- re-PTCA 
- re-CABG 
-AMI 
-Death 
LATE DEATH 
117 
7 
5 
4 
23 
2 (intracranial bleed) 
5 
53 
25 
10 
2 
7 
2 
3 (after CABG) 
26 
11 
4 
6 
3 
2 
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Chapter 9 
Directional atherectomy for treatment of restenosis within coronary stents: 
Clinical, angiographic and histologic results 
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Abstract 
In 9 patients (10 procedures) directional atherectomy was performed 82-1179 days for restenosis 
within a stented coronary segment. The tissue was subsequently studied for the presence of intimal 
hyperplasia, extent of proliferation and cell density. A control (non-stented) group consisted of 13 
patients who had restenosis tissue removed 14-597 days following an initial procedure (PTCA, 
atherectomy or laser). 
The atherectomy procedures within the stent were all technically successfuL In one case a small 
fragment of the stent was removed. For the entire group, the post atherectomy result was similar to the 
initial result after stenting (2.31 ~ 0.38 mm versus 2.44 ± 0.35 mm). Five patients had follow-up 44-131 
days after atherectomy, and three of the patients had diameter stenosis > 50%. Three patients required 
reintervention (surgery, n =2; repeat atherectomy and then laser angioplasty, n= 1). 
Intimal hyperplasia was identified in 80% of the specimens after stenting and in 77% after PTCA or 
atherectomy. No dtfferences were seen in tissue removed from stenting versus PTCA/atherectomy. In 
three stented patients (47-143 days after stenting) 70-76% of the intimal cells showed morphologic 
features of a contractile phenotype by electron microscopy. Evidence of ongoing proliferation (PCNA 
antibody studies) were absent in all specimens studied. Although large individual variability was present 
in the maxima! cell density of the intimal hyperplasia, there was a trend toward a reduction in cell density 
over time. 
Atherectomy can be safely performed for restenosis in stented coronary arteries with excellent initial 
results. However, restenosis continues to limit the late effectiveness. Intimal hyperplasia is a non-specific 
response to injury regardless of the method and accounts for about 80% of cases of restenosis. This 
preliminary study suggests that smooth muscle cell proliferation and phenotypic modulation towards a 
contractile phenotype are early events and largely completed by the time of clinical presentation of 
restenosis (ie. < 2months). Cellularity results suggest that lesions may be predominantly cellular, matrix 
or a combination at a particular time after a coronary procedure. 
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INTRODUCTION 
Restenosis remains the major limitation of percutaneous transluminal coronary angioplasty (PTCA), 
occurring in 20-40% of patients within the first 6 months after angioplasty (1). The implantation of stents 
in coronary arteries or saphenous vein bypass grafts as an adjunct or alternative to PTCA was initially 
proposed to prevent late restenosis (2). However restenosis has now been documented in a significant 
number of patients in the first 6 months following stenting (3,4). The optimal method to prevent 
restenosis or to treat its occurrence (or recurrences) after PTCA or coronary stenting is unknown. No 
pharmacological treatment has been consistently successful in reducing restenosis rates after PTCA (5). 
Although restenosis occurs with the use of mechanical devices other than PTCA. no randomized trials 
have yet been reported to determine if more favorable restenosis rates result from their use. Directional 
atherectomy is one of these alternative mechanical devices for nonoperatlve coronary vascularization. 
In selected patients excellent post procedural results have been documented (6). Furthermore, since the 
tissue can be removed, it offers a unique opportunity to study the histological features of the restenosis 
tissue. 
In the past two years. we have collected data from 10 procedures performed for restenosis within a 
stented coronary segment that were treated with directional atherectomy. The purpose of this study was 
twofold: 1) to determine the feasibility. safety and late results of directional atherectomy for treatment 
of restenosis within coronary stents and 2) to assess the tissue removed from the restenotic lesion that 
caused the narrowing within these stents. Although restenosis after PTCA has been characterized by 
proliferating smooth muscle cells associated with extracellular matrix formation, we were particularly 
interested if differences existed in restenosis after stenting. In addition, slnce the temporal changes ln 
the histological pattem following PTCA are largely unknown and have been studied in only a limited 
number of patients (7), we wanted to study the proliferation rates and cell density of restenosis tissue 
removed at specffic intervals of time to better characterize the development of restenosis. For the 
histological studies, we have compared tissue retrieved by coronary atherectomy in 9 patients with 
restenosis in stented arteries with tissue obtained from 13 patients with restenosis after PTCA or previous 
atherectomy without adjunct stenting. 
METHODS 
The stent study population consisted of 9 patients who underwent 10 separate atherectomy 
procedures within the stent. Five of the patients were treated in Rotterdam. 2 patients in Belgium. 1 
patient in United States and 1 patient in Toulouse, France. The clinical characteristics are presented in 
Table 1. Flve of the procedures were performed in stents placed in bypass grafts and the other 4 stents 
were implanted in native vessels (Table 2). Six of the stented vessels contained the WallstentR 
{Schneider, Zurich) which is a self expandable stainless steel woven mesh stent (3,4). Two patients had 
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been implanted with a Palmaz-Schatz ™ stent (Johnson and Johnson. Warren, New Jersey) which is a 
balloon expandable stainless steel tubular stent (8). One patient had received a WiktorTM stent 
(Medtronic, Minneapolis). a tantalum balloon expandable stent with a helical coil design (9). Five of the 
patients were stented for primary lesions. The remaining 4 patients were originally stented for restenosis 
after PTCA. Two of these patients (Patient 4 and 9) had multiple restenoses and one of these patients 
(Patient 4) underwent a second atherectomy procedure within the stent for a restenosis recurrence after 
the initial atherectomy. Atherectomy was performed within the narrowed stent 82-1179 days post 
stenting. Three of the patients had separate PTCA procedures for stent-re!ated problems prior to the 
atherectomy. Patient 1 initially underwent PTCA for restenosis 97 days after stenting and then required 
an atherectomy procedure 47 days later for a second restenosis within the stent. Patient 3 underwent 
balloon angioplasty for restenosis 21 0 days after stent implantation and then atherectomy 156 days later 
(366 days after stenting). Due to restenosis, a second atherectomy procedure was done 96 days after 
the first atherectomy (462 days after stenting). Patient 8 had a symptomatic acute occlusion fwe days 
after stenting. After recanalization with intracoronary streptokinase and PTCA, he had an uneventful 
recovery until he experience recurrence of angina 5 months later due to restenosis within the stent. 
Patient 9 received a second stent for a different lesion in the bypass graft 570 days after the first stent. 
A lesion subsequently developed in the initial stent and was treated by atherectomy 1179 days after the 
first stent implantation (609 days after the second stent). 
For the histological evaluation of the tissue, we selected a control group which consisted of all 
patients in the Thoraxcenter experience who underwent an atherectomy procedure for restenosis after 
PTCA, atherectomy or laser (n=13) (Table 5). This group consisted of 11 men and 2 women, and the 
ages ranged form 40-71. The interval of time between the most recent intervention and atherectomy for 
restenosis ranged from 4·597 days. 
Angiographic Analysis 
All cineangiograms were analyzed using the computer assisted cardiovascular angiography analysis 
system (CAAS) which has previously been discussed in detail (10). The important steps will be briefly 
described. Any area of size of 6.9 X 6.9 mm in a selected cineframe (overall dimensions 18 X 24 mm) 
encompassing the desired arterial segment can be digitized by a high resolution CCD-camera with a 
resolution of 512 X 512 pixels and 8 bits of gray level. Contours of the the desired segment are 
determined automatically, based on the weighted sum of the first and second derivative functions applied 
to the digitized brightness information along scanlines perpendicular to the local centerline of the desired 
segment. A computer-derived estimation of the original dimension at the site of the narrowing is used 
to define the interpolated reference diameter. This technique is based on a computer-derived estimation 
of the original diameter values over the analysed region (assuming there was no narrowing present) 
according to the diameter function. The absolute diameter of the stenosis as well as the reference 
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diameter are measured by the computer which uses the known outside diameter of the perspex model 
as a calibration factor. 
Tissue Analysis 
Following extraction of the tissue with the Simpson coronary atherocathR, the specimens were 
carefu!ly removed from the housing chamber of the catheter, washed with 0.9% saline and cut into 
pieces of approximately 1 mm by 1 ~2 mm. Representative pieces were fixed in 10% buffered formalin 
for light microscopy studies. The specimens were processed according to standard procedures and then 
paraffin sections were stained with haematoxylin and azophloxine, and with Van Giesen. Three to fwe 
slides were prepared at various levels through the paraffin block. The tissue was specifically assessed 
for the presence of intimal hyperplasia and atherosclerotic plaques according to the definitions of 
Johnson et a! (11). Jntimal hyperplasia was defined as highly cellular tissue consisting of randomly 
arranged stellate and spindle cells in an abundant, collagen containing extracellular matrix. 
Atherosclerotic plaques consisted of dense fibrous tissue with abundant collagen, scattered fibroblasts 
and occasional mononuclear cells, including lymphocytes, and macrophagesjfoam cells. 
Immunohistochemical studies 
In deparaffinized sections, immunostaining was performed with monoclonal antibodies directed 
against a!pha~smooth muscle cell actin (Sigma, St. louis, Missouri) using an indirect conjugated 
peroxidase procedure. Proliferating cells were identified immunoctyochemically using a monoclonal 
mouse anti-human proliferating ceU nuclear antigen (PCNA) antibody (DAKO~PCNA, PC10, Glostrup, 
Denmark). This antigen is a DNA polymerase auxiliary protein and is expressed during G1, S (DNA 
synthesis), and G2 phases of the cell cycle (12~14) but not in the quiescent G0 phase. 
Electron Microscopy 
Representative pieces were fixed in a solution of glutaraldehyde-formaldehyde (4CF-1 G). Postfixation 
was done with Os04 • The specimens were then embedded in epon and ultrathin sections were stained 
with uranyl acetate and lead citrate. All specimens contained smooth muscre cells with abundant 
extracellular matrix. Cells were assessed as either contractile or synthetic type smooth muscle cells 
based on the following morphologic features. The synthetic cells were characterized by an abundant 
cytoplasmic organelles including endoplasmic reticulum, Goigl apparatus and ribosomes, and by 
peripheral location of myofiiaments (Figure 1 a). The cytoplasm of the contractile cells consisted mostly 
of myofilaments and a few mitochondria (Figure 1b). Cells were counted in multiple fields (at least 150 
cells in total} and classified according to these criteria into the two phenotypes. 
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Figure 1. Transmission electron micrograph showing A) a smooth muscle celf with the synthetic 
phenotype. There are abundant cytoplasmic organelles including endoplasmic reticulum, Gofgi 
apparatus, and ribosomes. Only a few myofifaments are present and are located in the periphery of the 
cell. B) Contractile smooth muscle cell cytoplasm consists mostly of myofilaments and a few 
mitochondria. 
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Cell Density of Intimal Hyperplasia 
In haematoxylin and azophloxine stained sections, areas of intimal hyperplasia were identified and 
cell number was assessed in several fields by a computerized morphometry system (!BAS, Kontron, 
Oberkochen, Germany). The maximum value recorded was used for the determination of cell density 
which was expressed as cell number; mm2 Jntimal tissue. Specimens without intimal hyperplasia were 
excluded from this measurement since this part of the study was specifically designed to look for 
temporal changes in cellularity occurring in intimal hyperplasia formed in response to the coronary 
procedure. 
RESULTS 
Clinical 
All atherectomy procedures were technically successful (residual stenosis < 50% with retrieval of 
tissue) and there were no procedural complications other than a transient ischemic attack that occurred 
during a PTCA of a separate lesion in one patient. The only technical problem occurred with the 
Wiktor™ stent. Following the procedure, the configuration of the stent was disrupted although no 
complications ensued. Tiny fragments of the tantalum wire were observed in the atherectomy materia!. 
All of the patients experienced immediate improvement in their symptoms. At late follow-up (4-15 
months), Patient 2 died following bypass surgery for restenosis after atherectomy and Patient 5 died due 
to endstage renal failure. Two other patients required additional interventions for recurrence of symptoms 
due to restenosis after atherectomy. Patient 1 underwent bypass surgery 6 months after the atherectomy 
and Patient 4 was treated with excimer laser therapy. Five of the patients remained in NYHA Class 1-11. 
Quantitative Angiography (Table 3) 
Immediately after placement of the stent there was an overall significant increase in the minimal 
luminal diameter and a significant decrease in the percentage of the diameter with stenosis (changing 
from a mean [:;~:SD] of 1.12::':0.36 to 2.44::':0.35 mm and from 63:;~:9% to 21::!:10%, respectively; 
p<0.001). However, at follow-up prior to the atherectomy, all of the lesions had deteriorated to an overall 
value of 0.99::!:0.24 mm and 64:t7%. respectively. The immediate result after atherectomy was similar 
to the acute stenting results (2.31 :t0.28 mm, 27::':10%). late follow·up after atherectomy was only done 
in 5 of the lesions, with significant deterioration (loss of :<!0.72 mm) occurring in three lesions. An 
example of the angiographic appearance of the lesion pre and immediately post stenting, at follow-up 
(pre atherectomy) and post atherectomy is shown in Figure 2. 
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Figure 23. Stenosis in proximal bypass graft prior to stenting. Figure 2b.lmmediate result after stenting. 
Figure 2c. Restenosis in stent distal to original Site of stenosis. Figure 2d. Immediate result after 
atherectomy within the stent. 
Histology 
(i) After Stenting (fable 4) 
The characteristic feature in tissue obtained in 8 of the lesions was intimal hyperplasia defined as a 
proliferative cellular response associated with a matrix of loose connective tissue. The area of intimal 
hyperplasia was typically sharply demarcated from the underlying sclerotic plaque. However the 
cellularity. amount of collagen. and extracellular matrix of the intimal hyperplasia varied between patients 
(Figures 3 and 4). 
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-Figure 3. Haemotoxylin~azofluoxine stained section of tissue removed from a stem 89 days after 
stenting. The section has the typical appearance of intimal hyperplasia {highly cellular tissue consisting 
of randomly arranged stellate and spindle cells in a loose extracellular matrix). (original magnification 
25x). 
·. 
-
Figure 4. Haemotoxylin-azofluoxine stained section of tissue removed from a stent 156 days after 
stenting. No intimal hyperplasia was present. The tissue consisted of a few cells embedded in an 
abundant, collagen containing extracellular matrix. (original magnification 10X). 
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In eight of the lesions, the main cell type within the lesions was identified as smooth muscle cells based 
on presence of SMC specific alpha actin. Specific staining for endothelial cells and macrophages was 
negative in two specimens tested although lymphocytes were identified in tissue from Patient 3. No giant 
cells as evidence of a foreign body reaction were identified in any tissue specimen. In three of the 
specimens prominent capillary ingrowth was evident. In two specimens, the internal elastic lamina and 
adjacent media were identified. No evidence of adventitia was recovered (Figure 5). 
Ultrastructural studies in three of the stented patients (Patients 1, 6 and 8) showed that the majority 
{70-7SOk) of intimal cells were contractile in morphology. No differences could be appreciated at the 
different time intervals. 
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Figure 5. Haemotoxylin-azofluoxine stained section of tissue removed from a stent 82 days after 
stenting. The presence of the media is indicated by the internal elastic lamina (arrow) and the typical 
architecture of the smooth muscle cells in the media. (original magnification 10x). 
(ii) After PTCAjAtherectomy (Table 5) 
ln the control PTCAjatherectomy group. the histologic appearance of the tissue was indistinguishable 
from the stent tissue. Intimal hyperplasia was evident in 10 of the thirteen specimens. and again various 
stages of cellularity were evident. Media was obtained in 3 of the specimens (22%). No evidence of 
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adventitia was recovered. 
Proliferation studies {Table 5 and 6) 
In all specimens studied. no cells could be identified that reacted with the antibody to PCNA 
Cell Density 
The maximal cell density of the intimal hyperplasia in both the stent and control groups is shown in 
Figure 6. Although large individual variability was present, there was a trend towards a reduction in cell 
density of the intimal hyperplasia over time. 
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Figure 6. Maximal cell density (cell numberj mrrf) in restenosis lesions following stenting, and PTCA 
or atherectomy. The x axis represents the number of days after the procedure. Only restenosis lesions 
with intimal hyperplasia were evaluated. There is a trend towards decreasing cellularity over ti'me in 
these lesions although considerable individual variability is evident. 
DISCUSSION 
Restenosis persists as an important limitation to all forms of non-operative coronary revascularization, 
despite increasingly more complex forms of interventions such as stenting, atherectomy and laser-
assisted therapy. It remains to be established whether any mechanical method can effectively treat (and 
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prevent recurrent) restenosis after coronary balloon angioplasty or stenting. We studied the efficacy of 
directional atherectomy in 10 cases as a procedure to prevent recurrence of restenosis. This study 
illustrates in a limited number of patients that directional atherectomy can be safely performed within a 
coronary stent and provide immediate results comparable to the initial stenting procedure. In fact, 
atherectomy may be a safer procedure in stented than in nonstented vessels since the wires appear to 
limit the depth of the cutter into the vascular wa!l and thus reduce the possibility of perforation. However 
it is still possible to remove media (as in Patients 3 and S) either between the stent wires or if the stent 
wire has penetrated the internal elastic lamina. Restenosis occurred in both cases of medial resection. 
The problem of removing or disrupt~ng part of the stent should be particularly of concern when the 
restenosis occurs immediately proximal to the lesion and the cutter can abut against the proximal part 
of the stent. Although the immediate results of atherectomy were excellent, the recurrence of clinical 
restenosis in three of the patients (33%) in the first S months after the atherectomy procedure 
emphasizes that atherectomy alone will not prevent the restenosis problem. 
Histological evaluation of the tissue retrieved from restenosis lesions (after stenting, PTCA, 
atherectomy or laser) confirms the findings of previous studies that 1) in atherectomy specimens, intimal 
hyperplasia is the characteristic feature in 75-80% of cases, and that the remaining 20-25% of cases 
contain only atherosclerotic plaque material without the features of intimal hyperplasia {11) and 2) 
smooth muscle cells are the predominant ce!l type found in restenosis lesions (15·17). It is unclear 
whether the absence of intimal hyperplasia in restenosis lesions is due to a sampling error by the 
atherectomy catheter or due to another mechanism of restenosis such as elastic recoil or inadequate 
inital dilatation. If larger studies confirm this observation, the clinical importance is that restenosis 
interventional trials (pharmacological or mechanical) with the intention to prevent smooth muscle celt 
proliferation and the formation of intimal hyperplasia, can only potentially affect approximately 75% of 
the restenosis population at risk. Future study designs may consider this in the determination of sample 
size for restenosis trials. In addition our study also illustrates that intimal hyperplasia predominates in 
restenosis tissue, regardless of the initiating procedure, with no unique features attributable to senting 
in general or to a particular type of stent. This underscores the fact that intimal hyperplasia is a 
nonspecific response to vascular injury regardless of the method of damage (18, 19). 
The temporal sequence of events in the formation of intimal hyperplasia following coronary 
inter.tention remain largely unknown. Results from our study suggest that: 
1) Smooth muscle cell proliferation is an early event, and barely detectable 2 months after the 
procedure. To date. there is no data on the cell proliferation rates in humans following balloon 
angioplasty although the use of cyclin immunocytochemistry to label proliferating cells in human de-novo 
atherosclerotic plaques has previously shown a labeling index ranging from less than 1% to greater than 
4% (20,21). Our results. showing no proliferative activity in the smooth muscle cells 82 days to 700 days 
post stenting. suggest that smooth muscle cell proliferation is an early and limited process after vascular 
injury in humans. This is similar to the results following vascular balloon denudation in animals in which 
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SMC proliferation is first observed 48 hours after vascular injury and peak proliferation occurs at about 
1 week which is followed by a rapid decline reaching base-line values by a month after the vessel injury 
(22). Due to the limited period of SMC proliferation early after coronary angloplasty, pharmacological 
agents designed to reduce proliferation may only be required in the first two months after the procedure 
rather than the six months usually prescribed. 
2) The vast majority of smooth muscle cells modulate towards the contractile phenotype early 
after the procedure. Therefore only a relatively small percentage of the smooth muscle cells Qe. those 
with the synthetic phenotype) appear to be responsible for the synthesis of extracellular matrix proteins 
since in-vitro studies have shown that the production of proteoglycans and collagen is 5 fold and 26-45 
fold higher, respectively, in the synthetic phenotype (23,24}. In our study, synthetic type smooth muscle 
cells only comprised 24-30% of the overall smooth musde cells in the three patients who had 
atherectomy periormed 135-205 days post stenting. Jn contrast. Nobuyoshi et al identified Nsynthetic" 
type smooth musde cells as the predominant cell type ln the first 6 months and thereafter, the 
"contractile~ type smooth muscle cell was dominant (7). This earlier predominance of contractile smooth 
muscle cells in our study may be due to differences in methods of assessment (electron microscopy 
versus less reliable light microscopic features in Noboyoshi's series) or possibly related to differences 
in procedures (stenting versus PTCA alone). Interestingly, in a balloon-injury model in rats, Kocher et 
af observed a similar phenotypic change (ie. to a contractile type) to our study in lesions 75 days after 
injury. based on the ratio of smooth muscle to non muscle actins that had returned to levels of normal 
medial (contractile) SMCs (25). 
3) Lesion cellularity decreases as a function of time but with a large interindividual variability_ 
As a consequence, lesions may be predominantly cellular, matrix or a combination at a particular 
time after a coronary procedure. Restenosis has been regarded as a process that is largely completed 
by 6 months after a procedure. Although cellular proliferation and matrix synthesis are recognized as 
the components of the restenosis lesion, the remodelling of the vessel wall after vessel injury is not 
understood and the relative contribution (and possibly the preeminent role) of the matrix components 
(proteoglycans and collagen) has not been appreciated. A temporal relationship between the cellularity 
of the intimal hyperplasia lesions appears to exist (although large individual variability is present). Since 
cellular proliferation appears to be an early event. the cellularity of the lesion is primarily related to the 
amount of synthesized matrix. The wide range of cell density at a particular interval of time may be 
related to either inherent biological variability or possibly sampling error. The total amount of matrix 
present at a particular time is related to the synthesis and resorption of the particular component. The 
turnover of proteoglycans is unknown although the limited data shows low collagen and elastin turnover 
in experimental models of hypertension (26). The individual variability in cell density emphasizes the 
differential importance of matrix deposition in individual lesions. Further stlXlies to characterize the 
composition and extent of the matrix synthesis during remodelling of the vessel after atherectomy, 
stenting or PTCA should contribute to a better understanding of the restenosis process. Furthermore, 
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agents that interfere with matrix synthesis are a relatively untested form of therapy and may be 
synergistic to pharmacologic approaches to limit smooth muscle cell proliferation which to date have 
not affected the rate of restenosis. 
Study limitation 
This study is primarily limited by the relatively small amount of tissue extracted by the atherectomy 
catheter which causes a potential sampling bias error. In particular, the device may not have removed 
the region of intima! hyperplasia containing the highest cell density or high cetl proliferation or possibly 
even may have completely missed areas of intimal hyperplasia in specimens that only showed old 
atheroma. Therefore the findings from this study with respect to the remodelling of the lesion over time 
should be confirmed in larger studies. 
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Table 1. Clinical Characteristics 
Patient Age Sex Previous Ml Previous CABG Smoker Hypercholesterolemia OM Hypertension 
56 M 1986 23/9/82 + 
2 58 M + 
3 41 M + 
4b 55 M Inferior, 1977 1977/1983 + + 
5 64 M Sept 1986/Dec 1987 + + + + 
6 67 F Posterior NQMI 26/3/86 + 
7 67 M 17/1/89 
4a 55 M Inferior, 1977 1977/1983 + + 
8 44 M Inferior, 1989 No + 
9 76 M Inferior, 1974 1974 + 
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Table 2. Stent Characteristics 
Patient Stant Vessel Stent Type Stant Diameter Reason For Stant Time to Present Status 
(mm) Atherectomy (NYHA Class) 
CABG Wallstent 3.5 Primary 47 days (144) Surgery for restenosls 
2 LAD Palmaz-Schatz 3.0 Restenosls 82 days Surgery for restenosls 
3 LAD Palmaz-Schatz 3.5 Primary 89 days 
4b LAD Wallstent 3.5 Restenosls 96 days (462) Laser angioplasty 
5 Circumflex Wallstent 3.5 Primary 130 days 
6 CABG Wa!lstent 4.0 Primary 135 days 
7 CABG Wa!lstent 4.0 Primary 143 days II 
4a CABG Wallstent 3.5 Restenosls (x4) 156 days (366) see above 
8 RCA Wiktor 3.5 Restenosls 183 days 
9 CABG Wallstent 5.0 Restenosls (x2) 1179 days (609) 
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Table 3. Anglographlc Results 
Pre Stent Post Stent FU-S Stent Follow-Up Post Atherectomy Ath Follow-Up FU-Ath 
Patient Reference Diameter MLO OS MLO OS (days) MLO OS MLO OS MLO OS (days) 
(mm) (mm) (%) (mm) (%) (mm) (%) (mm) (%) (mm) (%) 
2.37 1.07 56 1.95 22 49 (144) 0.91 62 2.58 8 0.63 74 131 
2 2.94 1.15 59 2.67 5 82 1.19 56 2.26 24 1.89 39 14 
3 3.14 1.94 49 2.94 14 89 1.34 58 2.18 32 1.34 58 44 
4b 3.1 96 0.90 58 2.33 47 NA 
5 3.1 1.1 60 2.1 19 130 1.30 59 2.37 25 
6 2.9 0.6 72 2.0 38 135 0.63 78 1.77 32 2.46 22 186 
7 2.25 0.75 78 2.55 30 143 0.70 69 2.1 29 not done 
4a 3.1 1.2 61 2.8 15 156 (386) 1.03 86 2.81 21 0.9 58 96 
8 3.33 0.96 71 2.36 28 163 1.11 62 2.34 29 2.37 20 75 
9 2.75 1.40 94 2.71 21 1179 0.81 71 2.4 22 not done 
Mean 2.89 1.12 63 2.44 21 0.99 94 2.31 27 1.79 39 
(±SO) (0.35) (0.36) (9) (0.35) (10) (0.24) (7) (0.28) (10) (0.67) (19) 
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Table 4. Histology Results 
Patient Duration Post Intimal Media Adventnla Actin PCNA 
Procedure Hyperplasia 
47 days (144) ++ 
2 82 days + + NA NA 
3 89 days + ++ 
4b 96 days (462) + ++ 
5 130 days + + NA NA 
6 135 days + ++ 
7 143 days + ++ NA 
4a I 56 days (366) ++ 
8 183 days + ++ 
9 II 79 days (609) + ++ 
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Table 5. Histology Results of Restenosls after PTCA/Atherectomy 
Patient Age Sex Vessel Procedure Duration Post Intimal Media Adventitia PCNA 
Procedure Hyperplasia 
66 F lAD PTCA 14 days + 
2 51 M lAD Ath 27 days (58) + 
3 66 M RCA PTCA 56 days 
4 67 M lAD PTCA so days + 
5 60 M ex PTCA 88 days + NA 
6 75 M lAD PTCA 95 days NA 
7 56 M lAD PTCA 113 days + + NA 
8 52 M lAD PTCA 126 days (201) + NA 
9 40 M lAD Ath 133 days + 
10 71 F lAD PTCA 134 days + + NA 
11 49 M lAD Laser 165 days + NA 
12 64 M lAD Ath 195 days + NA 
13 58 M RCA PTCA 597 days + NA 
142 
References 
1. Detre K, Holubkov R., Kelsey S et al. One·year follow·up results of the 1985-1986 
National Heart, Lung, and Blood Institute's Percutaneous Transluminal Coronary 
Angioplasty Registry. Circulation 1989;80:421-428 
2. Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger L Intravascular stents to 
prevent occlusion and reste-nosis after transluminal angioplasty. New Engl J Med 
1987;316:701-706. 
3. Serruys PW. Strauss BH. Beatt KJ, Bertrand M, Puel J. Rickards AF, Kappenberger L 
Meier 8, Goy JJ, Vogt P, Sigwart U. Angiographic follow-up after placement of a self-
expanding coronary stent. New Engl J Med 1991;324:13-17. 
4. Strauss BH, Serruys PW. de Scheerder IK, Tijssen JGP, Bertrand M, Puel J, Meier 8, 
Kaufmann U. Stauffer JC, Rickards AF, Sigwart U. A relative risk analysis of the 
angiographic predictors of restenosis in the coronary WallstentR. Circulation 1991 (in 
press) 
5. Hermans WRM, Rensing BJ, Strauss BH, van den Brand M, Suryapranata H. de Feyter 
PJ, Serruys PW. Prevention of restenosis after percutaneous transluminal coronary 
angioplasty (PTCA): The search for a "magic bullet". Am Heart J 1991;122:171. 
6. Serruys PW, Umans VAWM, Strauss BH, van Suylen RJ, de Feyter PJ. Percutaneous 
directional coronary atherectomy: Short-term clinical and angiographic results. Br Heart 
J 1991;66:122-129 
7. Nobuyoshi M. Kimura T. Ohishi H. Horiuchi H, Nosaka H, Hamasaki N, Yokoi H, Kim 
K Restenosis after percutaneous transluminal coronary angioplasty: pathologic 
observation in 20 patients. J Am Coli Cardiel 1991 ;17:433-439 
8. Schatz RA Bairn DS. Leon M et al. Clinical experience with the Palmaz-Schatz coronary 
stent. Initial results of a multicenter study. Circulation 1991 ;83:148-161. 
9. van der Giessen WJ, Serruys PW. van Beusekom HMM, van Woerkens W, van Loon H. 
Strauss BH, Verdouw PD. Coronary stenting with a new, radiopaque. balloon 
expandable endoprosthesis in pigs. Circulation 1991;83:1788-1798. 
143 
10. Reiber JHC, Serruys PW, Kooijman CJ et al. Assessment of short-. medium. and long-
term variations in arterial dimensions from computer-assisted quantitation of coronary 
cineangiograms. Circulation 1985;71 :280-288. 
11. Johnson DE, Hinohara T, Selmon MR, Braden W, Simpson JB. Primary peripheral 
arterial stenoses and restenoses excised by tranluminal atherectomy: a histopathologic 
study. JAm Coli Cardiol1990;15:419-425 
12. Bravo R. Synthesis of the nuclear proteln cyclin (PCNA) and its relationship with DNA 
replication. Exp Cell Res 1986;163:287-293 
13. Robbins BA, de Ia Vega D, Ogata K, Tan EM. Nakamura RM. Immunohistochemical 
detection of proliferating cell nuclear antigen in solid human malignancies. Arch Pathol 
Lab Med 1987;111:841-845 
14. Kurki P, Ogata T, Tan EM. Monoclonal antibodies to proliferating cell nuclear antigen 
(PCNA}jcyclin as probes for proliferating cells by immunofluorescence microscopy and 
flow cytometry. J lmmunol Methods 1988;109:49-59 
15. Essed CE, Brand van den M. Becker AE. Transluminal coronary angiop!asty and early 
restenosis: fibrocellular occlusion after wall laceration. Br Heart J 1983;49:393-396. 
16. Austin GE. Ratliff NB, Hollman J, Tabei S. Phillips DR. Intimal proliferation of smooth 
muscle cells as an explanation for recurrent coronary artery stenosis after percutaneous 
coronary angioplasty. JAm Coli Cardiel 1985;6:369-375. 
17. Waller SF, Rothbaum OA, Garfinkel HJ. Uibright TM, Unnemeier TJ. Berger SM. 
Morphologic observations after percutaneous transluminal balloon angioplasty of early 
and lateaortocoronary saphenous vein bypass grafts. JAm Coli Cardiol1984;4:784-792. 
18. Waller BF, Pinkerton CA, Rothbaum DA, UnnemeierTJ, Orr CM, VanTassel JW, Slack 
JD. Restenosis tissue following hot tip laser, excimer laser, primary atherectomy and 
balloon angioplasty procedures: Histologically similar intimal proliferation in 33 
atherectomy procedures. Circulation 1990;82:111-312 (Abstract) 
144 
19. Karsch KR. Haase KK. Wehrmann M, Hassenstein S, Hanke H. Smooth muscle cell 
proliferation and restenosis after stand~alone coronary excimer laser angioplasty. JAm 
Coil Gardiol1991;17:991-994 
20. Gordon 0, Schwartz SM. Benditt EP, Wilcox JN. Growth factors and cell proliferation 
in human atherosclerosis. Transplant Proc 1989;21:3692-3694 
21. Gordon 0, Reidy MA, Benditt EP, Schwartz SM. Cel! proliferation in human coronary 
arteries. Proc Natl Acad Sci USA 1990;87:4600-4604 
22. Clowes AW, Reidy MA. Clowes MM. Kinetics of cel!ular proliferation after arterial injury. 
Smooth muscle growth in the absence of endothelium. Lab Invest 1983;49:327-333 
23. Ang AH, Tachas G. Campbetl JH. Bateman JF, Campbell GR. Collagen synthesis by 
cultured rabbit aortic smooth~muscle cells. Alteration with phenotype. Biochem J 
1990;265:461-469 
24. Merrilees MJ, Campbell JH, Spanidis E. Campbell GR. Glycosaminoglycan synthesis by 
smooth muscle cells of different phenotype and their response to endothelial celt 
conditioned medium. Atherosclerosis 1990;81:245-254 
25. Kocher 0, Skalli 0, Bloom WS, Gabbiani G. Cytoskeleton of rat aortic smooth muscle 
cells: normal conditions and experimental intimal thickening. Lab Invest 1984;50:645-
652. 
26. Keeley PN, Elmoselhi A, Leenen FHH. Effects of antihypertensive drug classes on 
regression of connective tissue components of hypertension. J Cardiovasc Pharm 
1991;17[suppi2]:S64-S69 
145 

Chapter 10 
Donor origin of intimal smooth muscle cells in a de novo human coronary artery stenosis after 
heart transplantation: polymerase chain reaction analysis of VNTR loci 
BH Strauss. RJ van Suylen, PJ de Feyter, AG Uitterlinden, 
WJF de Leeuw, GJJM Trommelen, PW Serruys 
(submitted) 
147 

Abstract 
Smooth muscle cells are the predominant cell type found in the intimal lesions of atherosclerosis and 
restenosis following percutaneous transluminal coronary angioplasty. Animal studies have suggested the 
cells are derived from the vessel wall and not the circulation, although it has never been shown in man. 
In this study. tissue was removed by a Simpson coronary atherocath from a severe narrowing that had 
developed in the circumflex artery of a male who had undergone an orthotopic cardiac transplantation 
almost 5 years previously. The origin of the cells (donor versus recipient) was determined by amplifying 
the DNA by the polymerase chain reaction and comparing the electrophoresis pamem of three separate 
highly polymorphic variable number of tandem repeat (VNTR) gene loci in the atherectomy specimen. 
a donor myocardial biopsy performed immediately after the transplant, and a sample of the recipient 
blood. The DNA profiling results for the three VNTR loci showed that the coronary intimal tissue and the 
donor myocardial biopsy share the same alleles and that this pattern consistently differed from that of 
the recipient's blood. These results support the concept that the vascular intimal lesions typically seen 
in atherosclerosis and restenosis consist primarily of smooth muscle cells that are derived from within 
the vessel wall and not from the circulation. 
key words: atherosclerosis, restenosis, smooth muscle cells, polymerase chain reaction 
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INTRODUCTION 
Focal intimal thickening, common to primary atherosclerotic lesions and restenosis after mechanical 
coronary interventions such as percutaneous transluminal coronary angioplasty (PTCA), is a non-specific 
response of the vessel wall to a variety of injuries. The predominant cellular component in fibrous plaque 
is the smooth muscle cell (1 ). It remains unknown whether the smooth muscle cell in human coronary 
lesions is derived from cells circulating in the blood or from the vessel wall itself. Evidence in support 
of either possibility has appeared ln the literature although animal studies have suggested that the tunica 
media or subintimal space is the source of the smooth muscle cells (2-5). Atherosclerotic lesions 
developing in the coronary arteries after orthotopic heart transplantation provide a unique opportunity 
to identify the origin of the cells constituting the atherosclerotic plaque since the donor and recipient 
invariably differ in their genetic content. Such genetic differences can be shown by electrophoretic 
analysis of alleles from the highly polymorphic Variable Number of Tandem Repeat (VNTR) gene loci 
which have a widespread occurrence in the human genome (6,7). The 01$80 (8), Apo 8 3' VNTR locus 
(9) and the D17S5/D17S30 VNTR locus (10) represent such independent and highly polymorphic DNA 
markers which can be used for biological identification purposes. In this case report, we show by 
electrophoretic analysis of alleles from three separate VNTR loci amplified by the polymerase chain 
reaction (PCR) technique (11), that the smooth muscle cells present in a de novo human coronary lesion 
after heart transplantation are derived from the donor vessel walt and not from circulating recipient cells. 
Case History: A 37 year old male underwent orthotopic cardiac transplantation in January 1985 
because of endstage biventricular heart failure due to idiopathic dilated cardiomyopathy. The donor heart 
came from a 34 year old woman with no previous cardiac history. At the conclusion of the 
transplantation, a baseline myocardial biopsy (81) was taken from the right ventricle and immediately 
frozen in isopentane in liquid nitrogen at -70° C. As part of routine follow-up, yearly coronary angiograms 
were performed (Figure 1A). In January 1990, a new 60% diameter stenosis had developed in the mid 
circumflex coronary artery (Figure 1 B). On the basis of a reversible Th201 perfusion defect in the left 
ventricular posterior wall, the patient underwent percutaneous directional coronary atherectomy in 
October 1990 without complication (82). Venous blood (Blo) was drawn from the patient for DNA 
profiling studies. The tissue removed from the coronary artery was immediately frozen in isopentane in 
liquid nitrogen at -70° and representative sections were stained with haematoxylin-azofloxine and van 
Giesen stains. The remainder of the coronary tissue, the myocardial biopsy and the donor blood were 
then sent for PCR analysis of the three VNTR loci. 
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Figure 1a. Angiogram from 1989. No discrete lesions are evident. 
Figure 1b. Angiogram from 1990. A 60% eccentric stenosis has developed in the circumflex artery 
(arrow). 
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MATERIALS AND METHODS 
Genomic DNA was isolated from the biopsies(± 1 mm3) by lysing the tissue in a solution of 400 J.l.l 
containing 10 mM Tris-HCI, pH 8.0; 10 mM Na,EDTA; 100 mM NaCI; 0.5% SDS; 500 ~I proteinase K 
(Merck) and incubating at ssoc for 4 h under gentle shaking. The lysis mixture was extracted once with 
Tris-saturated phenol and once with chloroform-isoamylalcohol (24:1) and subsequently ethanol-
precipitated. The DNA was dissolved in a solution containing 10 mM Tris-HCI (pH 8.0) and 1 mM 
Na,EDTA Biopsy #1 was dissolved in 15 ~I (800 ngj~l) and Biopsy #2 was dissolved in 20 ~I (20 
ng/J.I.I). For DNA isolation from blood (BI), the erythrocytes were first lysed by adding 3 volumes of lysis 
buffer (155 mM NH4CI, 10 mM KHC03 and 1 mM Na,..EDTA) and incubating on ice for 30 min. After 
centrifugation, the pellet containing the white blood cells, was resuspended and incubated in 10 mM Tris-
HCI (pH 8.0); 10 mM Na,EDTA; 100 mM NaCI; 0.5% SDS; 500 ~g/ml proteinase K (Merck) at 65°C for 
4 h under gentle shaking. The lysis mixture was extracted once with Tris-saturated phenol and once with 
chioroform-isoamylalcohol (24:1) and subsequently ethanol-precipitated. The DNA was dissolved in 10 
mM Tris-HCI (pH 8.0) and 1 mM Na2EOTA to a concentration of approximately 800 ng/J.I.I. The yield of 
genomic DNA from whole blood was 35 1-1-g/ml blood. 
For the polymerase chain reaction (PCR) analysis, 10 ng of genomic DNA was added to a solution 
(with a final volume of 50 J.l.l) containing 1.5 mM MgCI2 (01 S80 and Apo B 3' VNTR) or 1.0 mM MgCI2 
(D17S5/D17S30), 50 mM KCI, 10 mM Tris-HCI (pH 8.3), 200 ~M dNTPs (Pharmacia, Sweden), 10% 
glycerol (Merck, Germany), 0.2 mgjml acetylated BSA (Gibco-BRL, USA), 300 ng primers, 1 unit Taq 
polymerase and 5% of a detergent solution according to the manufacturers (Gibco-BRL USA) 
instruction. Before entering the temperature cyding, the solutions were overlaid with SO !J.l Nujol mineral 
oil (Perkin-Elmer, USA). After an initial denaturation of 4' at 94"C, 30 cycles of incubations at different 
temperatures specific for each focus (the 01 S80 locus: denaturation for 2' at 94°C, annealing for 2' at 
6S"C, and primer extension for 4' at 72"C with a final primer extension for 10' at 72"C; the Ape B 3' 
VNTR locus: denaturation for4' at 94°C, annealing/primer extension for6' at SB"C and a final extension 
for 10' at SS"C; the D17S5jD17S30 locus: denaturation for 4' at 94°C, annealing for 30" at 55" C. 
primer extension for 4' at 72"C and a final extension for 10' at 72°C) were performed in a thermal cycler 
apparatus (BIOMED, Germany). 
After completion of the PCR reaction, samples of 5-30 iJ.l of the solution were analysed on a 9 % 
polyacrylamide gel (acrylamide:bisacrylamide=37:1) run in 1xTAE (40 mM Tris-HCl, pH 7.4; 20 mM Na-
acetate. 1 mM N~EDTA) for 1.5 hours at 200 V in a vertical slab gel electrophoresis apparatus placed 
in a buffertank kept at SO"C (12). After electrophoresis the separation pattern was stained in a solution 
containing 30 IJ-9/ml ethidium bromide and documented by polaroid photography under 302 nm (UVP 
products, USA). 
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RESULTS 
The specimen contained cells with the morphologic appearance of smooth muscle cells but were not 
arranged with the architecture of a tunica media (Figure 2). The smooth muscle cell identity was 
confirmed through immunoreactivity for smooth muscle cell specific alpha actin as detected by 
immunohistochemistry with monoclonal antibodies (Sigma, St. Louis)(Figure 3). A few celts stained with 
leukocyte common antigen. Monoclonal antibodies directed to macrophages and endothelial cells were 
negative.1 
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Figure 2. Coronary atherectomy specimen (haematoxylin-azofluoxine stain) containing intimal tissue. 
Figure 3. Coronary atherectomy specimen. Smooth muscle cells are identified by the dark staining. An 
antibody specific for smooth muscle alpha actin has been coupled to a peroxidase reaction and is 
responsible for the dark colour. 
The results of gel electrophoretic separation obtained after PCR amplifcations of alleles of the 
Dt7$5jS30 locus Oanes 2-4). the Dt$80 locus (lanes 6-8), and the Ape 6 3' VNTR locus (lanes 11-13) 
are shown in Figure 4. The donor myocardial biopsy (81) and the coronary intimal tissue (82) shared 
the same alleles and this pattern consistently differed from that of the recipient's blood (Bio). For the 
D17$5jS30 locus Oanes 2-4) PCR products of 372 base pairs (bp) and 550 bp (the latter one is faintly 
visible due to inefficient amplification of larger alleles of this locus: see Horn et al., 1989) were observed 
in the blood. ln 81 and 82, only the 372 bp was faintly visible, and in addition, these biopsies shared 
a fragment of 236 bp. which would correspond to homozygosity of the locus for this allele in both 
biopsies. Similarly. for the D1S80 locus Oanes 6-8), two alleles, of 420 bp and 460 bp, were observed 
for the blood DNA while the biopsies were homozygous for an extra band of 510 bp. 
017$5/$30 01$80 
M1 81 82 Blo M2 B1 82 Blo M1 M2 61 
Apo B3' 
B2 Blo M1 
Figure 4. Gel electrophoretic analysis of products obtained after PCR amplification of the three VNTR 
loci D17S5/S30, D1S80, and Apo B 3' from genomic DNA isolated from donor myocardial tissue (81}, 
coronary intimal tissue (82) and blood (Bio) of the recipient. M1 is part of the •t kb ladder" size marker 
and M2 is part of the •123 bp ladder" size marker (Gibco 8RL, USA). bp =base pairs. 
PCR amplification of the Apo 8 3' VNTR locus (lanes 11-13) in genomic DNA isolated from recipient 
blood (biopsy 3) resulted in the detection of three fragments of 570, 720 and 880 base pairs. The 
generation of three bands, which all are within the expected size range of the Apo 8 3' VNTR alleles, 
instead of the expected two fragments is unexplained. Nevertheless, both in 81 and 62, an extra band 
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of 690 bp was observed. Because two bands (690 and 720 bp) in the biopsies are more intense than 
the other bands, the biopsies are heterozygous at this locus with alleles of 690 and 720 bp. Apparently, 
one of these alleles (the 720 bp) is shared with the blood. The slight upward bandshift seen in all lanes 
containing PCR products from biopsy #2 (most notably in lanes 3 and 7) is most likely caused by the 
larger sample volume, and consequently a higher absolute amount of salt was loaded on the gel (30 IJ-1 
for biopsy #2 compared to 5 IJ-1 for biopsy #1). 
Faint bands corresponding to the blood pattern (Blo) were evident for all three gene loci (except the 
570 bp allele of the Apo B3' gene) in biopsies 1 and 2. The relative intensity differences of blood~specific 
bands and biopsy~specific bands for the three loci, as measured by image analysis of the polaroid 
photo, suggest a 10% contamination of blood in biopsies #1 and #2. This is most likely due to 
unavoidable contact of the recipient's blood with both the myocardial biopsy (taken immediately after 
completion of the heart transplantation procedure) and the atherectomy obtained coronary specimen. 
DISCUSSION 
In a previous review on the pathogenesis of atherosclerosis. Ross wrote that "It may never be possible 
to determine with certainty the specific events that lead to atherosclerosis in humans" (1). As a result, 
many concepts of the sequence of events have been based on animal studies. Recent advances in 
molecular biology combined with recent technological innovations such as the atherectomy catheter 
have allowed us to biopsy and study coronary material to address basic questions related to the 
development of an atherosclerotic lesion. Coronary artery lesions in a transplanted heart are likely the 
only human clinical setting in which one can define the origin (blood borne versus vessel wall) of the 
smooth muscle cells found in the intimal lesion. 
In this case, an advanced coronary lesion consisted primarily of donor cells that originated from within 
the vessel wall. A slight degree of DNA from the recipient was seen in the atherectomy sample as well. 
There are two possible explanations. Since a comparable band was seen in the myocardial biopsy (taken 
directly after transplantation) as in the atherectomy specimen, contamination with the recipient's blood 
during removal of the specimens is probably the main reason. However it is also possible that a small 
contribution to the DNA band is due to the small number of lymphocytes and posssible macrophages 
that were part of the lesion. The DNA profiling results for the three VNTR loci analyzed support the hypo~ 
thesis that the myocardial and coronary intimal biopsies are derived from the same individual and are 
different from the pattern seen in the recipient's blood. Immunohistochemistry studies of the coronary 
intimal tissue confirm that the smooth muscle cells are the main cell type found in the lesion and must 
therefore originate from within the vessel wall, although it can not be stated whether the cells are from 
the media or the subintimal space. Although it may be argued that the coronary lesion predated the 
heart transplantation, the results of the yearly angiograms prior to 1990 along with the fact that the heart 
donor was a young woman without a cardiac history are convincing evidence that the lesion developed 
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after cardiac transplantation. 
ln conclusion, the results of this study support the concept previously suggested by animal studies 
that the smooth muscle cells in vascular intimal lesions typically seen in atherosclerosis and restenosis 
are derived from within the vessel wan and not from the circulation. 
Acknowledgement 
We are grateful for critical review of the manuscript by Prof. Dr. F.T. Bosman. 
156 
References 
1. Ross R. The pathogenesis of atherosclerosis- an update. New Engl J Med 1986;314:488-
500 
2. Poole JCF, Cromwell SB, Bend itt EP. Behavior of smooth muscle cel!s and formation 
of extracellular structures in the reaction of arterial walls to injury. Am J Path 
1971 ;62:391-404 
3. Spaet TH, Stemerman MB, Veith FJ, Lejnieks I. Intimal injury and regrowth in the rabbit 
aorta. Medial smooth muscle cells as a source of neointima. Circ Res 1975;36:58-70 
4. Clowes AW, Reidy MA, Clowes MM. Kinetics of cellular proliferation after arterial injury. 
Smooth muscle growth in the absence of endothetium. Lab Invest 1983;49:327-333. 
5. Jorgensen l, Rowsell HC, HovigT, Mustard JF. Resolution and organization of platelet-
rich mural thrombi in carotid arteries of swine. Am J Pathol 1967;51:681-719 
6. Jeffreys AJ, Wilson V, Thein Sl. Hypervariable "minisatellite" regions in human DNA. 
Nature 1985;314:67-73-
7. Nakamura Y, Leppert M, O'Connell P, Wolff R. Holm T, Culver M, Martin C, Fujimoto E. 
Hoff M, Kumlin E, White R. Variable number of tandem repeats (VNTR) markers for 
human gene mapping. Science 235:1616-1622. 
8. Budowle 8, Chakraborty R, Giuisti AM. Eisenberg AJ, Allen RC. Analysis of the VNTR 
locus Dt SSO by the PCR followed by high-resolution PAGE. Am J Hum Gen 
1990;48:137-144. 
9. Boerwinkle E, Xiong W, Fourest E, Chan l. Rapid typing of tandemly repeated 
hypervariable loci by the polymerase chain reaction: Application to the apotipoprotein 
B 3' hypervariable region. Proc Natl Acad Sci USA 1989;86:212-216. 
10. Horn GT, Richards B. Klinger J<:N. Amplification of a highly polymorphic VNTR segment 
by the polymerase chain reaction. Nucleic Acids Res 1989;17:2140. 
157 
11. Saiki RK, Gelfland OH, Stoffel SJ, Scharf SJ, Higuchi R, Horn GT, Mullis KB, Erlich HA. 
Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. 
Science 1988;239:487 -491. 
12. Uitterlinden AG. Mullaart E, Morelli B, Vijg J. Genome scanning by two-dimensional DNA 
typing using micro- and minisatellite core probes. Methods. a companion to Methods 
in Enzymology, in press. 
158 
Chapter 11 
Human coronary smooth muscle cells in culture: 
Phenotypic features, proliferation and extracellular matrix production 
BH Strauss, M de Jong, A Verkerk, RJ van Suylen, VAWM Umans, PJ de Feyter, 
CMC van Hooije, DC Macleod, WJ Visser, JF Jongkind, PO Verdouw, PW Serruys 
(in preparation) 
159 

Abstract 
Cell cultures were attempted in coronary tissue that was obtained from 85 atherectomy procedures (82 
patients) using the Simpson coronary AtherocathR. Primary de novo lesions and restenosis after a 
previous coronary intervention accounted for 78% and 22% of the procedures, respectively. Cell 
outgrowth was seen in 40% of cultures although serial ( > 2) passages were obtained in only 1 0 patients. 
Cell growth was enhanced by the explant technique and in tissue with cell density > 700 cell/ mm2• No 
differences were evident between the type of lesion and the ability to serially passage cells. 
Two types of cells were observed in culture. The predominant type had the typical morphological 
features of smooth muscle cells. These cells were of the synthetic phenotype based on the low incidence 
of cells that stained positively with antibodies to smooth muscle cell alpha-actin and the appearance of 
abundant Golgi apparatus and endoplasmic reticulum and peripheral location of myofibrils on electron 
microscopy. In a few primary cultues, cells that resembled macrophages proliferated for up to 2 weeks 
and could not be passaged. 
ln~vitro studies of proliferation rates and matrix production were performed in the coronary cells in 
passages 2-5 and compared with smooth muscle cells isolated from the media of human umbilical 
arteries. Significantly slower population doubling times were seen in the coronary cells compared with 
the control umbilical cells {51 ±9 hours versus 33±12 hours, p< 0.05). However, matrix synthesis was 
significantly greater in the coronary cells than the umbHical cells. Cotlagen production was 50% higher 
and glycosaminoglycan synthesis was more than two- fold greater in the coronary cells. 
Smooth muscle cells from primary atherosclerotic and restenotic coronary lesions can be 
successfully grown in culture. The specialized functions of proliferation and matrix production that are 
responsible for the development of these coronary artery lesions can be studied in this modeL 
Preliminary data suggests that the cells originating from coronary plaques are particularly active in matrix 
synthesis. 
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INTRODUCTION 
The pathologic processes in both coronary atherosclerosis and restenosis following percutaneous 
trans!uminal coronary angioplasty (PTCA) are characterized by the proliferation of intimal smooth muscle 
cells (SMC) and extracellular matrix formation (1,2). Cell culture is an important aspect of research in 
this field since specific properties of individual cell types can be studied without the complexities of 
interactions occurring in the intact organism. In-vitro studies of the proliferative and synthetic properties 
of SMCs have been primarily performed in cells isolated from normal media of animal vessels or from 
experimentally induced intimal thickenings (3). The study of SMCs from human atherosclerotic lesions 
has been limited and predominantly restricted to peripheral arteries that have been surgically amputated 
or removed post-mortem (4,5). 
The development of a percutaneous directional atherectomy catheter that can remove obstuctive 
material from the vascular wall has opened new possibilities of vascular research. It is now possible to 
study human vascular tissue from a much broader range of patient than was previously possible. In 
particular. we now have access to material from restenosing lesions that in the past has been extremely 
difficult to obtain. Initial work in culturing material removed by the atherectomy device was performed 
in tissues obtained from peripheral vessels (6-9). 
In September 1989, coronary atherectomy was initiated at the Thoraxcenter. With this unique 
opportunity of acquiring human coronary tissue from a variety of patients and clinical settings. a cell 
culture programme was set up to isolate SMCs and to define the important baseline properties of these 
cells. We have focussed on the aspects of these cells that are important in the development of vascular 
intimal lesions, namely growth characteristics and synthetic capacity. Collagen and proteoglycans are 
important components of the extracellular matrix produced by the SMC and are thus central to studies 
of the synthetic behaviour of SMCs. Collagen is a major structural element of the extracellular matrix of 
the arterial wall, comprising 20-50% of the dry weight (1 0,11 ). Proteoglycans are macromolecules that 
consist of negatively charged complex carbohydrates (sulfated glycosaminog!ycans) linked covalently 
to the serine residues of a central protein core. Glycosaminoglycans are made up of repeating 
disaccharides, each containing a uronic acid linked to a hexosamine (amino sugar) residue. In the vessel 
wall, proteoglycans are usually a minor component, 2-5% of dry weight. However, proteoglycans 
accumulate in atherosclerotic lesions and in the intimal hyperplasia that occurs after vessel injury (12, 13). 
Proteoglycans have important roles in cell adhesion and migration. cell proliferation, lipid metabolism 
and thrombosis (14) and may also be important in the progression of lesions since they are involved with 
the binding of macromolecules in the intima, including the uptake of LDL by macrophages. 
In this chapter, we report the preliminary results of studies of the proliferative behaviour and matrix 
prcxiuction of SMCs isolated from coronary artery lesions compared to SMCs originating from the 
normal media of human umbilical arteries 
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METHODS 
Patients with suitable coronary anatomy underwent percutaneous coronary atherectomy following 
infonned consent and according to a protocol approved by our Institutional Review Board. Patients were 
specifically classified according to the clinical status and the type of lesion (primary atherosclerotic 
plaque or restenosis following previous angioplasty). The atherectomy procedure using the Simpson 
coronary atherocathR has been described elsewhere (15). Under stenle conditions, the specimens were 
removed from the housing of the atherectome, washed with 0.9% saline and placed in M199 culture 
medium without serum supplementation for transfer to the culture laboratory. 
Histology 
The specimens were cut with a sterile knife to a size of about 1 mm by 1 mm. One to two pieces were 
immediately fiXed in 10% buffered formalin, and in some cases in a solution of gtutaralc;tehyde-
fonnaldehyde (4CF-1 G) for transmission electron microscopy. The maximal cen density On the initial12 
patients that had the explant method) of the tissue specimens removed by atherectomy was detennined 
as follows: In haematoxylin and azofloxine stained cross-sections, the number of cell nuclei was 
assessed in several fields by a computerized morphometry system (!BAS, Kontron, Oberkochen, 
Gennany). The maximum value recorded was used for the detennination of cell density which was 
expressed as cell number j mm2 intimal tissue. 
Cell Culture 
The remaining tissue was placed in cell culture according to the two methods described by Bauriedel 
et at (6-9). First, tissue explants were placed on fibronectin coated (10 ugjcm~ glass cover slips in 2 
cm2 wells and then the culture medium (M199, supplemented with glutamine, 10% human serum, 10% 
fetal calf serum, penicillin 100 IUjml and streptomycin 0.1 mgjml) was added. In primary cultures, 
conditioned medium from actively growing cell lines was mixed 1 :1 with the culture medium described 
above. For secondary cultures, culture medium was not supplemented with conditioned medium. 
Second, the tissue was enzymatically disaggregated for 30 minutes at 3rC in dispase grade II (2.4Ujml, 
Boehringer Mannheim) containing 1 mgjml collagenase Worthington CLS Ill (229 Ujmg, Worthington 
Biochemical Corporation, New Jersey) and then the solution was supplemented with 20% human serum 
and centrifuged. The supernatant was discarded and the pellet was again incubated in the following 
enzyme mixture: 10 ml of HEPES-buffered culture medium containing 18 mg collagenase, 2 mg elastase 
from pancreas (Boehringer Mannheim. Germany) and 10 mg trypsin inhibitor from soybean (Sigma) for 
60-180 minutes at 3rC to isolate individual cells which were then plated as previously described for the 
explants. Cell culture was carried out in a 5% C02 incubator at 3rC. At confluency, cells were 
subcultured by trypsin. 
SMCs obtained from the media of human umbilical arteries were used as control cells. 
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Immunological Identification 
Cells of passage 2-4 were seeded on round glass cover slips at a density of 5000 cel!sjmm2• After 
4S hours, the cover slips were rinsed in PBS (pH 7.4) and then fixed in acetone at ~20°C. 
lmmunostaining was performed with monoclonal antibodies directed against SMC alpha~actin (Sigma, 
St. Louis, USA) using an indirect conjugated peroxidase procedure. Specificity of staining was done by 
exclusion of the primary antibody. In addition to coronary and umbilical artery SMCs, cultured human 
skin fibroblasts were included in this experiment in order to provide a negative control. 
Electron Microscopy 
For electron microscopy, the cells cultured in 35 mm diameter petridishes (Costar, ) were ftxed in a 
phosphate buffered mixture of 4% paraformaldehyde and 1% glutaraldehyde, postftxed in 1% Os04 , 
dehydrated in a graded series of alcohol and finally embedded in epon. For the embedding in epon, 
embedding~capsules filled with epon were placed upside down on the cell monolayer. After 
polymerisation of the epon, the epon blocks were separated from the plastic by immersion in liquid 
nitrogen. Ultrathin sections were cut on Reichert Omll3 Ultramicrotome (Reichert, Wien, Austria), stained 
with uranyl acetate and lead citrate and examined ln a Philips E.M. 400 electron microscope. 
Population Doubling Times 
Cells in the second to fifth passage were seeded in 2 cm2 culture wells at a density of 3000 cellsjcm2• 
At 24 hours after seeding and on every third day thereafter, the medium was exchanged. At appropriate 
times, cells of three wells were washed with PBS. trypsinized for 5 minutes at 3'rC. and were counted 
in a haematocytometer. The mean values for cell number at each counting interval were plotted on 
logarithmic scale versus the number of hours in culture and population doubling times were derived. 
::lH-Thymidine Incorporation Assay 
Celis were grown on coverslips in 2 cm2 well plates. During the logarithmic phase of cell growth (day 
5-7), 3H~thymidine stock solution was added to the medium (final concentration 0.1 uCijml) for 24 hours. 
The experimental medium was then removed and the monolayer was rinsed with PBS. The cover slips 
were ftxed in Bouin fiXative, coated with photographic emulsion IIford ~ and developed after exposure 
for 10 days. Nuclei were stained with haemotoxylin and eosin and the thymidine index was determined 
as the proportion of nuclei showing silver grains in the light microscope. At least 200 cells were counted 
on each triplicate slide. 
Determination of collagen synthesis 
Collagen was determined with a bacteria!~collagenase digestion method modified from Peterkofsky 
and Degelmann (16). ln confluent 2 cm2 culture wells. cells were incubated for 4S hours at 3rC in 0.5 
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ml of M199 supplemented with 5% human serum, 5% fetal calf serum, 2 uM ascorbic acid, and 5 ul H3-
proline (1 OuCijml). Preliminary experiments from Janssen Research Foundation in Beers, Belgium 
indicated that it was unnecessary to separately determine the cell associated collagen and the collagen 
in the medium. All experiments were performed in triplicate. 
At the completion of the incubation period, the medium was removed from the monolayer and both were 
separately precipitated as follows: the medium was precipitated by 20% TCA 1 mM proline at 4°C for 
24 hours. After centrifugation (SOOOg x 10 minutes at 4°C), the pellet was washed with 20% TCA 1 mM 
proline and then with 10% TCA 1 mM proline. The monolayer was precipitated with 20% TCA 1 mM proline 
overnight, then washed with 20% TCA 1 mM proline and then 19% TCA 1 mM proline. The precipitate 
was dissolved in 0.5 ml 0.2N NaOH overnight at 4° in a humidity chamber and 25 ul was counted in 
lnstagel II. Then 400 ul from the dissolved monolayer was added to the pellet derived from the medium 
and 50 ul was counted in lnstagel II. The rest of the resuspended monolayer (75 ul) was used to 
determine the total amount of protein with the Pierce BCA protein assay (Pierce Rochford, Illinois, USA) 
utilizing BSA (bovine serum albumin) as standard (17). 
Two 75 ul samples of the combined medium and monolayer were mixed with 100 ul of a HCI buffer (75 
ul 1M HEPES pH 7.3, 2.5 mM CaCI2 with 120 ul 0.15N HCI). The samples were then incubated with a 
collagenase solution (7 ul clostridium histolyticum -Type Ill, Calbiochem 2600 U/ml to 25 ul [TRIS-HCI 
(50mM) pH 7.6 + 5 mM CaC!2]) or control (minus the collagenase) for 2 hours at 3rC and precipitated 
in ice-cold 10%TCA/ 5% Tannic acid. and centrifuged. The supernatant was collected and 500 ul was 
counted in lnstagel 11. Collagen synthesis was expressed as nmoles [3H]-prolinejug total cell protein 
/hour. 
Determination of Sulfated Glycosaminoglycan Synthesis 
In confluent 2 cm2 culture wells, cells were incubated for 48 hours at 3rC in 0.5 ml of M199 
supplemented with 5% human serum and 5% fetal calf serum and 20 uCijml 35$-sulfate {10uCijm!). The 
medium from 35$-sulfate labelled cells was washed with PBS to a final volume of 2.5 mi. Two hundred 
and fifty microliters were applied onto a disposable Sephadex G-25M (PD10, Pharmacia) gel filtration 
column equilibrated and run in urea SMjTriton X100 0.5%/NaCL 0.15MjNa acetate SO mM pH 6.0 (18). 
Fractions of 300 ul were collected, mixed with !nstagel II and fractions 845 were counted. The sum of 
the counts in the initial peak (dpm) was used to determine the degree of glycosaminoglycans synthesis 
which was expressed as nmo!jug protein. 
Statistical Analysis 
Comparisons between coronary cells and the control umbilical cells were performed using the two-
sample t test. A p value < 0.05 was considered statistically significant. 
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RESULTS 
Culture Success Rates 
Cell cultures were attempted in coronary tissue obtained from 85 atherectomy procedures (82 
patients) in a 2 year period (September 1989 to September 1991 ). Twenty (22%) of the procedures were 
performed for restenosis. Cell outgrowth, was seen in 40% of cultures although serial passages (up to 
7) were obtained in only 10 patients (120k), all by the explant method (Table 1). Cells started to grow 
out from the explants after 4-8 days and confluent multilayer primary cultures in the 10 patients were 
established in 4-6 weeks. Cell growth was enhanced by the explant technique, and in tissue with cell 
density > 700 cellsjmm2 (Figure 1). The enzyme technique was abandoned after the initial 9 patients 
in favour of the more successful explant method. No differences were evident between the ability to 
serially passage cells and the type of lesion (primary atherosclerotic or restenosis). 
1) METHOD OF CULTURE 
PRIMARY 
ENZYME 115 
EXPLANT 23/59 
RESTENOSIS 
1/4 
9/18 
TOTAL 
2/9 (22%) 
32/77 (42%) 
2) CELL DENSITY I mm 2 TISSUE (12 PTS) 
UNSUCCESSFUL 231 <o 200 (RANGE 35-500) 
SUCCESSFUL 922 t 215 (RANGE 687-1320) 
Figure 1. The two determinants of success in establishing cell outgrowth in cultures were explant 
nethod (cell outgrowth in 400.-b of lesions attempted} and high cell density in tissue that was removed 
(> 700 cells/ mrrl tissue). Primary: primary atherosclerotic lesion. 
Cell types 
Two types of cells were seen in culture. The predominant type was seen in subconfluent cultures as 
a network of multilayered elongated cells in interlacing bands separated by empty areas. In confluent 
cultures the cells formed whorls giving a hill-and-valley pattern typical of cultured SMCs (Figure 2a). In 
all serially passaged cell lines, this pattern was seen and persisted throughout the passages. 
In a small number of primary cultures, a second type of cell was seen that was rounded in 
appearance and usually contained small inclusions. These cells would proliferate for up to 1-2 weeks 
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and then stop (Figure 2b). The appearance and size of these cells was typical of macrophages 
(Immunohistochemistry studies pending). 
Figure 2a. Phase contrast micrograph showing hill-and-valley pattern typical of smooth muscle cells 
in culture. 
Figure 2b. Phase contrast micrograph showing round cells containing inclusions. 
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Transmission Electron Microscopy 
The cells in culture had the phenotypic features of a myofibroblast (synthetic SMCs). The cytoplasm 
contained numerous endoplasmic reticulum, Golgi apparatus and ribosomes (Figure 3a). Myofibrils were 
present in the periphery of some of the cells (Figure 3b). 
Immunohistochemistry 
The human skin fibroblasts (negative control) demonstrated non~specffic background staining (Fig. 
4a). A minority of the coronary artery cells (approximately 1 0%) in secondary cultures contained fibers 
that stained with anti~SMC alpha~actin characterizing these cells as SMCs (Figure 4b). These cells were 
larger and well~spread on the culture plate. The majority of the cells had diffuse background staining with 
alpha~actin without obvious fiber formation and were more elongated in shape. Variable staining with 
antibodies to SMC~specffic alpha~actin was evident in the control umbilical artery cells (Fig. 4c). In most 
of the cell strains the majority of the cells contained alpha-actin positive fibers (even up to the seventh 
passage), but in a few cell strains the situation was similar to the coronary cells in culture. The umbilical 
artery cells also had the hill and valley culture morphology. 
Population Doubling Times (Table 2) 
The coronary cells had a 50% longer doubling time than the control umbilical SMCs (51 ±9 hours 
versus 33±12 hours, p< 0.05). No significant differences were found between coronary cells from 
primary atherosclerotic and restenosing lesions. 
Thymidine labelling (Table 3} 
Both umbilical and coronary artery cells had a high percentage of cells proliferating during the 24 hour 
period of labelling (Fig. Sa. b) although the former cells had a larger proportion of proliferating cells (71% 
versus 47.5%). 
3H-Proline Incorporation (Table 4) 
Collagen synthesis, based on the incorporation of radioactive proline, was not significantly greater in 
coronary SMCs (0.0335 ::!: .0124 nmoles proline; ug total cell protein) than control umbilical SMCs 
(0.0188 ± 0.0062). No significant differences were found between primary atherosclerotic and restenosis 
lesions. In the coronary cells, there was a trend towards decreased collagen synthesis with later 
passages. 
35$-Sulfate Incorporation (Table 5) 
Glycosaminoglycan synthesis, based on the incorporation of radioactive sulfate, was 2.2-2.4 tlmes 
greater in coronary cells than in the control umbilical SMCs. 
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Figure 3. Transmission electron micrographs showing synthetic phenotype of smooth muscle cells in 
culture. A) Abundant cytoplasmic organelles including Golgi apparatus, endoplasmic reticulum and 
ribosomes. B) Myofibrils were located in the periphery of some cells. 
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Figure 43. Monoclonal antibody directed against smooth muscle cell specific actin (1/400 dilution). 
fibroblast: negative staining, only nonspecific background staining. 
Figure 4b. Coronary anery cells: a few cells contain fibers that stain positive for alpha-actin but the 
majority of cells only show nonspecific background staining. 
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Figure 4c. Umbilical artery cells: some fibers stain positive for alpha-actin. 
Figure sa. Thymidine labelling of proliferating cells. Control umbilical cells: the majority of cells (71%) 
are labelled (multiple dark grains in the nucleus) 
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Figure Sb. Thymidine labelling of proliferating cells. Coronary artery cells- staining is present but less 
marked than in the umbilical cells. 
DISCUSSION 
Feasibility and Phenotypic Features of SMCs from Coronary Atherectomy 
This study shows that SMCs can be grown in culture from primary atherosclerotic and restenosed 
human coronary artery lesions. Tissue characteristics (high cell density) and culture conditions (explant 
technique) enhance the overarr success rate. Since only 12% of the specimens attained extended 
passage in culture, considerable selection bias may be occurring within culture and care must be taken 
in extrapolating the results to the overall population. It remains to be shown whether culture yields can 
be improved by other methods (collagen gels etc). Despite these limitations, several important 
observations emerge from this study. 
First, the coronary SMCs in early passages in culture have the features of synthetic SMCs (fibroblast-
like appearance) (19-20). Consistent with this phenotype are the fact that only a minority of cells stained 
positive with the antibodies to SMC alpha-actin, the hill and valley culture morphology, and the presence 
of many subcellular synthetic organelles (rough endoplasmic reticulum and Golgi apparatus) and 
peripheral myofibrils on electron micrographs. Gabbiani et al have shown that the phenotypic modulation 
of the SMC from the "contractileM phenotype, typical of the medial SMC. to the 8 syntheticu phenotype 
found in embryogenesis, atherosclerotic lesions, and in experimental models of intimal thickening is 
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characterized by a shift in the cytoskeleton proteins from SMC-specific alpha~actin to beta~ actin 
predominance (21 -23). Studies in vascular SMCs in culture have previously demonstrated that cultured 
SMCs undergo differential expression of isoactins in relation to their growth state. Owens et al showed 
in rat aortic SMCs that SMC a!pha-isoactin synthesis and content are low in subconfluent log phase 
growth cells but increase three-fold in density-arrested postconfluent cells (24). Similarly. Fager et al 
found an inverse relationship between the expression of contractile proteins (SMC specific alpha-actin) 
in stress fibers and the proliferative state of the ce!ls (25). In growth arrested cells, 80% of celts showed 
stress fibers containing SMC-specific alpha-actin. However, only 4% of cells had positive staining with 
a monoclonal antibody against SMC alpha-actin after 4 days of growth in serum enriched growth 
medium. 
It is uncertain from our study whether the coronary SMCs grown in culture underwent phenotypic 
changes in culture or already had a synthetic phenotype in the tissue prior to culture. The coronary cells 
in this study originated from advanced atherosclerotic and restenotic coronary intimal lesions. Although 
previous work has suggested that human atheromatous lesions have a low SMC a!pha-actin content 
(22), we have seen extensive staining with monoclonat antibodies directed against SMC alpha-actin in 
atherectomy obtained tissue from 15 restenosis lesions (26). EM studies in three restenosis patients 83-
135 days after stent placement showed that the majority (70-75%) of intima! cells had phenotypically 
contractile features (extensive myofibrils, few endoplasmic reticulum or Golgi apparatus). Therefore the 
synthetic cel!s in culture may be derived from the smaller population of synthetic intimal cells or from 
phenotypic changes induced by the culture conditions. 
lt must also be recognized that SMCs are not the only ceHs that could be grown in culture. The presence 
of proliferating macrophages was noted in 5 cultures although growth in our experimental conditions 
could not be maintained beyond 1-2 weeks. 
Proliferation Rates 
Significantly lower growth rates (50%) were seen in the coronary celts compared with the control 
umbilical medial SMC's. Furthermore, sustained growth to confluency in primary culture could not be 
achieved in 88% of the specimens. A differential proliferative response between intimal and medial SMCs 
in human peripheral and aortic vascular tissue has been previously described (5). Ross et al have 
postulated that the reduced proliferative capacity of SMCs derived from the intima suggest senescent 
changes due to multiple previous divisions in vivo. Dartch et al previously reported in a similar cell 
culture model that cultured SMC from restenosing lesions grew at a significantly higher rate than cells 
from primary atherosclerotic lesions (7). They also described features of senescence in cells grown from 
primary atherosclerotic lesions such as inability to subculture more than two times, extensive cellular 
debris, and a prominent microfilament network with cytoplasmic vacuoles. In the limited number of cell 
lines studied in our study, we did not observe these differences in culture between the two types of 
lesions. This may be related to the artery (coronary versus peripheral vessels in Dartsch study), age of 
173 
the restenosing lesions prior to the atherectomy or selection bias since both studies had only limited 
number of restenosis lesions. Histological examination of representative samples of the specimens set 
up in culture has shown that the characteristic feature of restenosis, intimal hyperplasia, may also be 
present in primary atherosclerotic lesions. Although the primary atherosclerotic specimens in general 
were less cellular with more dense collagenous stroma, overlap in the histology between the two types 
of lesions was not uncommon. Therefore it seems somewhat artificial to describe primary atherosclerotic 
lesions or restenosis lesions as distinct and separate histologic and pathologic entities. 
Matrix Synthesis 
Although vascular SMCs in culture are known to produce collagen and proteoglycans, there is no data 
available on human coronary SMCs from primary atherosclerotic and restenotic lesions. Previous studies 
have shown that modulation of the SMC phenotype to the "synthetic" state is associated with large 
increases in collagen (30 fold) and glycosaminoglycans (5 fold) (27,28). Our preliminary results show 
that the origin of the vascular SMC appears to affect the synthesis of collagen and glycosaminoglycan 
(summarized in Table 6). in identical culture conditions, coronary SMCs produced 50% more collagen 
and more than two times more glycosaminoglycans than SMCs from the media of the umbilical artery. 
The enhanced matrix synthesis in the coronary cells may reflect a more specialized function of a SMC 
situated within an atherosclerotic or restenotic lesion. Previous studies have shown that the production 
of matrix components by vascular SMC is altered quantitatively and qualitatively in hypertension, 
atherosclerosis and angiogenesis (29). Based on our results, modulation of extracellular matrix 
components in vitro, may be a reflection of similar mechanisms operating in vivo. 
The production of collagens by cultured SMC has been shown to be selectively and quantitatively 
increased (as a percentage of total protein synthesis) by cyclic stretching (30) and heparin treatment 
(31). Cells cultured from atherosclerotic aortas (32) or treated with growth factors (33) have also been 
shown to produce more collagen per cell, although collagen production relative to total protein synthesis 
was unchanged. 
Previous studies have indicated that the synthesis of glycosaminoglycans and proteoglycans is 
complex and that alterations in ceil density. serum and pH result in marked changes to both the 
amounts and proportions of GAG (34). The source of SMC also appears to affect the synthesis of 
giycosaminoglycans. In almost a!! studies, the SMC have been derived from thoracic aortas and 
muscular arteries (eg coronaries) have rarely been used. Two animal studies have shown a higher rate 
of GAG synthesis in cells cultured from experimentally induced atherosclerotic lesions or from 
atherosclerotic susceptible White Garneau pigeons (3-4x greater compared with the atherosclerotic 
resistant Show Racer breed) (36) and that most of the increase was due to an increase in sulfate GAG, 
especially dermatan sulfate. Although the amounts and proportions of the various types of GAG are 
changed at sites of human atherosclerotic lesion formation, there is limited data on human in-vitro 
synthesis, particularly in cells originating from atherosclerotic lesions. No studies have been reported 
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on SMCs originating from coronary lesions. Our results suggest that these cells behave differently in 
culture than cells from the media of umbilical arteries and therefore may be a more useful model for the 
study of atherosclerosis. 
It is interesting to note the differences in proliferation rates and matrix synthesis between the coronary 
and umbilical SMCs in our study. Smooth muscle cell proliferation and synthesis of extracellular matrix 
are inversely related. Other examples are heparin and transforming growth factor-beta (TGF-8) which 
is the most potent of the growth factors in the control of extracellular matrix synthesis and increases the 
synthesis of chondroitin sulfate, the dominant extracellular matrix protein early in intimal hyperplasia, by 
20-fold (37,38). However TGF-8 may be a potent inhibitor of SMC growth in certain circumstances (39). 
Similarly, heparin has the dual action of inhibiting SMC proliferation and stimulating the synthesis of 
proteoglycans (14,40). 
In summary. coronary SMCs from primary atherosclerotic and restenotic lesions can be successfully 
grown in culture. The specialized functions of proliferation and matrix production that are responsible 
for the development of these coronary artery lesions can be studied in this modeL Preliminary data 
suggests that the cells originating from coronary plaques are particularly active in matrix synthesis. 
Future studies with this model will be aimed to determine the specific types of collagen and 
glycosaminoglycans produced by the umbilical and coronary SMCs and further evaluation of the 
differences in proliferation and synthetic functions between the two sources of SMCs. 
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Table 1. Patient characteristics of serially passaged cell cultures. 
Patient Sex Age Procedure Type Comments 
1 (16) M 48 Primary 
2 (19) F 71 Restenosis 
3 (20) M 69 Primary growth limited to second passage 
4 (45) M 40 Restenosis 
5 (46) M 66 Restenosls 
6 (52) F 58 Primary 
7 (68) F 49 Primary 
8 (72) M 49 Primary growth limited to third passage 
9 (83) M 50 Primary 
10 (84) M 68 Primary 
Table 2. Population Doubling times (hrs) 
Coronary 
a) Primary 16P4 43 
52P4 65 
68P2 53 
b) Resten 19P4 43 
46P4 46 
Total 50±9 
Control 7AP5 24 
7AP4 49 
7AP4 34 
7APS 24 
Total 33oo12 
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Table 3. Thymidine labelled cells (% of total cells) 
Coronary 
a) Primary 16P2 59.2% 
52P2 57.1% 
b) Restenosis 19P4 48.5% 
45P4 46.4% 
46P2 35.8% 
46P4 37.9% 
Control (Umbilical) 8AP3 78.9% 
9AP2 63.4% 
Table 4. H3-Proline Incorporation 
Type Number Protein nm 35H-Protine nm Proline/ ug protein 
Prim 16P2(3) 112 4.65 0.0416 
16P4(4) 31 0.56 0.0228 
52P2(3) 110 2.33 0.0410 
52P3(4) 44 0.50 0.0230 
68P2(4) 18 0.66 0.0380 
Rest 19P4(4) 68 2.47 0.0363 
19P4(3) 13 0.54 0.0478 
45P4(3) 53 0.62 0.0117 
46P2(2) 53 1.94 0.0366 
46P4(3) 36 0.69 0.0196 
46P4(3) 10 0.47 0.0503 
Cant 8AP2(3) 86 2.06 0.0239 
7AP4(3) 138 1.63 0.0118 
7AP4(4) 63 1.01 0.0205 
NumberO = cell line and the number of culture wells (replications) used in the experiment; nm = 
nanomoles; protein represents the total protein in the cell monolayer 
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Table 5. GAG f.ssay- Experiment #2 (September 1991) 
Type Number Protein moles S35 (x10.7) 
Prim 52P3-1 71 9.03 
52P3-2 71 5.60 
84P4-1 68 14.1 
84P4-2 68 13.7 
Rest 19P3-1 64 8.40 
19P3-2 64 9.27 
19P4-1 45 3.81 
19P4-2 45 3.84 
46P5-1 54 7.33 
46P5-2 54 5.75 
Cont 86GSP5-1 85 3.45 
86GSP5-2 85 3.05 
86GSP5-1 75 5.95 
86GSP5-2 75 4.59 
Table 6. Summary of Matrix Results 
Primary* 
Restenosis* 
Coronary1* 
Control 
Table 4 
0.0333 " 0.0096 
0.0337 " 0.0153 
0.0335 = 0.0124 
0.0188 " 0.0062 
Table 6 
15.37 ± 6.19 
11.47" 2.62 
13.03 " 4.54 
5.43" 2.00 
1 combined primary and restenosis results, * p < 0.05 versus control 
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nmoles; ug protein 
12.70 
7.89 
20.74 
20.15 
13.13 
14.48 
8.47 
8.53 
13.57 
10.65 
4.06 
3.59 
7.93 
6.12 
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Samenvatting 
Met de introductie van percutane transluminale coronaire angioplastie (PTCA) leidde Andreas Gruentzig 
in 1977 het tijdperk van interventie cardioiogie in (1). Het feit dat coronair angioplastie algemeen 
aanvaard is blijkt uit het grote aantal ingrepen (~ 300.000 procedures in de Verenigde Staten in 1990), 
het toenemende aantat indicaties en het bestaan van een uitgebreide infrastructuur om de techniek te 
ondersteunen Qnclusief de uitbreiding van catheterisatie laboratoria, op!eidingsplaatsen en wezenlijke 
betrokkenheid van de industrie die zich toege!egd heeft op voordurende verbetering van geavanceerde 
rOntgen afbeeldingstechnieken en angioplastie materialen). Naast de ballondilatatie werden in de 
afgelopen 5 jaar ook verschillende andere technieken geevalueerd als alternatieven of aanvumngen van 
PTCA zeals atherectomie. rotablator en verschillende vormen van laser therapie. Deze technieken 
werden ingevoerd vanwege de beperkingen van ballondilatatie, zoalsvroegtijdige afsluiting en restenose 
binnen de eerste 6 maanden na de procedure. Deze beperkingen zijn blijven bestaan ondanks intensieve 
pogingen om farmacologische oplossingen hiervoor te vinden (2-5). 
De eerste stent imp!antaties werden uitgevoerd in 1986 in Lausanne, Zwitserland, door Ulrich Sigwart 
en in Toulouse, Frankrijk, door Jacques Puel (4). 
Stents zijn hulpmiddelen die binnen in het bloedvat worden aangebracht om mechanische 
ondersteuning van de vaatwand te verienen. Een aantal types stents zijn ontwikketd die verschi!len in 
samenstel!ing, ontwerp en mechanisch gedrag. Volgens Dr. Philip Urban uit Geneve werden de eerste 
pogingen om buisjes in vaten te implanteren beschreven door Alexis Canel uit New York in September 
1912 in het Amerikaanse maandb!ad MSurgery, Gynaecology and Obstetrics" (6). In deze vroege 
experimenten werden bij 7 honden korte glazen buisjes in the thoracale aorta geimplanteerd, 3 beesten 
ontvingen aluminium buisjes en bij 1 beest werd een verguld aluminium buisje ingebracht via een 
chirurgische incisie van de thoraca!e aorta. In 5 geva!len thromboseerde het buisje tussen 5 en 97 dagen 
na de implantatie en twee beesten verbloedden 8 en 11 dagen na de operatie. In 1969 paste Charles 
Dotter dit concept opnieuwtoe toen hij ondoordringbare plastic buis prothesen implanteerde in normale 
arterieen (arteria femora!is en arteria poplitea) van honden. Zijn eerste pogingen faalden ten gevolgevan 
thrombosering binnen 24 uur. Het succes verbeterde toen hij de plastic buisjes verving door roestvrij 
stalen spiral en en heparine infusies toediende gedurende 4 dagen na de implantatie (8). Verschillende 
endovascu!aire stents worden thans klinisch en experimenteel geevalueerd. Veranderingen van ontwerp, 
het gebruik van legeringen en verk!eining van de endoprothese heeft geresulteerd in een groot aantal 
verschmende types voor experimentele en klinische evaluatie. 
De hoofdthema's van dit proefschrift zijn de coronaire stent en de reactie van de vaatwand na 
implantatie van de stent. In hoofstuk 2 wordt als inleiding tot de kwantitatieve angiografische analyses 
van de coronaire stent het idee om atheresclerotische stenoses te stenten als aanvulllng op bal!on 
dilatatie (angioplastie) alsmede het proces van reactieve intima hyperp!asie ten gevolge van de 
combinatie ba11on dilatatie met stent implantatie uitgewerkt. Dit aHes gebaseerd op onze 
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dierexperimenten en humane veneuze vaatenten die 3 dagen to 10 maanden na het stenten chirurgisch 
werden vetwijderd. 
In hoofdstuk 3 en 4 worden enkele methodologische aspecten van kwantitatieve coronaire 
angiografische metingen in gestente bloedvaten belicht De optimale methode om vroege en late 
angiografische resultaten na PTCA of stent implantatie te analyseren is nag niet vastgesteld. Hoewel 
contour detectie de belangrijkste analyse methode blijft, kan de toepassing hierva.n worden belemmerd 
in geval van eccentrische laesies, vooral als de anatomie van de vaatwand verstoord is door een 
dissectie. Oensitometrische analyse wordt dan aanbevolen als een a!ternatieve methode omdat deze 
methode theoretisch onafhankelijk is van de geometrische vorm van het b!oedvat 
In hoofstuk 3 wordt een in vitro studie beschreven waarbij de invloed van 3 onlangs geintroduceerde 
coronaire stent types op de densitometrische meting van een bekende stenose in een plexiglas model 
word geanalyseerd. Het blijkt dat de roestvrij stalen stents (de Wallstent en de Palmaz-Schatz stent) 
slechts een geringe toename (~8%) in het berekende oppervlak van de dwarsdoorsnede op de plaats 
van het minimale lumen veroorzaken. Echter, tantalum bevattende stents (Wiktor Stent) kunnen 
resulteren in een aanzienlijke overschatting van het dwarsdoorsnede oppervlak van de laesie bij 
densitometrische analyse, vooral als de contrast vloeistof verdund is of het vat niet goed is gevuld met 
contrasMoelstof. 
In hoofdstuk 4 vergeleken wij de resultaten van de oppervlakte van de dwarsdoorsnede op de plaats 
van het minimaie lumen verkregen door contourdetectie met densitometrie bij 19 patienten die coronair 
stenting ondergingen met de Wa!lstent. Hoewel een slechte correlaties tussen deze 2 methoden werd 
gevonden in eerdere studies na ballon dilatatie, werd door ons een veer duidelijkere correlatie 
waargenomen na stent implantatie, waarschijnlijk ten gevolge van vlakkere vaatwand contouren 
veroorzaakt door de stent en het zich vervormen van het gestente segment in een circulaire configuratie. 
In de hoofdstukken 5-8 worden de vroege en late fo!low·up resultaten van de eerste klinische 
geimplanteerde coronair stent, de Wallstent, besproken. De 6 Europese centra die betrokken zijn bij het 
onderzoeken van deze techniek kwamen overeen om een angiografische ~core laboratoriumn voor 
kwantitatieve angiografische analyse op te richten in het Thorax centrum in Rotterdam om een objectieve 
beoordeling van de resuitaten te waarborgen. Het Coronary Artery Analysis System (CAAS), dat zeer 
uitgebreid gevalideerd is, werd gebruikt voor alie kwantitatieve studies. Als aanvulling op de 
angiografische analyses waren klinische gegevens beschikbaar. Follow-up gegevens werden verkregen 
uit patienten statussen en gesprekken met deelnemende cardiologen. 
In hoofdstuk 5 worden de resultaten van de eerste 117 "zelf expanderende'" stents. gelmplanteerd bij 
105 patienten, beschreven. Deze studle vertegenwoordigt de eerste kwantitatieve follow-up studie van 
Mn van de nieuwe angioplastie technieken en is daarom van historisch belang. De belangrijkste 
bevinding van deze studie is het hoge occlusie percentage na stent implantatie (24%) hetgeen 
gedeeltelijk een gevolg bleek te zijn van patienten selectie. verschillende en veranderde antistollings 
protocollen in de verschillende centra en onervarenheid van de interventie cardiologen met de techniek. 
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Restenose werd vastge!egd in 14% van de doorgankelijke stents bij follow-up angiografie, hetgeen 
gunstig afsteekt bij vergelijkbare ballondilatatie studies. 
Hoofdstuk 6 en 7 bevatten de gegevens van 256 patienten waarbij een stent geimplanteerd werd (308 
!aesies) tussen Maart 1986 en Maart 1990. 
In hoofdstuk 6 hebben we angiografische voorspel!ers van restenose in de coronaire Wallstent 
geidentificeerd. gebruik makend van een relatief risico analyse; het gebruik van meerdere stents per 
!aesie, te grate stents (geexpandeerde stent diameter meer dan 0,7 mm grater dan de referentie 
diameter), stent implantatie in veneuze bypass vaatenten en een hoge residuele diameter stenosis 
hadden een significante hager rislco op restenose. Aangezien enkele van deze factoren vermeden 
kunnen worden (implantatie van te grate stents, gebruik van meer stents, suboptimale dilatatie) konden 
aanbevelingen gedaan worden om het risico ap restenose na stent implantatie te verminderen. 
In haofdstuk 7 wordt een uitgebreide analyse van klinisch resultaten, afsluitings en restenose 
percentages beschreven voor de gehele studie groep en ingedeeld naar het tijdstip van implantatie en 
het type bloedvat. Daar onze ervaring met stent implantatie de eerste in zijn soort was. evolueerden de 
indicatie voor imp!antatie en de behandeling van patienten na imp!antatie met toename van ervaring en 
kennis. Bij de eerste groep patienten (gedeeltelijk beschreven in hoofdstuk 5) werden voomamelijk stents 
geimplanteerd in kranslagvaten waarin eerder een restenose was opgetreden. De volgende groep 
bestand hoofdzakelijk uit patienten met primair vernauwde veneuze vaatenten en oorspronkelijke 
kranslagvaten die gestent werden als onderdeel van een "bail out" procedure na een gecomp!iceerde 
ballondilatatie. Alhoewel statistisch niet significant was er in deze groep een reductie van de 
thrambotische occlusies tijdens de opname in het ziekenhuis tot 12% gevolgd door een toename van 
het restenase percentage van 21% naar 32%. De palliatieve rot van stenting bleek oak duidelijk door de 
lage gebeurtenis vrije overleving voor zowel kransslagvaten (46% na 40mnd) als voorveneuze vaatenten 
(37% na 20mnd). 
In hoofstuk 8 worden de afzonderlijke Thoraxcentrum ervaringen van stent implantatie in 
gestenoseerde veneuze vaatenten in detail beschreven. De toepassing van stent implantatie als 
behandelings mogelijkheid voor deze groeiende groep patienten die meestal niet gebaat ztjn bij 
reoperatie of conventionele ballondilatatie, wardt in dit hoofstuk besproken. Aile in het Tharaxcentrum 
gestente patienten hadden ernstige angineuze klachten en de meerderheid werd beschouwd als hoog 
risico patient voor het ondergaan van een bypass aperatie of ballon dilatatie. Afsluiting tijdens ziekenhuis 
opname kwam voor bij 10% van de patienten en trad gewoonlijk op bij acuut ischaemisch hartlijden of 
anderbreking van de antistollingstherapie. Hoewel het percentage restenose na stent implantatie hoog 
was (47%) en reinterventie frequent noodzake!ijk was, kan caronaire stenting een effectieve behandeling 
zijn voor patienten die slechte kandidaten zijn vaor alternatieve behandelings methoden. 
In de hoofdstukken 9 tjm 11 worden de resultaten beschreven van onderzoek op coronair weefsel 
verkregen met behulp van de atherectomie catheter. 
In hoofdstuk 9 worden de vroege en late resultaten onderzacht van directionele atherectomie ter 
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behandeling van restenose in een coronaire stent bij 9 patienten (1 0 procedures). Het verwijderde 
restenose rnateriaal werd bestudeerd wat betreft eel indentfficaties, proliferatie activiteit en celluiariteit. 
Hiertoe werd gebruik gemaakt van een combinatie van lichtmicroscopie, electronenmicroscopie en 
immunohistochemische technieken. Deze resultaten werden vergeleken met een controle (niet gestente) 
groep patienten bij wie restenose weefsel was verwijderd 14-59 dagen na een eerdere ingreep {PTCA, 
atherectomie, laser). De angiografische resultaten toonden aan dat directionele atherectomie een 
effectieve behandelingsvorm is na restenose in de stent maar beperkt wordt door het optreden van re-
restenosen. De weefsel studies toonden aan dat de gladde spiercel het belangrijkste celtype is dat 
aangetroffen wordt in restenose laesies onafhankel1jk van het type van de eerdere ingreep, en dat 
proliferatie van gladde spiercellen een vroeg fenomeen is en 2 maanden na de procedure nag nauwelijk 
aantoonbaar is. Voorts blijkt dat de meerderheid van gladde spiercellen kort na de procedure het 
contractiele fenotype aannemen dat de ce!lulariteit afneemt in het verloop van de tijd. Er is echter een 
grate individuele variabiliteit 
In hoofdstuk 10 werd de afkomst van de gladde spiercellen in primaire coronaire laesies afkomstig 
uit een een kransslag vat na harttransplantatie aangetoond. Er werd gebruik gemaakt van een techniek 
(DNA fingerprinting) die gebaseerd is op verschillen in genetische samenstelling tussen donor en 
ontvanger van zogenaamde VNTR gen loci. Deze studies werden verricht op DNA dat geisoleerd werd 
uit een coronair atherectomie fragment en uit biopten van het donor myocard en bleed van de ontvanger 
na vermeerdering van het DNA door middel van een polymerase kettingreactie (PCR). De resultaten van 
de electrophorese bevestigden dat de intima laesies zeals gezfen bij atherosclerose en restenose 
voornamelijk bestaan uit gladde spiercellen die hun oorsprong hebben in de vaatwand en niet afkomstig 
zijn uit de circulatie. 
in hoofdstuk 11 worden de voorlopige kweek resultaten van gladde spiercellen uit coronaire 
atherectomie fragmenten (inclusief restenose laesies in gestente arterie&n) beschreven en vergeleken 
met gladde spiercellen die geisoleerd werden uit de media van arterien ult de menselijke navelstreng. 
De belangrijkste bevindingen van deze studie waren dat uit een minderheid van de lesies seriele passage 
mogelijkwas en dat deze cellen een lager proliferatie percentage (50%) vertonen maar een hogere graad 
van extracellulaire matrix componenten, collageen (50%) en gesulfateerde glycosaminogrycanen (2:2x) 
dan de navelstreng gladde spiercellen. Dit celkweek systeem btijkt een nuttig model te zijn bij de 
bestudering van processen zeals atherosclerose en restenose. 
Het doer van dit proefschrift is tweeledig. De interventie cardiologie is nu het post-ballon dilatatie 
tijdperk binnengetreden en we worden geconfronteerd met uitdagingen die 15 jaar geleden niet konden 
worden voorzien. We zijn getuige geweest van een explosie van alternatieve technieken voor 
ballonangioplastie zoals diverse types stents, tenminste 3 verschillende atherectomie catheters en een 
overv!oed van verschillende laser catheters. Klinische acceptatie van &en van deze nieuwe technieken 
wacht op uitgebreide wetenschappelijke evaluatie. Op dit moment kan dit aileen bewerkstelligd worden 
door het gebruik van kwantitatieve coronaire arteriografie. 
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Ondanks het feit dat andere evaluatie methoden in de toekomst toegepast zullen worden (bijv. 
intravasculaire echografie) moeten toekomstig onderzoek zich niet beperken tot de technische aspecten 
van deze meer eisende en meer gecompHceerde technieken, maar ook gericht zijn op het verwerven 
van nieuwe inzichten in de processen die het lange termijns resultaat van coronaire interventies kunnen 
beinvloeden. 
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